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1 Summary 
 
The main challenge of tissue proteomics arises from the intrinsic complexity of samples which 
impedes reliable data interpretation. Tissues are composed of different cell types and a specific 
extracellular matrix. Although tumors are supposed to arise from a single cell type (e.g. HCC from 
hepatocytes or liver stem cells), their composition is additionally influenced by e.g. the infiltration of 
immune cells, by changes in the abundance of cells constituting also non-tumorous tissues and by 
epithelial-mesenchymal transition of cells due to an increase of developmental plasticity and loss of 
differentiation state usually accompanying tumor progression as well as the extracellular matrix as 
crucial constituent of the tumor microenvironment.  
The aim of this work was to determine functional differences of non-tumorous liver and HCC tissue via 
proteomics methods (shotgun, mass spectrometry, 2D-PAGE). For data interpretation, the focus was 
laid on basic cell biological and metabolic alterations resulting in the loss or gain of functions rather 
than those occuring at the single gene (protein) level. Proteins were functionally clustered based on 
several databases (e.g. KEGG, PubMed) as well as biochemical and toxicological literature. Moreover, 
functional proteome alterations were correlated to physiologically, histologically, and cytologically 
observable alterations. In order to enable the comparison of immunohistochemically (from 
www.proteinatlas.org) and tissue proteomics-derived protein expression, a method for the elaboration 
of histologic data was introduced. In addition, proteome data were compared to those of 
“Encyclopedia of Hepatocellular Carcinoma genes Online” (EHCO), a database compiling eight gene 
set collections including PubMed, SAGE, microarray, and proteomics data (see citation in 1.1.2).  
HCC tissues generally exhibit reduced secretion performance and concomitantly enhanced 
cytoplasmic protein synthesis (see paper “A novel technique to specifically analyze the secretome of 
cells and tissues” [1]) although liver-specifically synthesized plasma proteins were found to be 
enriched in HCC compared to non-tumorous liver at the tissue proteome level. Hence, the quantitative 
and qualitative aspects of the tumor secretome are discussed as well as functional groups with 
influence on this phenotype including protein synthesis, import of proteins into the ER as prerequisite 
for secretion as well as chaperones and protein degradation. Furthermore, alterations of enzyme 
expression involved in glycolysis (Warburg effect), glycogen metabolism and fatty acid metabolism 
(altered composition of lipid composition of tumors) were determined. In additon, some liver-specific 
functions concerning detoxification in a broader sense are covered (urea cycle, phase I- and II-
system). Moreover, the involvement of e.g. c-Myc and Ras in tumor development or maintenance is 
indicated, the first based on the coordinated expression levels of five independent proteins, the 
second by being highly upregulated in HCC tissue. In addition, some other tumor-relevant proteins 
such as anti-apoptotic and drug resistance-mediating sorcin, the supposedly locally enriched 
cardiotrophin-1, and HRPAP20, which enhances the growth and survival of hormone-responsive 
tumor cells but has not been associated with primary liver cancer thus far, were found to be 
pronouncedly more abundant in HCC. 
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2 Zusammenfassung 
 
Die Interpretation von pathophysiologischen Veränderungen des Gewebsproteoms stellt aufgrund der 
Vielzahl von Einflussgrößen eine besondere Herausforderung dar. Gewebe bestehen aus 
verschiedenen Zelltypen, deren quantitative Zusammensetzung und qualitativer Funktionszustand 
sich unter pathophysiologischen Bedingungen drastisch verändert. So spiegeln sich beispielsweise 
die Infiltration von Immunzellen und die gesteigerte Durchblutung des Gewebes bei Entzündung, die 
epitheliale-mesenchymale Transition von transformierten Hepatozyten oder die Transdifferenzierung 
von Stellatzellen der Leber in Myofibroblasten im Zuge der Leberkanzerogenese im Proteomprofil des 
hepatozellulären Karzinoms wider.  
Das Ziel dieser Arbeit war, die Unterschiede der Proteomprofile von Leber und hepatozellulärem 
Karzinom auf funktioneller Ebene zu charakterisieren. Ein Hauptaugenmerk wurde auf Veränderungen 
basaler zellbiologischer (z.B. Proteinsynthese, -faltung, -degradation) und metabolischer Funktionen 
(Glykolyse, Fettsäuremetabolismus) sowie auf leberspezifische Funktionen (Fremdstoffmetabolismus, 
Harnstoffzyklus) gelegt. Die funktionelle Kategorisierung wurde anhand verschiedener Datenbanken 
(z.B. KEGG, PubMed) sowie biochemischer und toxikologischer Literatur erarbeitet. Soweit möglich, 
wurden funktionelle Proteomveränderungen mit physiologisch, histologisch und cytologisch 
beobachtbaren Veränderungen korreliert (z.B. Erbdefekte, dominant-negative Zelllinien, usw.) um die 
biologische Wirkung von gesteigerter oder verminderter Expression von Proteinen bewerten zu 
können. Um Proteomdaten mit immunohistochemischen Expressionsdaten („Human Protein Atlas“, 
www.proteinatlas.org) vergleichen zu können, wurde ein Verfahren etabliert, das es ermöglicht die 
unabhängigen histologischen Datensätze „Intensität“ und „Quantität“ miteinander zu verknüpfen. 
Weiters wurden die Proteomdaten mit jenen der „Encyclopedia of Hepatocellular Carcinoma genes 
Online“ (EHCO)-Datenbank korreliert. Diese umfasst u.a. SAGE-, Micorarray- und Proteomics-Daten. 
Im Vergleich zu normalem Lebergewebe zeigt das hepatozelluläre Karzinom charakterischerweise 
eine veringerte Sekretionsleistung bei gleichzeitig gesteigerter Synthese von zytoplasmatischen 
Proteinen (“A novel technique to specifically analyze the secretome of cells and tissues” [1]). 
Allerdings wurden im hepatozellulären Karzinom auf Gewebsproteomebene vermehrt leberspezifisch 
sekretierte Plasmaproteine detektiert. Daher werden mögliche physiologische und zellbiologische 
Einflussgrößen auf die Proteinsynthese und die quantitative und qualitative Zusammensetzung des 
Tumorsekretoms im Kontext des funktionell charakterisierten Tumorproteoms diskutiert. Weiters 
werden die tumor-relevanten Funktionen Glykolyse (Warburg-Effekt) und Fettsäuremetabolismus 
sowie Detoxifikation (Harnstoffzyklus, Phase I- und Phase II- Enzyme; Resistenz gegen 
Chemotherapeutika) behandelt und Proteine, die tumor-charakteristische Eigenschaften vermitteln, in 
Bezug auf vorhandene Literatur diskutiert. 
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3 Introduction 
3.1 The proteome 
3.1.1 General remarks 
The term proteome, coined in 1996 by M.R. Wilkins, indicates the set of proteins expressed by a 
genome or tissue [2]. It already implicates the ‘dichotomy’ of the theoretical (i.e. primary structure of 
proteins derived from DNA-sequences of all 'Open Reading Frames' (ORFs)) and the physiologically 
relevant proteome in anology to the difference between 'genome' and 'functional genome'.  
Sequencing of the human genome not only pushed open the door to comprehensively gather the 
theoretical proteome but put it also center stage for phylogenetic considerations. Decoding of the 
human genome revealed that it comprises a constant but astonishingly modest number of protein-
coding genes [3] which has actually been revised downwards in recent estimates and is now assumed 
to comprise about 22.000 ORFs [4, 5]. It is commonly accepted that sheer gene counts scarcely 
correlate with the complexity of organisms. Thus, the nematode Caenorhabditis elegans has a similar 
and the fruit fly Drosophila melanogaster about half the number of genes as humans [6]. The 
interactome, i.e. the total number of protein interactions, is now suggested the more reliable parameter 
to reflect the complexity of biological systems. Indeed, based on presently available interaction data, 
Stumpf et al. recently estimated the human, C. elegans, and D. melanogaster interactomes to contain 
about 650.000, 250.000, and 100.000 protein interactions, respectively, which seemingly approximate 
at least “our perception of the relative complexity" (Stumpf et al., [7]) of those species better than gene 
numbers [7]. In addition, genome-sequencing uncovered many proteins of yet uncharacterized or 
pleiotropic functions constituting a significant section of the theoretical proteome [8, 9] and offering the 
opportunity to targetly focus on their integration into the physiological context as constituents of a 
functional proteome. 
In contrast to the intrinsically static species-specific collection of genes as well as the theoretical 
proteome and protein interaction network derived thereof, gene expression is highly dynamic and 
temporally, spatially, and contextually regulated. In fact, only minor moieties of genes are expressed 
and thus just sections of the total proteome and interactome are realized under distinct physiological 
conditions. This implicates the emanation of numerously distinct functional proteomes and transitional 
states from a single theoretical proteome in the course of e.g. development, differentiation, 
regeneration, and cancer development. Indeed, the expression of the physiologically appropriate 
proteomes is decisive for development, maintenance, and homeostasis of (multi-cellular) organisms. 
Therefore, gene expression is tightly regulated at many levels in the course of information flow from 
DNA to RNA to proteins and beyond in order to provide systemic fidelity, robustness, and adaptability.  
The regulation of protein abundance and diversity concerns the accessibility of promoter elements for 
transcription factors by assembly, regulation, and remodeling of chromatin (reviewed in [10-12]), 
mRNA maturation including ‘capping’ [13] and alternative splicing (reviewed in [14, 15]), transport of 
mature mRNAs from the nucleus into the cytoplasm (reviewed in [16], see also [13]), mRNA stability 
by deadenylases, miRNAs [17, 18], and the exosome (reviewed in [19, 20], translation initiation 
(reviewed in [21, 22]), and protein degradation [23].  
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Moreover, many proteins require co- or post-translational, transient or constitutive modifications to 
exert their functions, to switch between active and inactive states, and to bind to interaction partners 
and, hence, to become integral parts of the physiologically relevant dynamic interactome. Frequent 
modifications include e.g. ubiquitinylation, sumoylation, neddylation, acetylation, phosphorylation, 
methylation, glycosylation, and prenylation. Ubiquitinylation is the common cellular mechanism 
dedicating proteins to proteasomal degradation. However, ubiquitinylation is also involved in DNA 
repair, transcription regulation including gene silencing (e.g. ubiquitinylation of histone H2A in yeast), 
regulation of transcription factor turnover and estrogen receptor degradation, the control of stability 
and activity of the tumor suppressor p53 (TP53), signal transduction (e.g. by modulating the 
transcripton of NFκB-dependent genes), and endocytosis (reviewed in [24] and citations therein). 
Phosphorylation plays a pivotal role in signal transduction. TP53, for instance, is a nodal point for 
many signaling pathways integrating a broad variety of stress signals such as DNA damage, hypoxia, 
and dNTP depletion. However, the cellular outcomes (cell-cycle arrest, DNA repair, apoptosis, 
senescence) are as diverse as the signals triggering the response and are cell type-, tissue-, and 
stimulus-dependent indicating the activation of different gene sets. In addition to stability- and activity-
providing modifications (see above), sequence-specific phosphorylation of p53 affords promoter 
selectivity in response to genotoxic stress leading to the expression of p53AIP1 which exerts pro-
apoptotic activity and eventually triggers programmed cell death (reviewed in [25]). A decisive aspect 
of the biological tumor-suppressing activity of p53 is its translocation from the cytoplasm into the 
nucleus. Interference with the contextually proper nuclear location is indeed a common pathogenetic 
mechanism of tumor-inducing viruses such as adenovirus and hepatitis B virus ([26, 27], for the latter 
see below).  
The subcellular localization of proteins is a crucial determinant of their function and has substantial 
implications for proteome analyses. It is either co-translationally (e.g. ER-resident, secreted, integral 
membrane proteins), post-translationally (e.g. mitochondrial proteins, nuclear proteins like histone 
proteins, RNA- and DNA-polymerases), or signal-dependently (e.g. nuclear localization of p53 (see 
above), reversible association of vesicle traffic-regulatory Rab GTPases with lipid membranes [28]) 
established. An impressive example for the correlation of biological function and subcellular location is 
cytochrome c which participates in the mitochondrial electron-transport chain under normal conditions 
but is released from mitochondria into the cytoplasm upon apoptotic stimuli and constitutes an integral 
component of the apoptosome there (reviewed in [29]). However, cytoplasmic cytochrome c does not 
necessarily lead to programmed cell death. The outcome, apoptosis vs. survival, rather depends on 
the cell biological context since autophagy as well as elevated levels of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and inhibitors of apoptosis proteins (IAPs) can effectively counteract the 
induction of apoptosis [30]. Indeed, increased expression of GAPDH and IAPs has been found in 
various cancers and is supposed to be involved in mediating resistance against apoptosis, one of the 
hallmarks of cancer [31-35].  
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3.1.2 The challenge 
The interpretation of proteome data derived from 2D-PAGE and shot-gun experiments is based on the 
comparative acquisition of differential gene expression patterns at the protein level (proteome 
profiling). The latter reflect e.g. characteristics of cell types (differentiation states), drug effects 
(pharmacoproteomics), disease-mediated alterations (normal vs. tumorous tissues), and physiological 
states (inflammation, activation, proliferation) [36-38]. Proteomics proves to be almost universally 
applicable, complements and extends insights from alternative investigative approaches (e.g. 
genomics, transcriptomics, etc.), and, hence, contributes to a more comprehensive understanding of 
(patho-) physiological processes and mechanisms. 
The biological and molecular heterogeneity of hepatocellular carcinoma tissues is a major challenge 
for extracting common features of statistical and medical relevance (biomarkers, treatment options, 
etc.). Serious efforts are made to globally assess the transcriptome and proteome of liver and tumor 
tissues in order to derive significant tissue-type specific differences. Although being promising 
approaches, they have methodically intrinsic limitations which might be generally assigned to the 
difficulty to distinguish the effect of different influencing variables on gene expression from actual 
cancer-relevant alterations and, hence, to define filter and selection criteria for the elaboration of large 
datasets. 
Variables with substantial impact on the molecular status of investigated samples are interindividual 
differences, different tumor etiologies, and the "ontogenesis" of liver cancer including e.g. the stage of 
cancer progression and the grade of dedifferentiation. It is, therefore, evident that the results of 
transcriptome and proteome studies strongly depend on and reflect the preselection of samples for 
comparative analysis which already presumes the relevance of the applied criteria. In addition, the 
availability and, hence, investigation of solid tumors is restricted to resection or transplantation-derived 
and, hence, advanced-stage samples. Nevertheless, the major goal is the identification of reliable sets 
of prognostic, predictive, and pharmacodynamic biomarkers as basis for decisions concerning the 
questions if a given treatment is advantageous for a patient, if a patient is responsive to a given drug, 
and which dose of a given drug should be applied, respectively.  
However, considering the heterogeneity and complexity of biological systems which e.g. manifest in 
the multitude of ways to gain common tumor traits (e.g. unrestricted proliferation, resistance against 
apoptosis), it is obviously improbable to find common biomarkers fitting to or reflecting the features of 
e.g. all hepatocellular carcinomas. Indeed, expression levels of proteins in histologic slices of normal 
liver tissues are commonly in a narrow (tissue-specific) range whereas those of tumorous tissues vary 
pronouncedly (www.proteinatlas.org). However, the probabilities of a given protein to be less, equally, 
or more abundant with respect to its expression level in normal liver tissue can be calculated and 
deliver ancillary infomations for the interpretation and evaluation of tissue proteomics data (see 
below). 
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3.1.3 The strategy 
The main intention of this work is to integrate proteome data of tissues of hepatocellular carcinoma 
and adjacent non-tumorous liver and in order to determine "real" functional shifts and to correlate 
those with anatomically, physiologically, histologically and cytologically observable alterations of liver 
vs. tumor tissue as well as with published data gathered via proteomics and 
alternative/complementary methodical approaches. Taken together, this strategy might allow a 
broader and more fundamental, since integrative, interpretation of alterations concerning gene 
expression and functionality of liver and HCC tissue although the intrinsic complexity of the biological 
network rising from the multitude of interdependencies and interconnections of system components 
are far from being understood. Nevertheless, there are some adjuvant data available which can be 
consulted to assess the impact of reduced/increased abundance of a given protein on the molecular 
process it accounts for (e.g. dominant-negative cell lines, genetic disorders ascribed to a certain gene, 
knock-out models). A further level of complexity results from the fact that liver and HCC tissue 
comprise several and most possibly different cell types and that the proteome of transformed 
hepatocyte-like cells of HCC tumor tissue itself might converge to that of cellular components of non-
tumorous liver tissue due to epithelial-mesenchymal transition. For that reason and in order to reduce 
complexity the main focus was laid on determining the functionality of the tissue/organ as a whole 
rather than to assigning it to certain cell types. It has to be stated that this work naturally represents 
just one of "many roads that lead to Rome". The shotgun proteomics approach for data acquisition is 
intrinsically holistic and has to be understood as hypotheses-delivering one. It is, therefore, well 
applicable to provide the basis for questions worth to be dealt with in detail. Although this method 
enables the detection of usually 1000- 1500 proteins in one experiment, this fraction represents just a 
section of the actually expressed functional proteome. However, it can be concluded that many 
biological functions are indispensable for the survival of cells in general although to a different extent 
and in dependency of the physiolgical contexts (e.g. glycolysis as primary energy-providing metabolic 
pathway for cells of avascular and hence oxygen-deprived tissues like cartilage or as pathway 
providing intermediates for biosynthesis by hepatocytes). Hence, the respective enzyme machinery 
has to be complete to fulfill its function. This assumption allows to fill gaps of not detected or 
detectable proteins and is also useful to conclude or hypothesize the involvement of e.g. signaling 
pathways involved in tumor progression and maintenance from proteins which are more easily 
detectable than the low-abundant, membrane-associated, or nuclearly localized signaling components 
themselves (see below). 
 
Principal approaches for the interpretation of tissue proteomics data:  
1. The analytical approach is based on the dissection of the proteomes of tissue-constituting and 
pathologically relevant cell types (e.g. cells of the immune system, blood cells, fibroblasts) in 
order to determine their contribution to the tissue proteome. This is achieved by the isolation 
of the distinct cell types, their expansion in vitro, and the subsequent determination of the cell 
type-specific proteomes. This approach has successfully applied by Slany and Haudek et al. 
who gathered the proteome profiles of primary human hepatocytes and of the hepatoma-
derived cell lines HepG2 and Hep3B [36]. They could demonstrate that the latter represent 
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two completely different manifestations of liver cancer cells. E.g. HepG2 expressed more liver-
specific proteins than Hep3B whereas the latter was suggested to having undergone 
epithelial-mesenchymal transition and, hence, to be originally derived from a more aggressive 
tumor than HepG2. The understanding of the spectrum of molecular alterations realized by 
cells constituting HCC tumors substantially facilitates the interpretation of tissue proteomes. In 
addition, it potentially helps to identify markers for the proper classification of tumors extending 
and supplementing the panel of criteria applied thus far (e.g. tumor-stage, etiology) which 
might significantly contribute to a more comprehensive insight into tumor biology. The cell-
based analytical strategy, however, has intrinsic limitations due to excluding the histological 
and molecular composition of the tumor stroma. The specific tumor microenvironment 
comprising e.g. the distinct composition of the extracellular matrix and soluble factors 
mediating autocrine stimulation or paracrine crosstalk between different cell types is supposed 
to have decisive impact on gene expression of not only transformed cells. Furthermore, gene 
expression and the microenvironment are influenced by physical parameters such as blood 
supply, material exchange processes, and pressure regimen (e.g. hydrostatic or colloid 
osmotic pressure). Liberating cells from their systemic context and, hence, deprivation of 
physical or molecular stimuli provided by the microenvironment (e.g. due to the enrichment of 
growth and survival factors) possibly lead to unpredictable changes in gene expression and 
phenotype.  
2. The data-driven approach correlates patterns to certain tumor traits (e.g those reviewed in 
[32]), thereby requiring no assumptions and being unbiased. A decisive aspect concerning the 
management of large datasets commonly gained by proteomics experiments is a reliable 
database featuring data quality-ensuring functions and faciltating multi-sample comparisons at 
the protein and even the functional level as it was introduced at the Medical University Vienna 
(lab of Prof. Gerner) in 2009 by Wimmer et al. (CPL/MUW database) [39].  
3. The knowledge-based approach uses data from literature concerning distinct traits. Alterations 
of the gene expression should be reproducibly present in the respective sample as starting 
point to consequently discover new molecular players and to reveal their interrelations and/or 
correlated expression.  
 
Principle considerations, assumptions, and procedures 
1. The interpretation of proteomics data applied in this study is primarily based on the 
knowledge-based approach. The aim was to determine and to functionally characterize 
alterations of the proteomes of hepatocellular carcinoma and adjacent non-tumorous tissue. 
The applied data interpretation strategy is based on the construction of functional clusters 
(e.g. ribosomal proteins, glycolysis, respiratory chain, fatty acid metabolism, etc.) and is 
different from cluster analyses applied in order to extract gene-expression signatures 
(clusters), referring to patterns shared by or unique for (sub)groups of investigated samples 
[40]. Whereas the principal entity of the latter is the expression level of a given gene, the 
functional cluster comprises the expression level of all (at the best) proteins (genes) involved 
in a pathway. The output of the functional cluster-based data interpretation is the loss or gain 
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of function rather than the up- or downregulation of individual proteins. Supposed that 
cancerogenesis is in part the result of the gain or loss of function irrespective of its actual 
biological/biochemical realization (e.g. involvement of different signaling pathways in HCC, 
defects of several enzymes involved in glycogen metabolism cause glycogen storage 
disorders manifesting in common symptoms like hepatomegaly, hypoglycemia, lipidemia) and 
hence the up- or downregulation of individual proteins, this approach might explain the 
contradictory or inconsistent data concerning the involvement of individual proteins in cancers 
(e.g. putative biomarkers) [41]. 
2. The proteome of HCC and non-tumorous tissue of one patient was analyzed by mass 
spectrometry. The efficiency of protein detection of both samples was comparable (similar 
overall total peptide numbers). 
3. For the semi-quantitative assessment of the abundance of a given protein the total peptide 
numbers of the respective proteins were taken. The preparation of protein samples for mass 
spectrometric analysis includes the digestion with site-specific proteases (e.g. trypsin, 
chymotrypsin) delivering peptides of defined amino acid compositions and, hence, predictable 
peptide masses. The latter are determined by the respective protein species and the protease 
used for digestion. The mass spectrometrical identification of proteins basically relies on the 
computational matching of actually determined and database-compiled theoretically calculated 
peptide masses of proteins. The proteins are characterized by distinct peptides assignable to 
the respective protein species. The number of distinct peptides (Dp) of a given protein and the 
percentage of amino acids identified (coverage (%)) are a measure for the reliability of protein 
identification. Although the number of distinct peptides reflects the abundance of protein 
species of the sample, the number of total peptides (Tp) is more convenient for quantification 
from theoretical considerations. The maximum number of Dp of a given protein is constant for 
a given protein species in contrast to Tp. This pertains particularly for small and/or highly 
abundant proteins. The correlation of Dp and Tp and their relevance for protein quantification 
is exemplified in figure 1. In addition, the mass spectrometrical identification of Dps (and Tps 
of the corresponding peptide) is influenced by covalent modifications (e.g. phosphorylation, 
glycosylation, acetylation) and requires algorithms incorporating the mass variance due to the 
attached functional groups. 
4. Proteins were assigned to functional clusters comprising highly homologous proteins which 
deliver similar sets of peptides after tryptic digest and are therefore prone to be falsely listed 
as distinct proteins. Peptides of those proteins were checked for specificity (BLAST, Basic 
Local Alignment Search Tool of NCBI). Proteins which were not uniquely identified were 
grouped (e.g. P…../Q…..) and the highest number of total peptides was taken to quantitatively 
represent the group. 
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Figure 1: The number of total and distinct peptides (Tp and Dp) as measure for the 
abundance of proteins identified via mass spectrometry 
 
5. Functional clustering was refined using the KEGG pathway database (Kyoto Encyclopedia of 
Genes and Genomes, see appendix), biochemical and toxicological literature, UNIPROT 
database, Pubmed. For clustering and, in particular, for chapter 3.3 and 5.9 the books 
“Biochemie und Pathobiochemie” (Löffler, Petrides, and Heinrich, 8
th
 edition, 2006), 
“Taschenatlas der Biochemie” (Koolman and Röhm, 3
rd
 edition, 2003), “Taschenatlas der 
Physiologie” (Silbernagl and Despopoulos, 6
th
 edition, 2003), “Taschenatlas der 
Pathophysiologie” (Silbernagl and Lang, 2
nd
 edition, 2005), “Lehrbuch Anatomie” (Lippert, 3
rd
 
edition, 1993), “Biochemistry” (Berg, Tymoczko, and Stryer, 5
th
 edition, 2006), “Casarett & 
Doull's Toxicology: The Basic Science of Poisons”, “Histologie” (Lüllmann-Rauch, 2003), 
“Immunobiology” (Janeway et al, 6
th
 edition, 2005), “Allgemeine und spezielle Pharmakologie 
und Toxikologie” (Aktories et al, 9
th
 edition, 2005), and “Molecular biology of the cell” (Alberts 
et al., 5
th
 edition, 2007) were consulted. 
6. Shotgun results were compared to immunohistochemical data from “Human Protein Atlas 
(www.proteinatlas.org) and data derived from “Encyclopedia of Hepatocellular Carcinoma 
genes Online” (EHCO) which was introduced in 2007 and compiles eight gene set collections, 
ranging across PubMed, SAGE, microarray, and proteomics data [41]. Intriguingly, the authors 
state that 77% of the 2,906 genes covered are included just once and that their relevance for 
HCC is not clear. A rich source for the evaluation of protein abundances in tissues is the 
antibody-based immunohistochemical staining of histological slices. “Human Protein Atlas” 
(www.proteinatlas.org) which delivers expression data of more than 5000 proteins was chosen 
to compare and correlate shotgun results with immunohistochemically obtained protein 
abundance data. However, in this database protein expression data are represented by two 
independent datasets, “intensity” and “quantity”. The first corresponds to the expression level 
per se whereas the second gives the percentage of cells expressing the respective protein. 
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Since both equally influence the amount of proteins extracted from homogenized tissue 
samples prior to mass spectrometry, “intensity” and “quantity” had to be correlated in order to 
make immunohistochemical and tissue proteomics data comparable. For that, a new method 
was introduced. Immunohistochemically derived protein expression data are represented 
either as probabilities for up- or downregulation or equal expression compared to liver (see 
appendix) or statistically processed using SPSS and depicted as boxplots for proteins 
discussed in more detail. The three data sets are compiled and their compliance is given in 
the appendix.  
7. For the determination of the biological impact of up- or downregulation of a given protein, data 
concerning dominant-negative cell lines, hereditary diseases, knock-out mice from PubMed 
and Uniprot were gathered.  
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3.2 Hepatocellular carcinoma (HCC) 
3.2.1 Why investigating HCC- the epidemiologist’s and clinician's point of view 
The general term "liver cancer" comprises histologically distinct tumors like cholangiocarcinoma, 
hepatoblastoma, bile duct cystadenocarcinoma, haemangiosarcoma, epitheloid 
haemangioendothelioma, and hepatocellular carcinoma, the latter making up 83% of all cases. 
Hepatocellular carcinoma (HCC, hepatoma) is a global health problem in terms of incidence and 
lethality with about 1 million new cases yearly and median survival rates of <25 months after resection 
or <6 months with symptomatic treatment, respectively [42]. Several coinciding parameters contribute 
to the fatality and the difficulty to manage this malignancy. Most patients are diagnosed not before 
having developed advanced-stage tumors [43] partially due to the lack of biomarkers for early 
detection. In addition, malignant hepatocytes commonly develop against the background of permanent 
inflammation (chronic hepatitis), tissue remodeling processes (fibrosis), and the loss of liver 
parenchyme (cirrhosis) [44-46]. Both, late detection and hepatic dysfunction, drastically limit the 
options for curative treatments like tumor resection and liver transplantation or predispose to early 
tumor recurrence after surgical intervention (recurrence rate up to 50% at 2 years) [47-50]. Moreover, 
HCC proves to be highly resistant to conventional chemotherapeutics and hormonal therapies 
diminishing the efficacy of adjuvant and palliative treatments [51, 52]. Today’s treatment options and 
their benefit to patients are summarized by Thomas and Zhu (Table 1, obtained from [50]).  
 
Treatment Option  Comments  References 
Liver transplantation  Historically low survival rates (20%-36%) recent improvement (61.1%; 1996-2001), 
likely related to adoption of Milan criteria at US transplantation centers 
Currently HCC represents 20+% of liver transplantations performed annually in the 
United States 
[53, 54] 
 
Surgical resection  Historical 5-year survival rates 30%-40%  
Recent series indicates 5-year progression-free survival as high as 48%; majority 
of patients develop recurrence or second primary tumors 
Resection in cirrhotic patients carries high morbidity and mortality 
[54-58] 
TACE  (transarterial 
embolization/ 
chemoembolization) 
 
 
 
 
 
 
 
Intra-arterial iodine-131–
lipiodol administration 
Multiple trials show objective tumor responses and slowed tumor 
progression but questionable survival benefit compared to supportive 
care; greatest benefit seen in patients with preserved liver function, 
absence of vascular invasion, and smallest tumors 
Modest survival benefit demonstrated for repeated TACE (82% 1-year 
survival) vs. supportive care (63%) in patients with preserved liver function, 
performance status 0, and small tumor burden; improvement in 1-year survival 
from 32% in controls (supportive care) to 57% for TACE shown in randomized 
study of 279 primarily HBV-positive patients with tumors < 7 cm 
 
Efficacy demonstrated in unresectable patients, those with portal vein 
thrombus, and as adjuvant therapy in resected patients 
[59-62] 
 
 
 
 
 
 
 
 
 
 
[63-65] 
 
Percutaneous 
treatments 
(ethanol injection, 
radiofrequency ablation) 
 
Percutanous ethanol injection well tolerated, high response rate in small (< 3 cm) 
solitary tumors; no randomized trial comparing resection to percutaneous 
treatments; recurrence rates similar to those for postresection 
[66-69] 
 
Hormonal therapy Antiestrogen therapy with tamoxifen studied in several trials, mixed results 
across studies, but generally considered ineffective 
Octreotide (somatostatin analogue) showed 13-month median survival vs. 4-month 
in untreated patients in a small randomized study; results not reproduced 
 [70-74] 
 
[75] 
 
Chemotherapy  Adjuvant: No randomized trials showing benefit of neoadjuvant or adjuvant 
systemic therapy in HCC; single trial showed decrease in new tumors in 
patients receiving oral synthetic retinoid for 12 months after resection/ 
ablation; results not reproduced 
 
Palliative: Regimens that included doxorubicin, cisplatin, fluorouracil, 
interferon, epirubicin, or taxol, as single agents or in combination, have 
[52, 76-79] 
 
 
 
 
[52] 
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not shown any survival benefit (response rate 0%-25%); a few isolated major 
responses allowed patients to undergo partial hepatectomy; no published results 
from any randomized trial of systemic chemotherapy 
Table 1:Treatment options for HCC 
 
3.2.2 Hepatocarcinogenesis 
3.2.2.1 General remarks 
Hepatocellular carcinomas (Figure 2) exhibit many phenotypic traits subsumed as “hallmarks of 
cancer” referring to e.g. independency from growth signals, reduced apoptosis, and unlimited 
proliferation potential [32]. In addition, metabolic alterations and the involvement of the immune 
system are also considered as characteristics of tumor cells and crucial determinants for tumor 
formation, respectively [80, 81].  
 
 
Figure 2: Liver tumor (Permission to use this image granted by the Brigham and 
Women's Hospital, Department of Radiology) 
 
 
However, apart from those common traits, the HCC-characteristic clinical aspects and 
sequence/timeframe of cell biological events occuring in hepatocarcinogenesis (Figure 3, modified 
from [82]), individual hepatocellular carcinomas are highly heterogenous concerning the underlying 
etiologies, the molecular alterations and differentiation status of transformed cells, the proliferative and 
metastatic potential, the histological appearance and their integration in the systemic context (e.g. 
vascularization). Nevertheless, some pathophysiological mechanisms are suggested to be commonly 
involved in hepatocarcinogenesis (Figure 4). 
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Figure 3: Timeframe for the development of HCC 
 
 
 
Figure 4: Pathophysiological mechanisms involved in hepatocarcinogenesis (modified 
from [83]) 
 
3.2.2.2 Etiologies 
3.2.2.2.1 Hepatotropic viruses and their role in heaptocarcinogenesis 
3.2.2.2.1.1 Hepatitis B virus... 
3.2.2.2.1.1.1 ...from the epidemiologist's point of view 
Hepatitis B virus (HBV) infection is one of the major risk factors for the development of HCC. About 
30-50% of HBV-related deaths can be attributed to HCC [83, 84]. However, just a minor proportion of 
HBV-positive individuals develop cirrhosis and of those only 5% end up with HCC 
  22  
(www.who.int/csr/disease/hepatitis/). The majority of acute HBV infections delivers alternative clinical 
outcomes and is overcome by up to 95% of individuals (Figure 5). However, there are about 350 
million people infected chronically and about 75% of the world's population lives in areas with high 
infection levels (www.who.int/csr/disease/hepatitis/) (Figure 6). 
 
 
Figure 5: Clinical outcomes of acute HBV infections (modified from [85]) 
 
 
Figure 6: Geographic distribution of chronic HBV infections (adapted from CDC
1
) 
 
                                                     
1
 Centers for Disease Control and Prevention 
  23  
3.2.2.2.1.1.2 ...from the virologist's point of view 
HBV is a small partially double-stranded DNA virus of the hepadnaviridae family [86]. The viral 
genome encodes proteins involved in replication (reverse transcriptase/DNA polymerase (pol), 
kinase), structural proteins (the capsid proteins HBc and HBe (core), envelope proteins L, M, S), and 
HBx, which fosters viral replication and transcription. The morphology of an infectious HBV particle is 
depicted in figure 7.  
 
 
Figure 7: Morphology and life cycle of HBV 
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The 'life cycle" of HBV (Figure 7): Infection is initiated by the binding of an HBV particle to a receptor at 
the cell surface of hepatocytes (possibly transferrin receptor, asialoglycoprotein receptor, liver 
endonexin). Then, the nucleocapsid enters the cell via a yet unkown mechanism and uncoats near the 
nucleus delivering the viral genome. The covalently bound HBV polymerase mediates its transport into 
the nucleus and completes subsequently the viral genome yielding a covantly closed circular (ccc) 
supercoiled DNA which serves as transcription template for viral RNAs and semiconservative 
replication. After poly-adenylation, the four primary transcripts (pgRNA (pregenomic RNA, 3.5 kb), 2.4 
kb, 2.1 kb, 0.7 kb) are transferred to the cytoplasm where translation of viral proteins takes place. The 
pregenomic RNA, DNA polymerase, and kinase are packaged into newly formed nucleocapsids for the 
conversion of viral RNA into genomic DNA. The latter process involves reverse transcription of RNA to 
DNA, DNA-dependent DNA polymerase activity, and nuclease activity for degradation of the original 
RNA template, all of which are accomplished by the multifunctional viral DNA polymerase. The new 
viral nucleocapsids can follow two alternative pathways leading either to the amplification of viral DNA 
or to the release of HBV virions. For amplification, nucleocapsids are reuncoated for the release of 
viral DNA which follows the way described for primary infection (see above). The virion assembly 
pathway comprises the integration of the envelope proteins (L, M, S) into the ER membrane and the 
budding of nucleocapsids into the ER gaining the native viral envelope. Viral particles are released via 
the cellular secretion pathway. Informations concerning the viral 'life cycle' were gathered from 
www.who.int/csr/disease/hepatitis/ (see also citations therein). 
 
3.2.2.2.1.1.3 … and hepatocarcinogenesis 
Hepatitis B virus DNA is capable of integrating into the host genome and is indeed commonly detected 
in cells isolated from HBV-associated HCCs. However, the impact of this mechanism on 
hepatocarcinogenesis is not clear yet. Integration is invariably associated with deletions and mediates 
secondary genomic rearrangements like translocations, inversions, deletions and possibly 
amplifications [87, 88]. However, contradictory results concerning the site-specificity of integration and, 
hence, the targeted activation of distinct proto-oncogenes have been reported [87, 89]. Although no 
preference for distinct pathways has been identified, cancer-relevant genes such as telomerase 
reverse transcriptase (TERT), platelet-derived-growth-factor receptor-β (PDGFRβ), mitogen activated 
protein kinase 1 (MAPK1), tumor suppressor genes, and genes for apoptosis control have been found 
to be affected disproportionately [90].  
HBx transactivates the expression of genes involved in cell cycle control and proliferation (e.g. Ras, 
Raf, MAPK, c-fos, c-jun, c-myc, EGF) [91-95] and can bind to and inactivate the tumor suppressor and 
master regulator of the DNA damage-checkpoint control, p53, which further fosters the accumulation 
of mutations [96]. In addition, there are indications for the X-mediated modulation of Ca-signaling and 
the consequent activation of Ca-dependent kinases (e.g. Pyk2) as well as the activation of protein 
kinase C (PKC), both pathways possibly leading to the activation of e.g. NFκB [97, 98].  
The envelope protein L has proved to be hepatotoxic and sufficient for inducing hepatocarcinogenesis 
[99, 100]. It is hypothesized that ER stress is at the basis of the observed carcinogenic effect. The 
overexpression and, hence, intracellular accumulation of viral glycoproteins induces ER stress which 
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in turn predispose cells to transformation [101]. The endoplasmic reticulum (ER) of hepatocytes is 
crucial for the assembly of HBV particles by providing the lipid membrane with integral viral proteins L, 
M, and S for the constitution of the viral envelope (Figure 7). Direct interaction of provirus particles with 
the ER [102] or the overloading of the cellular secretion apparatus induces ER stress and lead 
eventually to oxidative stress which can consequently stimulate growth- and survival signaling 
pathways, cause mutations due to free radicals, and activate stellate cells [103, 104]. 
Persistent rounds of hepatocyte necrosis, inflammation, and regeneration due to chronic active 
infections are supposed to contribute decisively to carcinogenesis (Figure 4) [103, 105]. Apart from 
inefficient virus particle clearance by the host immune system, mutations of HBV might lead to their 
retention within hepatocytes eventually leading to cellular damage and liver disease [106]. 
 
3.2.2.2.1.2 Hepatitis C virus... 
3.2.2.2.1.2.1 ...from the epidemiologist's point of view 
Hepatitis C virus (HCV) infection is a considerable risk factor for the development of chronic hepatitis, 
liver cirrhosis, and HCC. Unless HBV, the majority of acute HCV-infections (60-80%) end up in a 
chronic disease state. There is currently no preventive vaccine available and today’s standard therapy 
has only low efficacy. It is consequently expected that the number of HCV-infected individuals will 
further increase over the next 20 years and with that the incidences for liver cirrhosis and HCC [107-
109]. The geographical distribution of the prevalence of HCV infection is depicted in figure 8. HCV-
infection increases the risk to develop HCC 17-fold [110].  
 
 
Figure 8: Geographical distribution of the prevalence of HCV infection (from CTLT
2
) 
 
                                                     
2
 Center for Transforming Learning and Teaching 
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3.2.2.2.1.2.2 ...from the virologist's point of view 
HCV is a member of the flaviviridae family. Its positive-strand RNA genome encodes the core protein 
and two envelope proteins (E1 and E2) as well as a number of non-structural proteins comprising p7 
ion channel, the NS2-3 protease, the NS3 serine protease and RNA helicase, the NS4A polypeptide, 
the NS4B and NS5A proteins, and an RNA-dependent RNA polymerase (NS5B) [109].  
 
The ‘life cycle’ of HCV: HCV exists in various forms in the systemic circulation. It can be associated 
with low-density lipoprotein (LDL) and very-low-density-lipoprotein (VLDL) as well as bound to 
antibodies or circulate as free virion [111]. Several receptors have been proposed to mediate viral 
binding to the host cell surface including CD81 [112], the LDL receptor (LDLR) [113], SR-BI [114], and 
claudin-1 [115]. There are indications that they act cooperatively to allow viral attachment and 
subsequent entry into the host cell. HCV is internalized via clathrin-mediated endocytosis [116] and 
passes subsequently through endosomal compartments with decreasing pH (Figure 9) [117, 118].  
 
 
Figure 9: Mechanism of HCV cell entry (from [109]) 
 
The low pH triggers the fusion of the viral envelope and the endosomal membrane resulting in the 
release of the viral capsid into the cytoplasm. After uncoating, the 9.6-kb positive RNA genome is 
translated in an IRES-dependent manner and delivers a (potential) polyprotein which is co- and 
posttranslationally processed. The expression and processing of viral proteins strongly depends on 
the cellular machinery including e.g. translation initiation factors or ER signal peptidase, respectively. 
Amplification of viral genomic RNA occurs through the viral replication complex which is functionally 
associated with the host’s endoplasmic reticulum. At those sites, the shape and structure of the 
endoplasmic reticulum is drastically altered [119]. Several host factors contribute to productive 
replication. It has been shown that HCV replication is stimulated by saturated fatty acids and 
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decreased by polyunsaturated fatty acids or by inhibition of fatty acid synthesis indicating the 
importance of lipid metabolism [109]. Moreover, cellular cyclophilin B, a peptidyl-prolyl cis-trans 
isomerase, fosters replication by stimulating the RNA binding activity of NS5B. Recently, it has been 
shown that FKBP8 (FK506-binding protein 8) and Hsp90 regulate viral replication by forming a 
complex with NS5B [120].  
The late steps of HCV infection- packaging, assembly, particle release- is still obscure. Presumably, 
viral release occurs similar to that of HBV by budding into the ER and exiting through the secretory 
pathway. An overview of the infectious cycle is depicted in figure 10. 
 
 
Figure 10: Lifecycle of HCV (from [109]) 
 
3.2.2.2.1.2.3 … and hepatocarcinogenesis 
Mechanisms and proteins contributing to HCV-induced metabolic alterations and 
hepatocarcinogenesis: HCV infection is a major cause for liver injury such as steatosis, fibrosis, 
cirrhosis, and hepatocarcinogenesis. The impact of viral proteins on the latter, however, is still unclear 
considering the generally long latency of HCC in the face of a persistent infection (figure 3). However, 
epidemiologic studies proved differences in terms of hepatitis progression and tumor promotion 
caused by HCV and HBV infections concerning the incidence of and the predictive parameters for 
HCC development, the proportion of cirrhosis among individuals suffering from HBV- and HCV-
mediated HCC (50% vs. 70%), and the three-year-survival rates [121, 122]. At least three HCV 
proteins feature oncogenic potential by modulating cancer-relevant signaling pathways (see below). 
Accordingly, the carcinogenesis rate due to HCV infection has been shown to be significantly higher 
than due to HBV [122]. In addition, liver fibrosis is suggested a major risk factor and predictor for HCV- 
rather than for HBV- associated hepatocarcinogenesis [122]. This might indicate that the substantial 
tissue alterations occurring in consequence of liver injury play distinct roles in hepatocarcinogenesis 
with respect to the underlying viral etiologies albeit they are indisputably pivotal for HCC development 
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in general (Figure 4). Therefore, it is appropriate to regard HCC as the product of a complex interplay 
between viral and host factors, both contributing to a microenvironment susceptible for cancer 
progression. 
HCV vs. host immune system- persistent infection and collateral damage of the liver: Unlike 
HBV, HCV does not integrate into the host genome. Instead, persistent infection is established by 
interfering with and modulating the antiviral immune defense, in particular many parts of the adaptive 
immune system.  
HCV inhibits the trafficking machinery of cells and therewith prevents the release of cytokines (e.g. 
interferon-β) and the presentation of MHC class I-molecules loaded with viral proteins, both of which 
triggering the host immune response. Interferon-β is secreted by virus-infected cells and plays a 
crucial role for the antiviral defense. Binding to its receptor on the surface of cells enhances the 
synthesis of proteasomal and MHC class I proteins for antigen-presentation to T-cells as well as that 
of miRNAs inhibiting the translation of viral RNA [123, 124]. At least two viral proteins, NS4A/B 
precursor and NS5A, are involved in reducing the rate of ER to Golgi transport and, hence, attenuate 
cellular secretion performance [125]. Mechanistically, NS5A annexes TBC1D20, a Rab-GTPase 
activating protein for Rab1, to the viral-replication complex and prevents its normal cellular function in 
ER-Golgi transport [126, 127].  
HCV abrogates efficiently viral detection by infected hepatocytes and hinders consequently the onset 
of defense mechanisms such as the transcriptional activation of IFNs. In general, sensing of viral 
invaders is achieved by pathogen-recognition receptors (PRRs) which recognize pathogen-associated 
molecular patterns (PAMPs) like double-stranded RNA [128]. In hepatocytes, RIG-I activation by viral 
RNA triggers its binding to IPS-1 (IFN promotor stimulator 1) resulting eventually in transcription of IFN 
[129]. IPS-1 localizes to the mitochondrial membrane which has proved to be critical in this context. 
The NS3-4A protease cleaves IPS-1 which leads to the release from the mitochondrial membrane and 
thereby prevents RIG-I signaling [128, 129]. Futhermore, NS3-4A targets TRIF (Toll-interleukin-1 
receptor domain-containing adaptor inducing IFN) which is involved in signaling via TLR3, an 
additional sensor of viral infection. Hence, NS3-4A contributes decisively to the impairment of the 
host's first-line defense against viral invasion [130]. 
Apart from interfering with antiviral mechanisms of hepatocytes, HCV induces alterations of the 
immune response at the systemic level as well. Plasmacytoid dendritic cells, a subtype of dendritic 
cells occurring in blood and peripheral lymphoid organs, are capable to sense efficiently viral invasion 
and respond to it with the secretion of type I interferons (IFN-α, IFN-β). The HCV core protein, 
released into the systemic circulation, is implicated in the reduction of the number and the attenuation 
of the activatability of these cells and by means of that exerts a general immunosuppressive effect 
[131, 132].  
It is supposed that HCV affects globally the virus-induced cytokine expression profile which is crucial 
for the onset of an appropriate immune response including the activation and expansion of T-cells as 
hub of the adaptive immune system [133-135]. 
Interference with host cell-mediated antiviral defense mechanisms: IFN is a pivotal trigger for the 
onset of the cellular antiviral defense. It acts via the Jak-STAT pathway and eventually leads to the 
transcriptional activation of IFN-regulated genes such as PKR (protein kinase R), Mx proteins, and 
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RNase L. HCV replication strongly depends on the host cell endoplasmic reticulum which is 
consequently overloaded with viral proteins. Host cells react to that with the induction of the ER stress 
response which manifests in the upregulation of proteins for resolving this potentially harmful 
condition. One of those proteins is PP2A, a phosphatase involved in cell-cycle regulation and signaling 
and an effective inhibitor of the Jak-STAT pathway [136-139]. 
PKR shuts down protein synthesis and, hence, inhibits translation of cellular and, most notably, viral 
RNA. The HCV proteins, E2 and NS5A, are known to prevent PKR activation [139, 140].  
The contribution of HCV proteins- C, NS3, and NS5A- to hepatocarcinogenesis is 
comprehensively treated by Kasprzak and Adamek [141]. Those proteins affect many cell biological 
functions by modulating a broad variety of signaling pathways.  
The core protein (C) is the structural component constituting the HCV-nucleocapsid in which viral 
genomic RNA is encapsidated. Intracellularly, it is found on ER membranes, in membranous webs, on 
the surface of lipid droplets and in the nucleus [109]. The association with lipid droplets fosters the 
folding of C, might play a role in viral replication/virion morphogenesis, and is suspected to alter 
cellular lipid metabolism and hence to contribute to liver steatosis [109, 142, 143].  
Moreover, there are indications that it contributes to the establishment of persistent HCV infection and 
to transformation of hepatocytes and hence development of HCC. Several reports suggest that the 
core protein interferes with TNFα signaling. TNFα is a proinflammatory cytokine secreted by activated 
macrophages and T-cells and plays a pivotal role for the eventual clearance of viral infected cells by 
inducing FAS-mediated apoptosis [103]. The core protein prevents TNFα/FAS-mediated apoptosis by 
interacting with the cytoplasmic domains of TNFRI, lymphotoxin B receptor, and gC1q receptor [144-
147]. Furthermore, it modulates signaling upon proinflammatory stimuli by targeting transcription 
factors involved in immune response and proliferation such as NFκB and AP-1. Ectopic expression of 
the core protein has been shown to inhibit NFκB activation by preventing degradation of its inhibitor 
IκB whereas AP-1 is constitutively activated via JNK and MAPKK [148]. Moreover, core protein-
induced activation of ERK, JNK, and MAPK enables growth-factor (EGF, TGF-α) independent 
proliferation, a hallmark of cancer [149, 150]. However, there are indications that NFκB is rather 
upregulated and activated as has been shown in HCV core protein-transfected liver cells and in 
hepatocytes from chronically infected patients [151]. NFκB is frequently upregulated and activated in 
tumor tissue suggesting its role in hepatocarcinogenesis [152]. Indeed, core protein-expressing 
transgenic mice show increased HCC rates [153].  
NS3 is a non-structural multifunctional viral protein. It has protease, helicase, and NTPase activity 
[154]. In addition, it can translocate to the nucleus and bind to histones thereby interfering with PKA-
mediated histone phosphorylation [155]. However, NS3 mainly resides in the cytoplasm and the ER of 
infected hepatocytes [156, 157]. Cytoplasmic NS3 prevents translocation of PKA into the nucleus and 
hence histone phosphorylation and might interfere with other PKA-mediated functions as well [155].  
NS3 expression is sufficient to induce cell transformation in vitro [158, 159]. It is suggested that this 
effect is partially mediated by the protease activity which possibly degrades regulatory proteins [141]. 
In addition, NS3 can induce the activation of MAPK and JNK, foster DNA-binding activity of AP-1, and 
enhance c-jun expression [160, 161]. The NS3 protein binds to and affects the activity to p53 leading 
to the inhibition of p21 transcription, enhanced proliferation, and to the inhibition of apoptosis [162, 
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163]. NS3 secreted by infected hepatocytes can activate stellate cells which manifests in the 
augmented secretion of chemokines and TGF-β. The latter is a pro-fibrogenic factor which fosters 
collagen deposition by stellate cells eventually leading to liver fibrosis [164, 165].  
NS5A is a component of the viral replicase and implicated in HCV-induced carcinogenesis. It serves 
as a transcription activator for many genes. A disproportionately high number contain NFκB-binding 
sites in their promotors suggesting a crucial role of NS5A-induced NFκB activation [166]. The latter is 
suggested to prevent apoptosis and hence to contribute to hepatocarcinogenesis. The anti-apoptotic 
effect of NS5A is mediated by the inhibition of caspase-3 activation as well as poly(ADP-ribose) 
polymerase cleavage in TNFα-treated cells [167]. NS5A transcriptionally represses p21 in a p53-
dependent manner [168, 169].  
 
3.2.2.2.2 Dietary carcinogens and tumor promotors 
 
3.2.2.2.2.1 Alcohol 
Chronic alcohol intake induces fibrosis, cirrhosis, and increases the risk for hepatocarcinogenesis. 
Several mechanisms are supposed to contribute decisively to alcohol-induced pathophysiological 
alterations including the activation of cells of the innate immune system and the steady elevation of 
oxidative stress.  
Chronic alcohol consumption entails the activation of monocytes which in turn produce pro-
inflammatory cytokines like TNF and IL-8 as well as decreased levels of the antiinflammatory IL-10 
[170]. Moreover, alcohol sensitzes Kupffer cells to endotoxins delivered by the portal vein which 
causes the activation of LPS-responsive signaling pathways (TLR-4) and the consequent upregulation 
of proinflammatory cytokines and chemokines (TNFα, IL-1β, IL-6) [171, 172]. This effect might be 
further enhanced by the increased amount of endotoxins getting into the circulation due to the alcohol-
induced damage of the mucosa of the gastrointestinal tract [173]. In this context, the effect of chronic 
inflammation is further exacerbated by the increased sensitivity of hepatocytes to TNFα-mediated 
cytotoxicity [172].  
 
3.2.2.2.2.2 Aflatoxin B1 
Ingestion of aflatoxin B1-contaminated food increases the risk for the development of HCC. Aflatoxin 
B1 is a mycotoxin produced by Aspergillus flavus and parasiticus which infect crop particularly in warm 
and humid climates. Aflatoxin B1 is metabolized to aflatoxin M1 by hepatocytes. The latter is a highly 
reactive epoxide which forms DNA-adducts that might eventually lead to mutations. Indeed, the 
mutagenic activity seems to be the primary mechanism for the initiation of hepatocarcinogenesis since 
exposure does not correlate with cirrhosis incidence in contrast to other HCC etiologies [83]. Aflatoxin-
induced development of HCC is frequently associated with a specific mutation of p53, whereas the ras 
gene seems to be not affected by aflatoxin [174]. The co-occurence of aflatoxin and HBV increases 
the risk for liver cancer 4-10-fold compared to the carcinogenic effect of the single agents. 
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3.2.2.3 Common molecular themes in hepatocarcinogenesis- TP53 
 
The signaling pathways involved in HCC-tumor development, progression, and invasion have been 
comprehensively discussed by Zender et al. [175]. However, the tumor suppressor p53 occupies a 
central role by being functionally compromized in most human cancers and is indeed a common 
feature of hepatocellular carcinoma irrespective of the causative factor.  
The failure to accomplish its tasks contributes to the manifestation of well-defined tumor 
characteristics [32]. However, there are distinct mechanisms leading to its malfunction by interfering 
with the regulatory circuit controlled by p53 (Table 2, from [176]).  
 
Mechanism of inactivating p53 Typical tumors Effect of inactivation 
Amino-acid-changing mutation in the 
DNA-binding domain 
Colon, breast, lung, bladder, brain, 
pancreas, stomach, oesophagus 
and many others 
Prevents p53 from binding to 
specific DNA sequences and 
activating the adjacent genes 
Deletion of the carboxyterminal 
domain 
Occasional tumors at many different 
sites 
Prevents the formation of tetramers 
of p53 
Viral infection Cervix, liver, lymphomas 
Products of viral oncogenes bind to 
and inactivate p53 in the cell, in 
some cases stimulating p53 
degradation 
Deletion of the p19ARF gene 
Breast, brain, lung and others, 
expecially when p53 is not mutated 
Failure to inhibit MDM2 and keep 
p53 degradation under control 
Mislocalization of p53 to the 
cytoplasm, outside of the nucleus 
Breast, neuroblastomas 
Lack of p53 function (p53 functions 
only in the nucleus) 
Genomic multiplication of the MDM2 
gene 
Sarcomas, brain 
Extra MDM2 stimulates the 
degradation of p53 
Table 2: Mechanisms involved in the inactivation of p53 
 
The transcription factor p53 occupies center stage in an extended molecular network connecting 
pathways for cell-cycle control, apoptosis, DNA repair, and blood-vessel formation. It is activated upon 
cellular stress and damage induced by DNA double-strand breaks (e.g due to ionizing radiation), 
aberrant growth signals, as well as chemotherapeutics, phosphatase inhibitors, and UV radiation 
[176]. Although three distinct pathways are involved in sensing and signaling of those potentially 
harmful cellular conditions, all of them bring about the stabilization and hence an increase in 
concentration of the otherwise short-lived and latent p53.  
The abundance of p53 is principally regulated by the rate of its degradation. Under normal conditions 
p53 exists as heterodimer with MDM2, an E3 ubiquitin-protein ligase, which tags it for ubiquitin-
mediated proteolysis. Moreover, p53 serves as a transcriptional activator for MDM2 which in turn 
affects half-life of p53. This feedback loop allows the maintenance of a constantly low base level of 
p53 and provides concomittantly a rapid mechanism to increase its concentration and hence to adapt 
to cellular stress by factors interfering with MDM2-mediated degradation. This is the principal avenue 
pursued by pathways leading to p53 stabilization described below.  
However, additional regulatory levels are implemented controlling transcriptional activity of p53. An 
important role for p53 function play conformational changes triggered by the attachment or removal of 
functional groups like phosphate, acetyl, glycosyl, ubiquitin, methyl, NEDD (an ubiquitin-like protein), 
or sumo [177-180]. The carboxyterminus of p53 normally covers its DNA-binding domain inhibiting its 
transcription factor activity. Acetylation and phosphorylation at the carboxyterminus are supposed to 
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interfere with this folding and hence release the block of DNA-binding as basis for the observed 
increase of transcriptional activity. Although a consensus sequence in the promotor region of p53 
target genes exists, unique combinations of posttranslational modifications of p53 might provide the 
basis for the temporal and contextual finetuning of p53-mediated gene expression as proposed by 
Kruse and Gu [180].  
Crucial components of the pathway triggered by DNA double-strand breaks are the checkpoint 
proteins ATM (ataxia telangiectasia mutated), DNA-dependent kinase, Chk1, and Chk2 (Checkpoint 
kinases 1 and 2) [181]. All of these kinases, once activated by DNA damage, are capable to 
phosphorylate p53 in the proximity to its MDM2-binding region, thereby preventing interaction with 
MDM2 and hence ubiquitin-mediated proteolysis. However, there are indications that an alternative 
mechanism for p53 stabilization might exist in this context [177-179, 182]. 
Aberrant expression of oncogenes like Ras and Myc activate p53 via p14
ARF
, a product of the Ras-
responsive INK4a/ARF tumor supppressor locus [183, 184]. Those oncogenes increase the 
concentration of p14
ARF
 by stimulating its transcription or by stabilizing the protein. Two cooperatively 
acting or alternative mechanisms are involved to protect p53 from MDM2-dependent degradation. 
P14
ARF
 directly binds to and inactivates MDM2. In addition, P14
ARF
 mediates the sequestration of 
MDM2 in the nucleolus, a subcompartment of the nucleus dedicated to ribosomal biosynthesis, and 
hence spatially prevents its interaction with p53 which remains outside of the nucleolus. However, 
p16
INK4a
, an antagonist of cyclin D-dependent kinases, has to be expressed concomittantly for effective 
cell cycle arrest due to oncogenic Ras [185].  
The third pathway is triggered by chemotherapeutics, phosphatase inhibitors, and UV light and does 
not depend on the afore-mentioned factors for p53 activation (ATM, Chk2, p19
ARF
). In this context, the 
kinases ATR (ataxia telangiectasia related) and casein kinase II are considered to be the crucial 
signaling components [186]. 
The main function of activated p53 is the transcriptional activation of target genes which is prevented 
or compromized by all mutations known to occur in p53 [187, 188]. The first effect of p53 expression is 
the cell-cycle arrest. One of the target genes upregulated by p53 is p21
WAF1/CIP1
, an inhibitor of cyclin-
dependent kinases (CDKs) which, together with cyclins, drive cell cycle progression. Inhibition of 
CDKs leads to a block at the G1-to-S and G2-M checkpoints [176]. 14-3-3σ, another p53-dependent 
protein, participates in the maintenance of the G2 arrest by sequestering the cyclin B1- CDK1 complex 
in the cytoplasm [189, 190]. The impact of 14-3-3σ on the anti-proliferative effect of p53 is underlined 
by the observation that its inhibition is sufficient to induce indefinite proliferation in epithelial cell culture 
[191]. 
Another effect of p53 expression is the transcriptional activation of apoptosis-inducing proteins, such 
as Bax [192], NOXA [193], and P53AIP1 [194] or PIDD, a 'death signal'-receptor [195]. An alternative 
mechanism of apoptosis-induction might be the p53-mediated stimulation of mitochondria to produce 
ROS (reactive oxygen species). 
P53 is also involved in preserving genetic stability by inducing gene expression of components for 
DNA-repair (e.g. nucleotide-excision repair, recombination, chromosome segregation) [196, 197]. 
Moreover, it prevents the expression of genes triggering vascularization and inhibits angiogenesis 
[198, 199], a characteristic feature of tumor suppressors [200]. 
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3.3 The liver 
 
3.3.1 General remarks 
 
The liver is a prime example for complexity at many organization levels. Its enormous metabolic 
capacity is sustained by a variety of different cell types, spatially organized to small hexagonal 
functional units which, in their collectivity, constitute the largest gland and the most versatile organ of 
the human body. The liver is anatomically and functionally associated with the small intestinum. It 
serves as a filter for blood leaving the digestive tract via the portal vein before entering the systemic 
circulation. Hence, most absorbed compounds like nutrients (carbohydrates, amino acids, lipids), 
vitamins, ions, drugs or toxicants pass through the liver where they are metabolized, stored and/or 
released into the blood, (de)toxified and/or excreted into bile. Thus, the liver is crucial for the 
maintenance of metabolic homeostasis of the body and protection against potentially harmful 
substances.  
The high demands and its key position in metabolism require mechanisms to compensate for damage 
or loss of tissue. Indeed, the liver features an outstanding potential for regeneration which implies the 
ability of cells to dedifferentiate, proliferate, and redifferentiate in a temporally and spatially highly 
coordinated manner to recover full functionality. However, exuberant and/or permanent damage of 
liver tissue overloads or compromizes the fidelity of the regeneration process consequently leading to 
the loss of liver parenchyme (cirrhosis) or disproportioning of liver cell types by deposition of 
connective tissue (fibrosis). In addition, chronic or repetitive liver injury inducing persistent rounds of 
necrosis and regeneration associated with the obligatory activation of physiological mechanisms 
involved in defense and repair (inflammation, oxidative stress) lay also the (micro-) environmental 
basis for the initiation and/or progression of primary liver cancer and are, indeed, considered as 
common molecular prerequisites for hepatocarcinogenesis almost irrespective of its etiology (see 
figure 4). 
 
3.3.2 Microstructure of the liver and hepatocytes and how they account for liver 
physiology and function 
 
3.3.2.1 Liver parenchyme- hepatocytes 
Hepatocytes constitute about 70% of the overall liver volume and partially contain two nuclei or are 
tetraploid (age-dependently). The pronounced polarization of these epithelial cells and their 
arrangement in plates (Muralium simplex-architecture) provide the structural basis (concerning 
surface-volume ratio) for directed and regulated exchange processes. For that, two distinct 
compartments are in close contact with and are spatially separated by hepatocytes, the liver sinusoids 
as specialized part of the vascular system and the bile canaliculi derived from the apical cell surfaces 
of adjacent hepatocytes of the muralium simplex. The sinusoids are capillaries with an inner width of 
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up to 15 µm and are composed of extensively fenestrated endothelial cells lacking a basal membrane. 
This discontinous endothel (10-50 pores/ µm2) enables free access of blood components apart from 
blood cells and chylomikrones to the perisinusoidal space (space of Disse), the space between the 
sinusoidal lining cells and the microvilli-containing basal membrane of hepatocytes (extended surface 
area). The sinusoids receive oxygen-deprived, nutrient-enriched blood from the capillary bed of the 
gastrointestinal tract via the portal vein (Vena portae) as well as oxygenated blood via the liver artery 
(Arteria hepatica propria). On its way towards the central vein of the lobuli the blood serum enters the 
space of Disse, comes into contact with the hepatocytic cell surface where exchange processes occur 
and consequently its composition is drastically altered due to the metabolic and synthetic performance 
of hepatocytes. The blood is eventually released again into the systemic circulation via the Venae 
hepaticae. 
 
3.3.3 Other cell types of the liver 
 
3.3.3.1 The sinusoidal lining cells 
The sinusoids are built from fenestrated sinusoidal endothelial cells. They constitute sieve plates with 
10-50 pores/ µm2. 
 
3.3.3.2 Endothelial cells 
The pore size of endothelial cells is regulatable by serotonin. They synthesize v.Willebrand factor and 
contain heparin-releasable lipase, a clearing factor for lipoproteins which are consequently clathrin-
dependently endocytosed. 
 
3.3.3.3 Kupffer cells 
Kupffer cells are immigrated yolk sac or bone marrow macrophages. They are phagocytotic cells 
crucial for the clearance of immune complexes (via Fc-receptors, Crb-receptors), protease-
antiprotease complexes (e.g. thrombin-antithrombin), old erythrocytes, endotoxin or bacteria and 
lysosomal enzymes derived from peripheral tissue degradation. In addition, they serve as antigen-
presenting cells and participate in inflammation by producing e.g. IL-1 and IL-6. 
 
3.3.3.4 Stellate cells 
Stellate cells contribute to normal liver function constituting approximately 1/3 of non-parenchymal 
cells or 15% of the total number of resident cells of the normal liver and mediate fibrosis following liver 
injury. They are located in the subendothelial space, are typically spindle-shaped with prominent 
dendritic processes extending beneath endothelial cells and wrapping around sinusoids. These 
projections bear numerous spines making contact to hepatocytes on the lumenal side facilitating 
intercellular transport of soluble mediators and cytokines. Moreover, direct connections to nerve 
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endings might be important for neurally mediated vasoregulation. Stellate cells are the primary storage 
of vitamin A (histologically visible droplets). 
Following liver injury, they are activated and consequently transdifferentiate into myofibroblasts, a 
process mainly triggered by Kupffer cells and cytokines (e.g. IL-1, TGF-β). Protein synthesis and 
secretion performance is increased reflected by the enlargement of the rough endoplasmic reticulum 
and Golgi apparatus. Indeed, they synthesize collagen type I and III, dermatan- and heparan-sulfate 
and matrixproteins (fibronectin, laminin) as well as PDGF receptor (platelet-derived growth factor 
receptor) and α-smooth muscle actin. 
 
3.3.4 Metabolic and synthetic performance of hepatocytes and their role in the 
systemic/physiological context 
 
3.3.4.1 Carbohydrate homeostasis 
The liver plays a crucial role in glucose homeostasis by equilibrating resorption/postresorption phase-
derived fluctuations of glucose in blood plasma. An elevation of plasma levels of energy-rich 
compounds leads to an increased secretion of insulin and reduced synthesis of glucagon by β-cells 
and α–cells of the pancreatic Langerhans’ island, respectively. The increased insulin-glucagon ratio 
consequently forces their uptake and storage by hepatocytes. Glucose as well as fructose and 
galactose after being converted into glucose are stored as glycogen. In the postresorption phase the 
insulin-glucagon ratio is inverted triggering the mobilization of the glycogen depot and the release of 
free glucose into the systemic circulation. In the case of complete glycogen deprivation due to a 
prolonged starvation period, the liver performs gluconeogenesis from lactate and glycerine (products 
of glycolysis (Cori cycle) and lipolysis) as well as from glucogenic amino acids in order to ensure the 
glucose supply for erythrocytes, the central nervous system, and the Medulla renalis. Cortisol is the 
main signaling molecule which induces an increase of the activity of enzymes involved in 
gluconeogenesis and amino acid metabolism and a decrease of those involved in glycolysis.  
 
3.3.4.2 Lipid metabolism 
A main function of the liver in the resorption phase is the biosynthesis of triacyl glycerines, 
phosphoglycerides, and sphingolipids from dietary carbohydrates and lipids (degradation of LDL- and 
HDL-lipoproteins) as well as the biosynthesis and secretion of VLDL-lipoproteins. Depending on the 
availability of cholesterin, it also synthesizes and thereof provides cholesterin for the organism. In the 
postresorption phase, energy for hepatocytes is gained by fatty acid oxidation. Excess fatty acids are 
metabolized to keton bodies in order to cover the energy requirements of extrahepatic tissues. 
 
3.3.4.3 Amino acid metabolism 
Amino acids from nutriental proteins (resorption phase) as well as those released by protein 
degradation in extrahepatic tissues (postresorption phase) are taken up via a variety of amino acid 
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transporters of the cell membrane of hepatocytes. Glucogenic amino acids are used for 
gluconeogenesis whereas ketogenic amino acids serve as anaplerotic substrates for the citrate cycle 
following deamination. Ammonium is detoxicated in the urea cycle by conversion to urea, a speciality 
of hepatocytes, and consequently renally excreted. In the course of this process bicarbonate ions are 
needed which is a key metabolite for the regulation of the pH of blood. Indeed, the urea cycle is 
reduced in the case of acidosis. Under those conditions ammonium is fixed by the conversion of 
glutamate to glutamine by glutamine synthetase in order to avoid toxic effets. 
 
3.3.4.4 Protein metabolism 
Hepatocytes synthesize and release plasma proteins like coagulation factors, protease inhibitors (e.g. 
α1-antitrypsin, α-2-makroglobulin), transport proteins (e.g. transferrin, albumin) into sinusoids as well 
as prohormones (angiotensinogen, kininogen) and acute phase proteins. The latter increase 2- 1000-
fold 6-48 h after infection upon stimulation via IL-1 and IL-6 released by macrophages, endothelial 
cells, and fibroblasts and in the presence of glucocorticoids. Moreover, hepatocytes participate in the 
lysosome-mediated degradation of proteins, especially glycoproteins which are bound and internalized 
via the asialoglycoprotein receptor. 
 
3.3.4.5 Storage of vitamins and trace elements 
Hepatocytes contain significant amounts of water-soluble vitamins (e.g. thiamin, folic acid, vitamin 
B12, biotin). In addition, the liver hydroxylates vitamin D to the biologically active form 1,25-
Dihydroxycholecalciferol and converts thyroxin (T4) to triiodthyronin. The liver stores significant 
amounts of the trace elements iron and copper. 
 
3.3.4.6 Biotransformation- the liver as excretion organ 
The bile canaliculi comprise the second compartment of the liver. They unify to higher-order bile ducti 
and eventually end up in the ductus coledochus which discharge into the small intestine. The primary 
or liver bile is further modified by cholangiocytes in the course of its passage.  
Most xenobiotics, to which organisms are exposed, are lipophilic fostering absorption through epithelia 
and thereby hindering or retarding their elimination. Therefore, biotransformation processes for 
conversion to hydrophilic metabolites or derivatives are required to accelerate the excretion of 
potentially harmful substances. The intensity and duration of drug effects (pharmacodynamics) are 
largely determined by these processes. Hepatocytes express a variety of enzymes (constitutively or 
inducibly by xenobiotics) involved in biotransformation which characteristically feature broad substrate 
specificity by e.g. metabolizing endogenous substrates as well. They are divided into phase I and 
phase II enzymes reflecting the common two-stage biotransformation process. Phase I reactions 
expose or introduce functional groups (hydroxyl-, thiol-, carboxyl-groups) that largely constitute the 
molecular targets for phase II reactions (e.g. glucuronidation, acetylation) mediating the hydrophilic 
substance properties for biliary or urinary excretion.  
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4 Methods: Proteome analysis of liver and HCC tissues 
 
4.1 Tissue homogenization and cell lysis prior to proteome analysis 
 
For shotgun analysis, HCC and adjacent liver tissue samples (kept at -196°C) were thawed on ice, 
minced into small pieces, passed through a metal sieve of 80 µm mesh size, then through a 40 µm 
filter (Millipore), and were eventually homogenized using a tissue-grinder. All steps were performed at 
4°C and in the presence of protease inhibitors. Cells of the tissue homogenate were lysed in hypotonic 
lysis buffer (10mM HEPES/NaOH, pH 7.4, 0.25 M sucrose, 10 mM NaCl, 3 mM MgCl2, 0.5% Triton X-
100) supplemented with protease inhibitors and pressed through a 26 g syringe to induce cell lysis. 
The cytoplasmic fraction was separated from nuclei by centrifugation and precipitated by the addition 
of ethanol. Afterward, all protein samples were dissolved in sample buffer (7.5 M urea, 1.5 M thiourea, 
4% CHAPS, 0.5% SDS, 100 mM DDT) [36, 201], the protein mixture was pre-fractionated by PAGE 
and further processed for mass spectrometry analyses (see below). 
 
Metabolic labeling of tissue slices: Freshly resected human liver and HCC tissues were cut in slices of 
about 200 mm thickness, rinsed in Hank’s buffered saline solution (HBSS) and incubated in serum-
free, methionine and cysteine-free William’s E medium (ICN) in the presence of [35S]-labelled 
methionine and cysteine (Trans35- Slabel, Biomedica, MP Biomedicals) for 6 h at 377C. Supernatants 
were collected, filtered through a 0.22 mm filter (Millex-GP, Millipore, Billerica, MA, USA) to get rid of 
cell debris, soluble proteins were precipitated by the addition of ethanol. For the isolation of 
cytoplasmic proteins, all buffers were supplemented with protease inhibitors: PMSF (1 mm), aprotinin, 
leupeptin,and pepstatin A (each at 1 mg/mL). Cells were lysed in lysis buffer (10mM HEPES/NaOH, 
pH 7.4, 0.25 M sucrose, 10mM NaCl, 3mM MgCl2, 0.5% Triton X-100). The cytoplasmic fraction was 
separated from the nuclei by centrifugation and ethanol precipitated. Protein samples were dissolved 
in sample buffer (7.5 M urea, 1.5 M thiourea, 4%CHAPS, 0.5%SDS, 100mM DTT) and subjected to 
2D-PAGE. 
 
4.2 Separation of complex protein mixtures 
4.2.1 2D polyacrylamid gel electrophoresis 
Proteins were loaded by passive rehydration of IPG strips pH 5–8, 17 cm (BioRad, Hercules, CA) at 
room temperature. IEF was performed in a stepwise fashion (1 h 0– 500 V linear; 5 h 500 V; 5 h 500–
3500 V linear; 12 h 3500 V). After IEF, the strips were equilibrated with 100 mM DTT and 2,5 % 
iodacetamide according to the instructions of the manufacturer (BioRad). For SDS-PAGE using the 
Protean II xi electrophoresis system (BioRad), the IPG strips were placed on top of 1,5 mm 12 % 
polyacrylamide slab gels and overlaid with 0,5 % low-melting agarose. The gels were stained with a 
400 nM solution of Ruthenium II tris (bathophenanthroline disulfonate) (RuBPS) as described [202]. 
Fluorography scanning was performed with the FluorImager 595 (GE Healthcare, Fairfield, CT) at a 
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resolution of 100 µm. After scanning, the radioactively labeled gels were dried using the slab gel dryer 
SE110 (Hoefer, San Francisco CA, USA). After exposure to phosphor screens (Molecular Dynamics), 
the screens were scanned using the Phosphorimager SI (Molecular Dynamics) at a resolution of 100 
µm as previously described [1]. All 2-D gel data were independently reproduced for at least four times. 
Alternatively, gels were silver-stained, protein spots cut out of the gel and tryptically digested. After the 
trypitc digest of proteins the resulting peptides were mass spectrometrically analyzed and MS/MS data 
interpreted using the Spectrum Mill MS Proteomics Workbench software (see figure 11). 
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10- Q96AE4
15- P31040
21- P4974824- Q9H4M9
11- Q96AE4
 
Figure 11: Workflow for protein identification of 2D-PAGE- separated samples 
 
4.2.2 PAGE for subsequent shotgun analysis 
Cytoplasmic protein fractions were loaded on 12 % polyacrylamid gels, electrophoresis was performed 
until complete separation of a pre-stained molecular marker (Dual Color, Biorad, Hercules, CA) was 
visible. Gels were fixed with 50 % methanol/10 % acetic acid and subsequently silver stained as 
described below. Gel lanes were cut out of the gel and digested with trypsin as described below. 
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4.3 Selection and preparation of proteins for mass spectrometry 
4.3.1 MS-compatible silver staining procedure 
2D gels were fixed with 50 % methanol, washed and sensitized with 0,02 % Na2S2O3. The gels were 
stained with 0,1 % AgNO3 ice cold for 20 minutes, rinsed with bi-distillated water and subsequently 
developed with 3 % Na2CO3/0,05 % formaldehyde as previously described [203]. 
 
4.3.2 Tryptic digest 
Protein spots were cut out of the gel, the gel-pieces were destained with 15 mM K3Fe(CN)6/50 mM 
Na2S2O3 and intensively washed with 50 % methanol/10 % acetic acid. The pH was adjusted with 50 
mM NH4HCO3, and proteins were reduced with 10 mM DTT/50 mM NH4HCO3 for 30 minutes at 56°C 
and alkylated with 50 mM iodacetamide/50 mM NH4HCO3 20 minutes in the dark. Afterwards the gel-
pieces were treated with acetonitril and dried in a speedvac. Between each step, the tubes were 
shaken 5-10 minutes (Eppendorf Thermomixer comfort). Dry gel-spots were treated with trypsin 0,1 
mg/ml (Trypsin sequencing grade, Roche Diagnostics, Germany)/50 mM NH4HCO3, in a ratio of 1:8 for 
20 minutes on ice, afterwards covered with 50 mM NH4HCO3 and were subsequently incubated over 
night at 37°C. The digested peptides were eluted by adding 50 mM NH4HCO3, the supernatant was 
transferred into silicon-coated tubes, and this procedure was repeated two times with 5 % formic 
acid/50 % acetonitril. Between each elution step the gel-spots were ultrasonicated for 10 minutes. 
Finally the peptide solution was concentrated in a speedvac to an appropriate volume. 
 
4.4 Mass Spectrometry analysis 
 
For the identification of 2D spots, peptides were loaded on a Zorbax 300SB-C8 (5 µm, 0,3 mm, 5 mm) 
column and separated by nanoflow LC (1100 Series LC system, Agilent, Palo Alto, CA) with a Zorbax 
300SB-C18 (5 µm, 75 mm, 150 mm) column at a flow rate of 250 nl/min using a gradient from 0,2 % 
formic acid and 3 % acetonitrile (ACN) to 0,2 % formic acid and 45 % ACN over 12 minutes. In case of 
shotgun analysis, peptides were separated by nano-flow LC (1100 Series LC system, Agilent, Palo 
Alto, CA) using the HPLC-Chip technology (Agilent) equipped with a 40 nl Zorbax 300SB-C18 trapping 
column and a 75 µm x 150 mm Zorbax 300SB-C18 separation column at a flow rate of 400 nl/min, 
using a gradient from 0,2 % formic acid and 3 % ACN to 0,2 % formic acid and 50 % ACN over 60 
minutes. Peptide identification was accomplished by MS/MS fragmentation analysis with an iontrap 
mass spectrometer (XCT-Ultra, Agilent) equipped with an orthogonal nanospray ion source. The 
MS/MS data, including peaklist-generation and search engine, were interpreted by the Spectrum Mill 
MS Proteomics Workbench software (Version A.03.02, Agilent) allowing for two missed cleavages and 
searched against the SwissProt Database for human proteins (Version 20061207 containing 15.265 
entries) allowing for precursor mass deviation of 1,5 Da, a product mass tolerance of 0,7 Da and a 
minimum matched peak intensity (%SPI) of 70 %. Due to previous chemical modification, 
carbamidomethylation of cysteines was set as fixed modification. No other modifications were 
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considered here. The listed peptides were identified with the indicated scores. The scores were 
essentially calculated from sequence tag lengths, but also consider mass deviations. To assess the 
reliability of the peptide scores, we performed searches against the corresponding reverse database. 
5,9 % positive hits were found with peptides scoring >9,0, while 0,21 % positive hits were found with 
peptides scoring >13,0. Consequently, we set the threshold for protein identification to at least one 
peptide scoring higher than 13,0.  
To eliminate redundancy in the case of peptides matching to multiple members of a protein family, the 
following procedure was applied and realized with a self-made algorithm. All proteins containing the 
peptides in question were proposed. Each protein proposal listed all matching peptides provided with 
a number indicating how many proteins contained the identical peptide. A peptide found in three 
different proteins got the protein-count three, while a peptide occurring only in a specific isoform got 
the protein-count one. Of the proposed proteins, the candidates containing at least one peptide with a 
protein-count one were positively selected. If no peptide with a protein-count one was identified, the 
protein entry containing the largest number of different peptides was positively selected. If several 
proteins were proposed containing the same number of identical peptides, the first entry of the 
isoforms in question was chosen (one before two, A before B etc.). Proteins not fulfilling these criteria 
were negatively selected. As a result of the employed strategy, the reliability of each protein 
identification can be individually scrutinized based on the identification data contained in the html-files. 
 
4.5 Data preparation and correlation of histological data with shotgun results 
 
The „Human Protein Atlas” (www.proteinatlas.org) provides protein expression data derived from 
antibody-based proteomics. It comprises about 5 million images of immunohistochemically stained 
normal (e.g. liver) and tumorous tissues (e.g. liver cancer) representing more than 5000 human 
proteins [204]. Protein expression levels are delivered by means of two independent parameters, the 
staining intensity (negative, weak, moderate or strong) and the fraction of stained cells (rare, <25%, 
25-75% or >75%) (Figure 12). Both parameters equally contribute to the abundance of proteins 
reflected by the number of total proteins (Tp) delivered by mass spectrometry. In order to achieve 
comparability of immunohistochemical and shotgun data in terms of up- or downregulation with 
respect to normal tissue, intensity and quantity data have to be combined and compared to the 
combined data of normal liver tissue.  
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Figure 12: Representation of immunohistochemically derived protein expression data for 
liver cancer (above) and liver (below) in “Human Protein Atlas” 
(www.proteinatlas.org); example “Purine nucleoside phosphorylase” 
(P00491) 
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The following approach was applied and is exemplified via data for purine nucleoside phosphorylase 
(Figure 12): 
1. Assignment of weighted values to intensity and quantity levels of protein expression (table 3). 
 
Intensity Quantity Weighted 
value 
Strong >75% 1 
Moderate 75- 25% 0,6 
Weak <25% 0,2 
Negative Rare 0 
Table 3: Assignment of common weighted values to intensity and quantity levels 
 
2. Multiplicative correlation of the weighted values according to table 4. The resulting values 
correspond to relative expression levels (REL).  
 
  Intensity 
  Strong Moderate Weak 
>75% 1 0,6 0,2 
75- 25% 0,6 0,36 0,12 Quantity 
<25% 0,2 0,12 0,04 
Table 4: Matrix for the multiplicative correlation of weighted values 
 
3. Calculating the number of liver cancer samples belonging to the respective RELs. Two 
combinatorial border cases can be defined assuming a) the highest and b) the lowest possible 
inter-sample variability with respect to expression levels. Intensity and quantity data of purine 
nucleoside phosphorylase are summarized in table 5 (derived from figure 12), the 
combinatorial elaboration of the border cases is depicted in table 6. The results expressed as 
the number of samples of distinct RELs are depicted in table 7. 
 
Intensity Quantity 
Strong: 1 >75%: 6 
Moderate: 7 75- 25%: 3 
Weak: 2 <25%: 1 
Negative: 0 Rare: 0 
Table 5: Number of samples corresponding to the respective intensity and quantity levels 
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Negative/ Rare: 0
<25%: 1Weak: 2
75- 25%: 3Moderate: 7
>75%: 6Strong: 1
QuantityIntensity
Negative/ Rare: 0
>75%: 6Weak: 2
75- 25%: 3Moderate: 7
<25%: 1Strong: 1
QuantityIntensity
 
Table 6: Combinations for case a (left) and case b (right) 
 
 
  Intensity 
  Strong Moderate Weak 
>75% 1 5/4 2 
75- 25%  2/3 1 Quantity 
<25% 1  1 
 
REL Case a Case b 
1 1 0 
0,6 5 4 
0,36 2 3 
0,2 0 3 
0,12 1 0 
0,04 1 0 
0 0 
 
Table 7: Number of samples corresponding to distinct RELs for case a and b in the 
matrix (above) and tabularized (below) 
 
4. The expression level of the protein in liver is: Moderate intensity and quantity of >75% (figure 
12, below), hence, corresponds to the relative expression level (REL) of 0.6 which represents 
the treshold expression level for equal, up- and down-regulation of liver cancer. Since the total 
number of samples is 10, the result for case a is: 10% of the investigated HCC samples 
showed higher, 50% equal, and 40% lower expression levels compared to liver tissue. For 
case b: 40% equal and 50% lower expression levels (Table 8). 
 
up equal down 
10- 0% 50- 40% 40- 60% 
 
Table 8: Percentage of liver cancer samples with higher, equal, or less abundance of 
purine nucleoside phosphorylase compared to liver tissue 
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All proteins (936) identified by mass spectrometry were searched for protein expression data in 
“Human Protein Atlas”. Expression data for proteins represented in the data base (471 proteins) were 
elaborated as described above and compared with shotgun data (see list 2 in appendix). The data 
coincided with respect to up- and downregulation and equal expression levels to 83 % (392 proteins). 
For proteins covered in more detail, data for case a and b were combined and elaborated via SPSS 
and depicted as Boxplots. The blue lines and numbers given for each protein denotes the REL of 
normal liver. 
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5 Results: Functional characterization of HCC vs. liver proteomes 
 
5.1 Global comparison of the proteome profiles of non-tumorous liver and 
HCC tissues 
 
Proteins identified in non-tumorous liver and HCC tissue (548 distinct proteins) were divided in groups 
according to their relative abundance (Figure 13). The latter was calculated as the ratio of total peptide 
(Tp) numbers of the respective proteins. Proteins detected in both tissues showed a normal 
distribution with 343 proteins featuring a difference less than factor 2. They are suggested to exert 
functions indispensable for the survival of cells in general. Remarkably, 231 and 146 from overall 936 
different proteins were exclusively detected in liver and HCC tissue, respectively, reflecting a high level 
of adaptation to the respective tissue challenges (metabolism in liver vs. proliferation in HCC). 
Comparison of 2D-gels from liver and HCC cytoplasmic protein samples confirmed the diversification 
of protein expression patterns and the loss of liver-specific expression performance in HCC (Figure 14, 
note the spot pattern particularly at the basic part of the gels typically enriched with liver-specific 
proteins).  
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Figure 13: Overview of the differential protein expression of non-tumorous liver and HCC 
tissue 
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A B
 
Figure 14: Expression patterns of cytoplasmic proteins of non-tumorous liver (A) and 
HCC tissue (B) separated by 2D-PAGE 
 
In this study, the systemic and functional aspects were emphasized by accounting the loss or gain of 
groups of functionally associated proteins rather than distinct proteins. Thereof important determinants 
for cellular or tissue functionality were gathered with respect to enzymes involved in e.g. glycolysis 
and fatty acid metabolism as metabolic parameters or proteins mediating protein synthesis, protein 
folding as cellular functionality parameters. This approach might compensate for sensitivity limits of the 
method and reveals gaps (all enzymes of a pathway should be there for functionality) possibly worth to 
be challenged. 
The schematic representation of gene expression summarizes fundamental processes cells depend 
on in general (Figure 15). Basic cellular functions have a major impact on metabolic functionality in the 
broader sense. Therefore, a focus was laid on protein synthesis of cytoplasmic proteins (including 
those that are translocated into mitochondria and peroxisomes) and organelle-resident and secreted 
proteins. Another focus was laid on proteins mediating processes which influence the abundance 
and/or functionality of newly synthesized proteins (e.g. protein folding, protein degradation). The 
compartmentalization of certain metabolic functions implicates that they are considerably influenced 
by not only the expression and abundance of certain enzymes involved in the respective parts of 
metabolism but also by their proper location (e.g. machinery for co-translational import of proteins into 
the ER as well as consequent processes for protein maturation) and transport to their final destination. 
The latter is accomplished via vesicular traffic which strongly depends on the cytoskeleton (note the 
marked downregulation of cytoskeletal proteins indicated in figure 16, chapter 5.2) and on proteins for 
vesicle targeting and fusion. In addition, processes involved in "organelle distribution" of proteins are 
also crucial for secretion performance and, hence, the tumor microenvironment and/or the abundance 
of putative biomarkers in the serum of patients suffering from HCC.  
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Figure 15: Outline of gene expression and cellular processes with impact on results 
and their interpretation gathered via proteomics 
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5.2 Functions mediated by cytoplasmic proteins of liver vs. HCC- a global 
view 
 
Figure 16 depicts the functions associated with overall 427 cytoplasmic proteins detected in liver (A) 
and HCC tissue (B). Percentage values correspond to the sum of total peptides of proteins assigned 
to the respective functional group related to the overall number of total peptides derived from 
cytoplasmic proteins of non-tumorous liver tissue. Thus, values are directly comparable and allow the 
global assessment of "loss of function" and "gain of function" of HCC compared to non-tumorous liver 
tissue. Details with special emphasis on differential protein expression or on proteins being 
significantly up- or downregulated in terms of total peptide numbers in one of the two tissues are 
discussed in the context of the respective functional groups. The abundance of cytoplasmic proteins 
was markedly reduced in HCC in contrast to that of mitochondrial proteins (figure 16 and figure 32 in 
chapter 5.7.1).  
A 
 
B 
 
Figure 16: Comparison of cytoplasmic protein-mediated functions of liver (A) and HCC tissue (B) 
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Apart from components of the cytoskeleton, cytoplasmic enzymes involved in amino acid metabolism 
constituted the most pronouncedly affected functional group as it was observed for mitochondrial 
enzymes (figure 16 and figure 32 in chapter 5.7.1). This is exemplified by enzymes for serine 
biosynthesis (D-3-phosphoglycerate dehydrogenase (O43175), phosphoserine aminotransferase 
(Q9Y617)) and phenylalanine degradation (Homogentisate 1,2-dioxygenase (Q93099), phenylalanine-
4-hydroxylase (P00439) (Table 9). Immunohistochemial data available for the serine biosynthetic 
enzymes were in accordance to shotgun results. Shotgun results are depicted in figure 17, 
immunohistochemical and EHCO data for those proteins are summarized in figure 18. 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
O43175 D-3-phosphoglycerate dehydrogenase 8 13 19.9 0 0 0 
Q9Y617 Phosphoserine aminotransferase 6 8 18.9 0 0 0 
In liver only 
         
Q93099 Homogentisate 1,2-dioxygenase 5 6 17.3 2 2 8.3 0.3 
P00439 Phenylalanine-4-hydroxylase 3 5 8.8 0 0 0 In liver only 
 
Table 9: Cytoplasmic proteins involved in amino acid metabolism identified by mass 
spectrometry. The number of distinct peptides (Dp), total peptides (Tp), and 
coverage (Cov. (%)) of proteins of non-tumorous liver (blue) and/or HCC tissue 
(orange) as well as the ratio of Tp (HCC/liver) are quoted.  
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Figure 17: Abundance of cytoplasmic proteins involved in serine biosynthesis and 
phenylalanine degradation determined by mass spectrometry 
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Figure 18: Immunohistochemical (left) and EHCO data (right) concerning the relative 
abundance of cytoplasmic proteins involved in amino acid metabolism in non-
tumorous liver and liver cancer/HCC tissues. The blue lines and numbers 
depicted in the boxplot denote the expression level of the respective proteins in 
normal liver tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uniprot-ID up down 
O43175 2 0 
Q9Y617 No results 
   
Q93099 0 2 
P00439 0 3 
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5.3 The tumor secretome 
A characteristic feature of HCC tissue is the reduced synthesis and release of secreted proteins and 
the concomitantly increased expression of cytoplasmic proteins compared to adjacent non-tumorous 
liver tissue as revealed by 2D-PAGE of metabolically labeled proteins (method described in [1]). 
Figure 19 exemplifies the differential expression of the cytoplasmic and secretory protein fraction, 
respectively, associated with liver and HCC tissue slices. Some molecular features of HCC with 
implications for this phenotype are discussed in more detail below. 
However, secreted proteins were pronouncedly more abundant in HCC compared to liver tissue as 
determined by mass spectrometrical analysis of non-labeled (cold) proteins extracted from the 
respective tissues. In particular, levels of plasma proteins synthesized and secreted by hepatocytes 
(e.g. albumin (P02768), transthyretin (P02766) and transferrin (P02787)) as well as plasma retinol-
binding protein (P02753 ) which delivers liver retinol to peripheral tissues and is bound to transthyretin 
in plasma (Uniprot) was increased consistently about 2.5-fold compared to liver (see protein list in 
appendix). However, inconsistent data are delivered by EHCO and protein atlas (data not shown) 
possibly reflecting fundamental method-derived differences of sample preparation and data acquisition 
which manifest in particular in the non-cell-associated secretory and/or plasma protein fraction. This 
obvious contradiction, reduced expression and secretion vs. elevated levels of secreted proteins 
associated with the tumorous tissue, might be explicable by the massive histological and anatomical 
alterations known to occur in the course of hepatocarcinogenesis. The liver parenchyme is structurally 
optimized for efficient material exchange in contrast to tumorous tissue. In addition, haemodynamic 
parameters determining organ or tumor vascularity and perfusion are characteristically altered in HCC 
tissue. “Blood Flow” (BF (ml/100 g/min)), “Blood Volume” (BV (ml/100 g)) are increased and, 
correspondingly, the “Mean Transit Time” (MTT (sec)) of blood is reduced in advanced HCC [205]. 
Furthermore, BV correlates with the staging of astroglial brain tumors [206]. Increased blood volume 
might account for the elevated levels of plasma proteins detected in HCC. This is in accordance with 
the elevated abundance of hemoglobins found to be associated with the HCC tissue (data not shown). 
The “Permeability-Surface Area Product” (PS (ml/100g/min)) describes the “leakiness” of a capillary 
wall. Increased PS is a common feature of tumor blood vessels [205, 206] due to e.g. the effect of 
proangiogenic VEGF which is also a potent permeability factor [207]. Neoangiogenic vessels 
constitute higher permeability to macromolecules due to large endothelial cell gaps, incomplete 
basement membrane, and the lack of smooth muscle [206, 208]. Other permeability-influencing 
factors are the luminal surface area (see liver parenchyme as optimized structure) and interstitial, 
hydrostatic, and osmotic pressure across the endothelium [206]. In the face of an increased 
abundance of albumin which largely mediates colloid osmotic pressure of plasma, altered pressure 
ratios might be an essential parameter determining the protein composition of HCC tumors and, 
hence, the microenvironment of cancer cells. In addition, HCC tumors are embedded in a distinct 
physiological context. In fact, HCC progression is associated with an increasing arterial blood supply 
in contrast to the liver parenchyme which is largely perfused via the portal vein [209]. The 
microenvironmental aspect is also crucial concerning local concentrations of tumor-promoting, 
maintaining and protective proteins (and substances) possibly far exceeding that expectable from 
gene expression data. This putative local enrichment of otherwise low abundant proteins (e.g. in 
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plasma) is one of the most important advantages of tissue proteomics with respect to the quest for 
biomarkers.  
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Figure 19: Sections of 2D-gels of cytoplasmic proteins and secreted proteins isolated 
from radioactively labeled liver and HCC tissues. A,B: Cytoplasmic proteins of 
liver, C,D cytoplasmic proteins of HCC tissue; E,F: Secreted proteins of liver; 
G-H: Secreted proteins of HCC tissue (A,C,E,G: Proteins fluorescently labeled; 
B,D,F,H: corresponding autoradiographs) 
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5.3.1 Proteases and protease inhibitors 
Interestingly, proteases and protease inhibitors were differentially abundant in HCC compared to non-
tumorous liver tissue.  
The coagulation cascade is regulated by the molecular counter-players prothrombin (P00734) and 
anti-thrombin-III (AT-III, P01008). Thrombin exerts functions in blood homeostasis, inflammation, and 
wound healing. Its proteolytical targets are fibrinogen and the factors V, VII, VIII, and XIII leading to 
the formation of fibrin and the activation of the coagulation cascade, respectively. AT-III inhibits 
thrombin as well as several coagulation factors especially in the presence of heparin. Prothrombin and 
AT-III were differentially expressed in liver vs. HCC tissue. Notably, prothrombin was detected only in 
liver whereas AT-III was found only in HCC suggesting a modulation of the blood coagulation system 
in the tumor tissue. In addition, fibrinogen chains, which constitute the proteinous matrix of blood clots 
after being cleaved by thrombin, were less abundant in HCC compared to non-tumorous tissue. Alpha-
2-antiplasmin (P08697) is an inhibitor of the proteases plasmin, trypsin, and chymotrypsin. Alpha-2-
antiplasmin deficiency is associated with a hereditary disease leading to hemorrhagic diathesis, the 
predisposition for the leakage of blood from vessels. Plasmin cleaves fibrin, fibronectin, 
thrombospondin and other components of the extracellular matrix suggesting its role in tissue 
remodeling and tumor invasion. Alpha-2-antiplasmin was not detected in HCC in contrast to liver 
tissue. Alpha-1-antitrypsin (P01009) is an inhibitor of serine proteases. Its primary target is elastase 
with moderate affinity for plasmin and thrombin. Moreover, it inhibits trypsin, chymotrypsin and 
plasminogen activator. Alpha-1-antitrypsin was highly abundant in liver tissue but was not detected in 
HCC. Alpha-2-macroglobulin (P01023) is a potent inhibitor of all four classes of proteinases. Again, it 
was solely detected in liver. Taken together, inhibitors of proteinases involved in blood coagulation, 
mediating blood vessel leakage and the turnover of the extracellular matrix were consistently lacked or 
less abundant in HCC tissue suggesting tumor-associated alterations with respect to e.g. the structure 
and function of blood vessels.  
 
5.3.2 Clusterin 
The abundance of clusterin (P10909) was pronouncedly increased in HCC tissue (see protein list in 
appendix). Clusterin is a heterodimeric glycoprotein involved in apoptosis, cell cycle regulation, 
complement regulation and many other processes decisive for carcinogenesis. Its expression is 
upregulated in many human cancers like prostate, breast, lung, bladder, colon as well as in a majority 
of HCC cancers whereas it is downregulated in some others ([210] and citations therein). Interestingly, 
expression data obtained from EHCO and “Protein Atlas” delivered contradictory results and indicate 
tendential downregulation of clusterin, respectively (data not shown). One of the many biological 
implications of clusterin is its complement-modulatory effect. It is noteworthy, that it is possibly 
involved in preventing complement-mediated cell lysis via the classical pathway even in the increased 
presence of immunoglobulins and the concomitant low abundance of the C1 inhibitor protein in HCC 
tissue compared to the non-tumorous liver tissue. 
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5.3.3 Concluding remarks concerning the secreted protein fraction determined via 
shotgun-based tissue proteomics 
Many other secreted/extracellular proteins were found to be differentially abundant in liver and HCC 
tissue (e.g. cardiotrophin-1, hepatoma-derived growth factor described in chapter 5.10 and serum 
paraoxonase in chapter 5.9) reflecting the tissue-specific microenvironment. However, it is noteworthy, 
that the latter is determined by several parameters. Apart from the differential expression of non-
tumorous and tumorous tissues, it is potentially influenced e.g. by haemodynamic parameters, by 
pressure ratios of plasma and the tumorous interstitial fluid, by the unique composition of the 
extracellular matrix possibly providing the physical capability to retain and, hence, locally enrich 
distinct proteins even at normal or low expression levels exerted by tumor cells (e.g. cardiotrophin-1), 
by recruitment and local enrichment of plasma proteins potentially serving as a protective shield 
against oxidative stress or chemotherapeutics (e.g. albumin). All of those parameters might 
cooperatively act to lay the systemic basis for the development and maintenance of tumors. By all 
means, inconsistencies of data in literature especially concerning the expression and biological 
relevance of secreted proteins for carcinogenesis in general and discrepancies of results obtained by 
tissue proteomics and protein expression studies in particular might be partially ascribed to the 
different hierarchical levels treated (cell vs. tissue). However, the combination of 2D-PAGE of 
metabolically labeled protein fractions and shotgun-based tissue proteomics enables to bridge the gap 
between gene expression and the tumor-specific microenvironment, respectively. 
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5.4 Protein synthesis, folding, and degradation 
 
5.4.1 Ribosomal proteins 
Comparison of the abundance of ribosomal proteins constituting the 40S and 60S ribosomal subunits 
revealed a distinct tissue-specific pattern. Of overall 25 different 40S ribosomal proteins, two proteins 
were detected only in HCC and five proteins were exlusively found in liver or were significantly 
downregulated in HCC (Table 10, figure 20). Proteins of the 60S ribosomal subunit showed even 
higher diversification than those of the small subunit. Overall 32 identified 60S ribosomal proteins 
included 10 proteins which were significantly more abundant or solely detected in HCC and 11 were 
found only in liver or considerably downregulated in HCC tissue (Table 11, figure 20). In addition, 
translation initiation factors and elongation factors were also differentially expressed in liver and HCC 
tissue (data not shown). The differential expression of ribosomal proteins was also underlined by 
immunohistochemical and EHCO data (figure 21). 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P62266 40S ribosomal protein S23 0 0 0 2 2 15,4 
P61247 40S ribosomal protein S3a 0 0 0 1 1 6,4 
In HCC only 
P62269 40S ribosomal protein S18 9 16 43,4 12 27 53,9 1,7 
P62753 40S ribosomal protein S6 2 2 6,4 3 3 18,1 1,5 
P25398 40S ribosomal protein S12 3 5 22,7 2 6 15,9 1,2 
P62701 40S ribosomal protein S4, X isoform 3 4 13,3 2 4 4,6 1,0 
P46782 40S ribosomal protein S5 2 5 14,2 3 5 18,6 1,0 
P62249 40S ribosomal protein S16 6 7 30,8 6 7 41,1 1,0 
P08708 40S ribosomal protein S17 6 8 51,1 5 8 34,8 1,0 
P23396 40S ribosomal protein S3 1 1 3,7 1 1 5,3 1,0 
P62277 40S ribosomal protein S13 6 13 28,5 6 12 32,5 0,9 
P62081 40S ribosomal protein S7 8 10 27,3 6 9 22,7 0,9 
P62851 40S ribosomal protein S25 3 5 24 2 4 16 0,8 
P62847 40S ribosomal protein S24 3 5 29,3 2 4 20,3 0,8 
P39019 40S ribosomal protein S19 8 11 36,6 5 8 27,6 0,7 
P60866 40S ribosomal protein S20 2 8 19,3 3 5 25,2 0,6 
P62854 40S ribosomal protein S26 2 5 20,9 2 3 20,9 0,6 
P62244 40S ribosomal protein S15a 5 5 38,5 2 3 16,9 0,6 
P62841 40S ribosomal protein S15 3 5 22,1 2 3 22,1 0,6 
P62263 40S ribosomal protein S14 7 12 41,7 6 7 41,7 0,6 
P46783 40S ribosomal protein S10 8 11 48,5 4 5 27,3 0,5 
P62241 40S ribosomal protein S8 4 6 24,5 2 2 12 0,3 
P62280 40S ribosomal protein S11 2 2 19,6 0 0 0 
P08865 40S ribosomal protein SA 4 4 23,7 0 0 0 
P15880 40S ribosomal protein S2 2 3 8,5 0 0 0 
In liver only 
 
Table 10: Components of the 40S ribosomal subunit identified by mass spectrometry. 
The number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. 
(%)) of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as 
well as the ratio of Tp (HCC/liver) are quoted.  
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Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
P46779 60S ribosomal protein L28 0 0 0 2 3 17,5 
P62899 60S ribosomal protein L31 0 0 0 3 3 18,4 
P83731 60S ribosomal protein L24 0 0 0 3 4 19,1 
P40429 60S ribosomal protein L13a  0 0 0 1 1 5,4 
P49207 60S ribosomal protein L34  0 0 0 1 1 6,8 
P61353 60S ribosomal protein L27  0 0 0 1 1 6,6 
P62917 60S ribosomal protein L8  1 1 4,3 2 4 10,5 
P05386 60S acidic ribosomal protein P1 1 1 14 2 4 14 
P62750 60S ribosomal protein L23a  2 2 8,3 3 4 21,8 
P46776 60S ribosomal protein L27a  1 1 14,9 2 2 22,3 
P35268 60S ribosomal protein L22  5 7 39,8 5 8 39,8 
P50914 60S ribosomal protein L14  4 5 21,1 2 5 10,8 
P30050 60S ribosomal protein L12 6 6 47,3 5 6 43 
P47914 60S ribosomal protein L29  1 1 9,4 1 1 9,4 
P62829 60S ribosomal protein L23  2 4 27,1 3 4 34,3 
P18124 60S ribosomal protein L7  2 4 10,1 4 4 21 
P05388 60S acidic ribosomal protein P0 (L10E) 4 7 16,1 3 6 11 
P62913 60S ribosomal protein L11  6 6 23 5 5 21,9 
P05387 60S acidic ribosomal protein P2 4 10 41,7 4 7 31,3 
P62910 60S ribosomal protein L32  2 3 17 1 2 9,6 
Q07020 60S ribosomal protein L18 4 5 20,2 3 3 19,7 
P62888 60S ribosomal protein L30 4 6 51,3 3 3 34,8 
P32969 60S ribosomal protein L9  1 2 5,7 1 1 7,3 
P46777 60S ribosomal protein L5  3 3 12,5 1 1 5,7 
P62424 60S ribosomal protein L7a 3 6 15 1 2 4,9 
Q02878 60S ribosomal protein L6  5 5 24,3 1 1 5,2 
P26373 60S ribosomal protein L13  3 5 13,7 1 1 6,2 
P39023 60S ribosomal protein L3 1 2 5,5 0 0 0 
P18621 60S ribosomal protein L17 (Human) 2 2 15,8 0 0 0 
P36578 60S ribosomal protein L4 (L1)  5 5 16,4 0 0 0 
P18077 60S ribosomal protein L35a 1 1 9,1 0 0 0 
P42766 60S ribosomal protein L35 3 3 26,8 0 0 0 
 
Table 11: Components of the 60S ribosomal subunit identified by mass spectrometry. 
The number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. 
(%)) of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) are 
quoted.  
 
Diversification with respect to the expression and modification (e.g. methylation) of ribosomal proteins 
as mechanisms to regulate, in a broader sense, the availability of components of the translation 
machinery and, hence, translation efficiency of all (or distinct subgroups) of mRNAs seems to be 
rather the rule than an exception (see references in this chapter). With respect to modification it has to 
be stated that low amounts of a given peptide and its highly abundant but modified counterpart could 
not be dissolved by the applied algorithm for protein identification via mass spectrometry. 
Consequently "low abundance" of proteins in terms of total peptide numbers might mask the existence 
of high amounts of peptides which are methylated/ glycosylated and vice versa. Therefore, the applied 
methodical approach impacts the result and has to be taken into account especially with respect to 
comparability of data concerning differential expression of ribosomal proteins (or proteins in general) 
gathered via e.g. RNA-based methods (e.g. microarray, RT-PCR). 
Nevertheless, the structure of ribosomes and/or the abundance of their components is influenced by a 
variety of parameters like cell type and developmental stage [211] as well as physiological conditions 
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like starvation or hypothermia [212, 213]. Studies in yeast confirmed the impact of distinct ribosomal 
proteins on the translation machinery as a whole (including the differential requirement of translation 
factors). On the one hand they demonstrated that some ribosomal proteins were dispensable although 
with influence on translation efficiency and on the other hand that alternative ways of compensating for 
the loss of distinct ribosomal proteins might exist [214-216]. These results and others concerning the 
putative mechanistic base led to the postulation of the "ribosome filter hypothesis" by Mauro and 
Edelmann [217]. In short, they postulate a regulatory function of ribosomal proteins apart from their 
known function with respect to translation of certain subpopulations of mRNAs (based on the presence 
of cis-sequences to which ribosomal proteins can bind) which can thereby either be enhanced or 
inhibited (by sequestration). Nevertheless, this issue is far from being commonly accepted and subject 
of discussions up to date [218]. A systematic investigation of this question might have considerable 
impact on cancer biology and possibly targeted (local) cancer treatment (ribosomal proteins as drug 
targets, e.g. cycloheximide) taking into account that ribosomal proteins are reported to be differentially 
expressed in tumor vs. non-tumorous tissues in liver/HCC and many others [219-224].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  58  
 
0 0
16
2
5
4
5
7
8
1
13
10
5 5
11
8
5 5 5
12
11
6
2
4
3
2
1
27
3
6
4
5
7
8
1
12
9
4 4
8
5
3 3 3
7
5
2
0 0 0
0
5
10
15
20
25
30
P6
22
66
P6
12
47
P6
22
69
P6
27
53
P2
53
98
P6
27
01
P4
67
82
P6
22
49
P0
87
08
P2
33
96
P6
22
77
P6
20
81
P6
28
51
P6
28
47
P3
90
19
P6
08
66
P6
28
54
P6
22
44
P6
28
41
P6
22
63
P4
67
83
P6
22
41
P6
22
80
P0
88
65
P1
58
80
Uniprot-ID
N
u
m
b
e
r 
o
f 
to
ta
l p
e
p
tid
e
s
 (
T
p
)
liver
HCC
 
0 0 0 0 0 0
1 1
2
1
7
5
6
1
4 4
7
6
10
3
5
6
2
3
6
5 5
2 2
5
1
33 3
4
1 1 1
4 4 4
2
8
5
6
1
4 4
6
5
7
2
3 3
1 1
2
1 1
0 0 0 0 0
0
2
4
6
8
10
12
P4
67
79
P6
28
99
P8
37
31
P4
04
29
P4
92
07
P6
13
53
P6
29
17
P0
53
86
P6
27
50
P4
67
76
P3
52
68
P5
09
14
P3
00
50
P4
79
14
P6
28
29
P1
81
24
P0
53
88
P6
29
13
P0
53
87
P6
29
10
Q
07
02
0
P6
28
88
P3
29
69
P4
67
77
P6
24
24
Q
02
87
8
P2
63
73
P3
90
23
P1
86
21
P3
65
78
P1
80
77
P4
27
66
Uniprot-ID
N
u
m
b
e
r 
o
f 
to
ta
l 
p
e
p
ti
d
e
s
 (
T
p
)
liver
HCC
 
Figure 20: Abundance of 40S (above) and 60S ribosomal proteins (below) determined 
via mass spectrometry 
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Figure 21: Immunohistochemical (left) and EHCO data (right) concerning the relative 
abundance of ribosomal proteins in non-tumorous liver and liver cancer/HCC 
tissues. The blue lines and numbers depicted in the boxplot denote the 
expression level of the respective proteins in normal liver tissue. 
 
 
In conclusion 
1. Ribosomal proteins are differentially expressed in HCC and liver. 
2. The possible biological implications are far from being understood although the 
requirement/usage of diverse sets of ribosomal proteins seems to be a common phenomenon. 
3. Differential expression of translation factors has to be regarded in the context of those of 
ribosomal proteins (e.g. EF-2- independent translation mechanism). 
 
 
 
 
 
 
 
 
 
 
 
Uniprot-
ID up down 
P62269 1 0 
P62753 1 0 
P62701 1 0 
P62847 3 0 
P60866 2 1 
P62241 2 0 
P08865 4 0 
P15880 1 1 
P61353 1 0 
P62917 2 0 
P05386 3 0 
P30050 1 0 
P18124 2 0 
P05388 3 0 
P05387 2 0 
P62888 4 0 
P39023 1 0 
P42766 2 1 
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5.4.2 Proteins involved in protein folding 
 
5.4.2.1 Cytoplasmic chaperones 
Cytoplasmic chaperones identified via mass spectrometry are listed in table 12. Shotgun data, 
immunohistochemical and EHCO data are compiled in figure 22. Hsp27 (P04792) was markedly 
upregulated in HCC. This is in accordance with reports concerning the obviously decisive implications 
of this multi-faceted protein on the expression of cancer-related phenotypes and resistance against 
anti-cancer treatments. Therefore, considerable efforts were undertaken to elucidate the mechanism 
of action of Hsp 27 and the signaling pathways it is involved in or depends on. Hsp27 was related to 
multidrug resistance (e.g. against vincristine) in hepatocellular, gastric carcinoma and breast cancer 
cell lines [225-227] and was suggested a factor influencing radiosensitivity of bladder cancer [228]. 
Moreover, overexpression of Hsp27 correlated with poor prognosis for patients suffering from prostate 
cancer [229]. The mechanisms of action and signaling pathways in which it is integrated comprises a 
putative effect of Hsp27 on apoptosis in metastatic HCC cells via modulation of the NF-kB pathway 
activation [230], the correlation of high amounts of non-phosphorylated Hsp27 to a high extracellular 
signal-regulated kinase activity which is known to provide a crucial proliferation signal in 
hepatocarcinogenesis [231] and the involvement in PKCβ-mediated HCC cell motility and invasion 
with Hsp27 as phosphorylation target [232]. The latter seems to be crucial for promoting cancer 
phenotype and is additionally regulated by PKCδ and p38 MAPK [232]. Hsp27 was one of 3 
chaperones (among Hsp70 and Grp78, and ER-resident chaperone (P11021), see table 13 and figure 
24 in chapter 5.4.3) which were significantly upregulated in HCC based on a proteomics approach 
[233]. Indeed, Hsp70 and Grp78 (see below) were also upregulated in the investigated HCC sample 
compared to liver tissue although to a lesser extent than Hsp27. Upregulation of these proteins was 
confirmed by immunohistochemical data (Figure 22). However, Hsp70 isoforms (Heat shock 70 kDa 
protein 1/2/6; P08107/P54652/P17066) are highly homologous and therefore could not be uniquely 
identified via mass spectrometry. Hence, histologically derived expression data of all three isoforms 
are represented in figure 22. Furthermore, two different antibodies were used to detect Grp78 
delivering contradictory results. Expression data of both are included in figure 22 (P11021-a and 
P11021-b for antibodies CAB005221 and CAB019420, respectively; see www.proteinatlas.org).  
Hsp27 is also increased in an HCV-infected cell line and interacts with HCV proteins playing a putative 
role in virus maintenance [234] and is, furthermore, involved in progesterone signaling which is 
underlined by the fact that the expression of Hsp27 gene is upregulated in response to progesterone 
[235]. Of special importance with respect to (early) diagnosis of HCC is that Hsp27 might be a useful 
biomarker since it was found to be enriched in the serum proteome of HCC patients [236]. By the way, 
it would be interesting to know the mechanism of delivery of a normally cytoplasmic protein into the 
patient's serum. It might be interpreted as a consequence of simple cell decay by necrosis or possibly 
provide an indication for alternative ways for protein release occuring in solid tumors like HCC (see 
chapter 5.3).  
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Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/Liver) 
P04792 Heat shock 27 kDa protein 2 3 12,7 12 19 60,5 6,3 
O75347 Tubulin-specific chaperone A 3 3 26,9 4 6 26,9 2,0 
P08107/ 
P54652/ 
P17066 
Heat shock 70 kDa protein 1/2/6 15 31 30,4 17 58 28,4 1,9 
P07900/ 
P08238 
Heat shock protein HSP 90-alpha/-beta 19 67 29,8 10 43 17 0,6 
Q16543 Hsp90 co-chaperone Cdc37 1 1 3,7 0 0 0 
O14558 Heat-shock protein beta-6  1 1 8,1 0 0 0 
In liver only 
         
P11142 Heat shock cognate 71 kDa protein 23 46 36,4 22 47 36,2 1,0 
P31948 Stress-induced-phosphoprotein 1 (STI1) 1 2 2,4 1 2 2,9 1,0 
P50502/ 
Q8IZP2 
Hsc70-interacting protein (Hip)/ Protein FAM10A4 1 4 3,8 0 0 0 In liver only 
           
P62942 FK506-binding protein 1A(Immunophilin FKBP12) 2 2 13 2 2 13 1,0 
P62937 Peptidyl-prolyl cis-trans isomerase A  13 24 67,9 13 23 67,9 1,0 
         
Q9NQP4 Prefoldin subunit 4   0 1 1 9 In HCC only 
Q9UHV9 Prefoldin subunit 2 3 4 29,9 1 1 7,8 0,3 
Q99471 Prefoldin subunit 5 1 1 11,7 0 0 0 In liver only 
         
P40227 T-complex protein 1 subunit zeta (TCP-1-zeta) 2 4 7,2 2 4 4,3 1,0 
P50990 T-complex protein 1 subunit theta (TCP-1-theta) 2 4 4,9 1 2 2,7 0,5 
P78371 T-complex protein 1 subunit beta (TCP-1-beta) 3 4 8,4 1 1 3,7 0,3 
P48643 T-complex protein 1 subunit epsilon (TCP-1-epsilon) 2 3 6,1 0 0 0 
Q99832 T-complex protein 1 subunit eta (TCP-1-eta) 1 2 4,6 0 0 0 
In liver only 
         
P22061 Protein-L-isoaspartate(D-aspartate) O-methyltransferase 0 0 0 4 5 27,3 In HCC only 
P10599 Thioredoxin (ATL-derived factor) (ADF) 3 4 23,8 2 5 12,4 1,3 
 
Table 12:Cytoplasmic chaperones identified by mass spectrometry. The number of 
distinct peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins 
of non-tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of 
Tp (HCC/liver) are quoted. 
 
Two cytoplasmic peptidyl-prolyl cis-trans isomerases (P62942, P62937) were identified. They show no 
differences in the expression levels of HCC compared to liver indicating that the catalysis of the 
otherwise slow cis-trans isomerization of proline in nascent proteins is not affected in HCC. 
Irrespective of their putative role as target for the anti-cancer drug rapamycin they seem to prepare 
proline for phosphorylation for conformation-specific proline-directed kinases and phosphatases 
(reviewed in [237]).  
 
Prefoldin subunits and TCP1 subunits (see table 12) are involved in the folding of nascent actin and 
tubulin monomers to their native conformation (reviewed in [238]). Both show significant 
downregulation in HCC as well as differential expression of subunits comprising the functional 
complex. Interestingly the TCP1-chaperonin cofactor A which supports folding of those cytoskeleton 
proteins is one of the significantly upregulated proteins in HCC. Nevertheless, there might be a 
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correlation with the finding that actin and tubulin are also pronouncedly downregulated in HCC 
compared to liver (data not shown). 
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Uniprot-ID up down 
P04792 4 1 
   
P08107 2 1 
P54652 No results 
P17066 No results 
   
P07900 3 0 
P08238 No results 
   
P11021  3 1 
 
 
 
Figure 22: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of cytoplasmic chaperones in 
non-tumorous liver and liver cancer/HCC tissues. The blue lines and numbers 
depicted in the boxplot denote the expression level of the respective proteins in 
normal liver tissue. 
 
One methyltransferase, Protein-beta-aspartate methyltransferase or PIMT, involved in protein repair 
was exclusively detected but most probably just strongly upregulated in HCC considering its 
postulated ubiquitous expression [239]. PIMT catalyzes the repair of proteins with isoaspartyl residues 
which enrich during aging of proteins. Aged or irreparably non-functional proteins are delivered to the 
ubiquitin-proteasome machinery for degradation and recycling of amino acids. Upregulation of this 
0,12 0,12 0,12
0,2
0,6 0,6 0,6
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protein might be induced in the case of insufficiency of this machinery. Indeed there is an indirect 
indication for deprivation of activated ubiquitin (loss of ubiquitin-activating enzyme in HCC) as a 
prerequisite for the consequent steps of the degradation process (see protein degradation). It might be 
assumed that an increased proportion of proteins found in HCC are altered and concomittantly might 
cause increased cytosolic stress by the enrichment of misfolded proteins (proteinous inclusion 
bodies?) which in turn would induce the expression of stress-response proteins (see chaperones 
mentioned above). 
 
5.4.3 Proteins for co-translational import of proteins into ER, quality-control proteins, 
and ER-resident folding proteins 
Proteins for protein import into the ER, proteins involved in quality control and folding identified via 
mass spectrometry are listed in table 13. Shotgun data are depicted in figure 24, 
immunohistochemical and EHCO data available for those proteisn are compiled in figure 23 and figure 
25. 
 
Translation into ER Dp Tp 
Cov. 
(%) Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/Liver) 
P51571 
Translocon-associated protein delta subunit precursor 
(TRAP-delta) 3 5 24,9 1 1 11 0,2 
Q9P2E9 Ribosome-binding protein 1 (Ribosome receptor protein) 18 35 16,9 6 7 5,9 0,2 
         
Glycosylation/reglycosylation        
O75356 
Ectonucleoside triphosphate diphosphohydrolase 5 
precursor, (NTPDase 5) 9 10 27,3 3 4 10,7 0,4 
P04844 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 63 kDa subunit 1 1 1,9 0 0 0 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 precursor 1 1 1,1 0 0 0 
Q14165 Malectin 1 1 4,1 0 0 0 In liver only 
         
Quality control        
P27824 Calnexin precursor 0 0 0 1 2 3 In HCC only 
O60613 15 kDa selenoprotein precursor 1 1 9,9 1 3 9,9 3,0 
P27797 Calreticulin precursor (CRP55) 8 10 33,3 12 17 37,2 1,7 
         
Chaperones        
Q9UBS4 DnaJ homolog subfamily B member 11 precursor (ErJ3) 1 1 3,1 2 2 7,8 2,0 
P11021 78 kDa glucose-regulated protein precursor (GRP 78) 32 52 46,5 43 92 56,7 1,8 
Q9Y4L1 
150 kDa oxygen-regulated protein precursor (Orp150) 
(Hypoxia up-regulated 1) 8 14 13,3 11 18 18,3 1,3 
P14625 
Endoplasmin precursor (94 kDa glucose-regulated 
protein) (GRP94) 38 102 52,8 32 110 45 1,1 
 
 
Protein disulfide-isomerases        
P07237 
Protein disulfide-isomerase precursor (PDI) (Prolyl 4-
hydroxylase beta subunit) 27 50 51,8 29 69 60,6 1,4 
P13667 Protein disulfide-isomerase A4 precursor (ERp72) 20 23 38,8 17 29 28,2 1,3 
P30101 Protein disulfide-isomerase A3 precursor (ERp57) 23 33 50,5 24 41 43,8 1,2 
Q15084 
Protein disulfide-isomerase A6 precursor (Protein disulfide 
isomerase P5) 12 22 39,3 12 25 37,7 1,1 
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Thioredoxindomain containing proteins 
       
P30040 
Endoplasmic reticulum protein ERp29 precursor (ERp31) 
(ERp28) 6 6 19,9 9 10 38,7 1,7 
Q8NBS9 
Thioredoxin domain-containing protein 5 (Endoplasmic 
reticulum protein ERp46) 5 8 14,1 5 8 12,5 1,0 
O95881 
Thioredoxin domain-containing protein 12 (Endoplasmic 
reticulum protein ERp19) 3 3 22,1 3 3 22,1 1,0 
Q9BS26 
Thioredoxin domain-containing protein 4 precursor 
(Endoplasmic reticulum resident protein ERp44) 3 3 11,6 2 3 6,4 1,0 
 
 
Peptidyl-prolyl cis-trans isomerases        
P23284 Peptidyl-prolyl cis-trans isomerase B precursor 16 24 69,2 20 37 63 1,5 
P26885 FK506-binding protein 2 precursor 6 7 47,9 6 8 33,8 1,1 
 
Table 13: ER chaperones and folding proteins identified by mass spectrometry. The 
number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) 
of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as well as 
the ratio of Tp (HCC/liver) are quoted. 
 
The capability to perform co-translational transport of proteins through the ER membrane might be 
strongly compromized although not completely eliminated in HCC. Two proteins involved in this 
process were identified, TRAP-delta (P51571) which is a component of the translocon complex of the 
ER membrane and ribosome-binding protein 1 (p180, Q9P2E9) which mediates the interaction of the 
ribosome with the ER membrane. Expression of both was reduced and that to the same extent with a 
ratio of HCC/ liver of 0,2. Benyamini et al. recently demonstrated that p180 is necessary and sufficient 
for the secretory phenotype in mammalian cells by extending rough ER and Golgi as well as the 
secretion performance as a whole although it seems to be not the master regulator for enhancement 
of protein secretion since protein synthesis remained unaffected by overexpression of p180 [240, 241]. 
Reduced abundance of p180 is in accordance to EHCO data (data not shown). However, 
immunohistochemical evaluation revealed a pronounced tendency for upregulation (see histologic 
slices at www.proteinatlas.org and figure 23; note that normal liver as well as liver cancer tissue have 
RELs of 1). 
 
Glycosylation of proteins in the ER might also be reduced in HCC. Four proteins involved in this 
process were identified and all of them were either significantly less abundant or not detected in HCC 
tissue in accordance to immunohistochemical and EHCO data (Figure 23). Apart from enzymes 
involved in primary glycosylation and the functionally yet un-characterized protein malectin, NTPDase 
(O75356) is assumed to promote reglycosylation reactions in the course of protein folding and quality 
control in the ER (http://www.uniprot.org/uniprot/O75356). Although the identified proteins represent 
just a small section of the whole spectrum of proteins participating in this process, there is a noticable 
"trend" towards reduction of glycosylation capability in HCC.  
Interestingly, proteins mediating the calnexin-calreticulin cycle, calnexin (p90, P27824), calreticulin 
(Erp60, P27797), and Erp57 (P30101), a protein-disulfide isomerase, were found to be upregulated in 
HCC. Calnexin was detected only in HCC, calreticulin was moderately and Erp57 slightly upregulated 
in HCC, the latter two with ratios of total peptides found in HCC/liver of 1,7 and 1,2, respectively. The 
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elevated abundance of these proteins is underlined by histological and EHCO data (Figure 23). The 
primary function of this triade is the quality control of newly synthesized glycoproteins. An additional 
function of calnexin and calreticulin might be the regulation of Ca-homeostasis (reviewed in [242]). 
The biological meaning or significance of this finding against the background of a putative reduction of 
proteins translocated into the ER as well as diminished glycosylation in the ER might be worth to be 
considered in detail. Nevertheless, it might be suggested either as a reaction of HCC cells to 
enhanced ER-stress by accumulation of non- and falsely glycosylated proteins (irrespective of the 
reduced protein import into the ER) or reflect changes of Ca homeostasis in HCC compared to liver (or 
both). The first suggestion presumes that glycosylation deficiency comprises a bottleneck for proteins 
on their track through the secretory pathway but not the reduced protein import rate. Whereas it is 
evident that both parameters together influence the secretion performance as a whole, just the first 
might have impact on the expression of other ER-resident proteins responding to stress derived from 
accumulation of misfolded or insufficiently glycosylated proteins. 
1 11
0,2
1
0,6
 
Figure 23: Immunohistochemical data concerning the abundance of proteins involved in 
the co-translational ER transport, glycosylation, and quality control in non-
tumorous liver and liver cancer/HCC tissues. The blue lines and numbers 
depicted in the boxplot denote the expression level of the respective proteins in 
normal liver tissue. 
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Figure 24: Abundance of proteins mediating protein import into ER, quality-control 
proteins, and ER-resident folding proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Immunohistochemical (left) and EHCO data (right) concerning the relative 
abundance of ER chaperones and disulfide isomerases in non-tumorous liver 
and liver cancer/HCC tissues. The blue lines and numbers depicted in the 
boxplot denote the expression level of the respective proteins in normal liver 
tissue. 
 
None of the identified chaperones, proteins with protein disulfide-isomerase and peptidyl-prolyl cis-
trans isomerase activity was downregulated in HCC vs. liver. Among the proteins classified as 
chaperones, ErJ3 (Q9UBS4) showed the most pronounced upregulation in HCC, followed by Grp78 
(P11021), Orp150 (Q9Y4L1), and endoplasmin (P14625), the latter with an expression level almost 
Uniprot-ID up down 
Q9UBS4 No results 
P11021-a 3 1 
P14625 1 3 
P07237 0 2 
P13667 No results 
P30101 3 0 
Q15084 0 1 
Q8NBS9 1 0 
Q9BS26 2 0 
P23284 3 1 
P26885 No results 
P55327 2 0 
Q02818 1 2 
0,6 0,6 0,6 0,6
0,2
0,6 0,6
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equal to that detected in liver tissue. Four different members of the protein-disulfide isomerase family 
were identified (P07237, P13667, P30101, Q15084), all of which were slightly to moderately more 
abundant in HCC whereas the thioredoxin domain-containing proteins (Q8NBS9, O95881, Q9BS26) 
which are functionally (catalytically) equivalent to the disulfide isomerases were equally expressed in 
both tissues except for ERp29 (P30040) which proved to be moderately overexpressed in HCC (ratio 
of HCC/liver of 1,7). Focusing on the enzyme-mediated functions instead of individual proteins, the 
chaperone group features an average ratio of HCC/liver (based on total peptide numbers) of 1,55, 
disulfide-isomerase activity-mediating enzymes (protein-disulfide isomerases and thioredoxin domain-
containing proteins) an average ratio of 1,2, and peptidyl-proly cis-trans isomerases (P23284, P26885) 
a ratio of 1,3. The upregulation of proteins involved in protein folding is less pronounced as expectable 
(see above). Nevertheless, it is evident that the effects of reduced protein import and reduced 
glycosylation implicating a possible accumulation of not correctly folded and/or glycosylated proteins 
are opposed. Thereof it might be assumed that the findings (most of the ER proteins slightly to 
moderately overexpressed irrespective of their individual functions/targets) reflect a tissue-specific 
shift of the balance between protein import and export into and out of the ER, respectively. 
 
In conclusion these results indicate 
1. the differential expression of chaperones in accordance to published data, 
2. that co-translational import into and modification of proteins in the ER might be compromized. 
As a possible consequence, proteins for protein folding in the ER are upregulated although to 
a different extent with respect to their catalytic functions. 
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5.4.4 The ubiquitin-proteasome system 
 
Ubiquitin (Ub) is an important player in a broad variety of cell-physiological processes including protein 
degradation, cell division, signal transduction, vesicle trafficking, and protein quality control (reviewed 
in [243]). The mechanism is based on the regulated cycling of free and protein-bound ubiquitin. For 
targeting of proteins to proteasome-mediated degradation highly specific ubiquitin ligases conjugate 
Ub which constitute the degradation signal or "degron" for the 26S proteasome. A prerequisite for that 
is the activation of Ub by the energy-dependent attachment to the ubiquitin-activating enzyme E1 
which subsequently transfers monomeric Ub to members of a second class of enzymes involved in 
this process, the ubiquitin-conjugating enzymes E2. By means of the substrate specificity-providing E3 
ligases Ub is transferred from E2 to their substrates in order to constitute poly-Ub degrons. 
Ubiquitinylation can also be reversed by deubiquitination enzymes delivering the substrate and 
ubiquitin which is again available for activation (see figure 26; reviewed in [244]). 
 
 
Figure 26: The ubiquitin conjugation machinery (slightly modified from [244]) 
 
The kind of linkage of Ub with respect to the involvement of one of its seven lysines contributes to the 
determination of the fate of the target proteins. E.g. linkage through Lys
48
 provides proteasome 
targeting whereas linkage via Lys
63
 is involved in DNA damage tolerance, endocytosis, and ribosomal 
protein synthesis [245]. In addition, Ub signal-specificity is achieved by selective Ub conjugation and 
deubiquitination. 
The possible implications of disturbed ubiquitination for tumor biology are manifold. Of special 
importance might be a possibly altered growth factor abundance at the cell surface and thereof 
responsivity to signals [246]. This effect relies on the alteration of the preferentially used endocytosis 
  69  
mechanism which massively influences the fate of the receptor inside the cell. E.g. association of the 
TGF-beta receptor with the Smad7-Smurf2 E3 ligase determines its association with caveolae and 
subsequent rapid degradation [247]. Otherwise it is internalized via clathrin-coated pits enabling 
further signaling from an endosomal compartment [248]. Moreover, it has been shown that signals 
initiated at the plasma membrane and at internal compartments are integrated differently by cells. 
Whereas membrane-located TrkA supports NGF (nerve growth factor)-mediated cell survival the 
internalized receptor induces differentiation [249]. In addition, it is suggested that mono-ubiquitination 
of EGFR forces its uptake via clathrin-independent endocytosis in the presence of the normally 
clathrin-coated pit-localized proteins Eps15, Eps15R, and epsin [250, 251]. A further example is the 
strong impact of ubiquitination on Notch (regulator of cell development and cell fate [252]) signaling 
and its modulation and termination. Whereas Delta and Serrate (type I membrane proteins and ligands 
of Notch) need to be ubiquitination-dependently internalized for activity it has been shown that 
ubiquitination is also necessary to terminate signaling. E.g. Uba1 was implicated as possible tumor 
suppressor since failure in ubiquitylation leads to exuberant Notch signaling and overgrowth in mutant 
Drosophila [253].  
 
Proteins involved in ubiqutinylation and detected via mass spectrometry are listed in table 14.  
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P61956 Small ubiquitin-related modifier 2 precursor (SUMO-2) 1 6 12,6 1 9 12,6 1,5 
P61081 NEDD8-conjugating enzyme Ubc12 2 2 10,9 2 4 9,3 2,0 
         
P22314 Ubiquitin-activating enzyme E1 (A1S9 protein) 12 13 16,9 0 0 0 In liver only 
         
P60604 Ubiquitin-conjugating enzyme E2 G2 0 0 0 1 1 14,5 In HCC only 
P62256 Ubiquitin-conjugating enzyme E2 H  0 0 0 1 1 8,2  
P62837 Ubiquitin-conjugating enzyme E2 D2  0 0 0 2 4 23,8  
P61088 Ubiquitin-conjugating enzyme E2 N  6 8 48,7 6 6 42,1 0,8 
P68036 Ubiquitin-conjugating enzyme E2  5 7 48,7 4 4 31,2 0,6 
Q13404 Ubiquitin-conjugating enzyme E2 variant  5 14 19 4 7 16,3 0,5 
Q15819 Ubiquitin-conjugating enzyme E2 variant 2  6 15 29 0 0 0 
O14933 Ubiquitin-conjugating enzyme E2 L6  1 1 17,1 0 0 0 
In liver only 
         
P15374 Ubiquitin carboxyl-terminal hydrolase isozyme L3 0 0 0 1 3 8,7 In HCC only 
P54578 Ubiquitin carboxyl-terminal hydrolase 14  1 1 4,9 0 0 0 In liver only 
Table 14: Proteins involved in ubiquitinylation identified by mass spectrometry. The 
number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) 
of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as well as 
the ratio of Tp (HCC/liver) are quoted. 
 
Interestingly, the ubiquitin-activating enzyme E1 was not detected in HCC whereas it was significantly 
abundant (in terms of Tp) in liver. Taking into account the crucial role in basic cell physiology this 
finding might be worth to be considered in detail with respect to consequences for tumor growth and 
maintenance. Indeed, it has been shown that inhibition of E1 in the presence of wild-type p53 leads to 
apoptosis of tumor cells [254]. Since this mechanism relies on functional p53, it might be supposed 
that this tumor suppressor is functionally inactive in the investigated sample. To my knowledge this is 
the first report concerning a pronounced downregulation of the ubiquitinylation capacity in HCC cells. 
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Furthermore, this finding underlines that the efficiency of tumor drugs to affect tumor growth by 
inhibition of E1 has to be regarded in the context of e.g. the expression of functional p53. Indeed, 
UBE1, an E1-like enzyme, causes suppression of lung cancer growth by targeting cyclin D1 [255] 
underlining the importance of E1 for cell cycle progression and, hence, tumor growth. In addition, 
altered ubiquitinylation capacity might affect protein degradation even in the face of the more or less 
unaltered expression of proteasome components (table 15, figure 28). 
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Figure 27: Abundance of proteins involved in ubiquitinylation in non-tumorous liver and 
HCC tissues determined by mass spectrometry 
 
In general, a pronounced diversification concerning the expression of different ubiquitin-conjugating 
enzymes was observed (Figure 27). Ubiquitin-protein ligase G2 (P60604), H (P62256) and D2 
(P62837) were detected only in HCC tissue. G2 is associated with ER-associated degradation (ERAD) 
and ubiquitinylates Cyp3A4 which is involved in the metabolism of more than 50% of clinically 
prescribed drugs [256]. Ubiquitin-protein ligase H capable to ubiquitinylate histone H2A and D2 
mediates the selective degradation of short-lived and abnormal proteins and functions in the E6/E6-
AP-induced ubiquitination of p53. 
E2 L3 mediates the selective degradation of short-lived and abnormal proteins and functions in the 
E6/E6-AP-induced ubiquitination of p53/TP53. E2 variant 1 (Q13404) has no ubiquitin ligase activity 
on its own. The UBE2V1/UBE2N heterodimer (Q13404, P61088) catalyzes the synthesis of non-
canonical poly-ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitinylation is 
involved in NF-κ-B mediated signaling and contributes to the control of cell cycle and differentiation.  
Ubiquitin carboxyl-terminal hydrolase isozyme L3 (L3, P15374), a deubiquitinylating enzyme, was 
detected solely in HCC tissue. It is involved in the processing of ubiquitin precursors and of 
ubiquitinated proteins by hydrolyzing a peptide bond at the C-terminal glycine of ubiquitin or NEDD8. 
The upregulation of L3 at the mRNA level was detected in breast cancer tissue and was suggested a 
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biomarker for tumor recurrence and bad prognosis [257]. In addition, its activity was consistently 
increased in cervical carcinoma biopsies compared to adjacent non-tumorous tissue [258]. 
 
Proteasome activator complex subunits 
Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
Q9UL46 Proteasome activator complex subunit 2 6 8 39,3 8 13 51 1,6 
Q06323 Proteasome activator complex subunit 1 6 8 36,1 8 11 42,2 1,4 
26S protease regulatory subunits        
P43686 26S protease regulatory subunit 6B 0 0 0 1 1 3,3 
P62195 26S protease regulatory subunit 8 0 0 0 1 1 3,9 
In HCC only 
P62191 26S protease regulatory subunit 4 1 1 3,4 1 1 3,4 1,0 
P62333 26S protease regulatory subunit S10B 2 4 7,7 0 0 0 In liver only 
26S proteasome non-ATPase regulatory subunits        
P48556 26S proteasome non-ATPase regulatory subunit 8   0 1 1 5,8 In HCC only 
Q9UNM6 
26S proteasome non-ATPase regulatory subunit 
13 
2 2 8,8 1 2 4 1,0 
O00231 
26S proteasome non-ATPase regulatory subunit 
11 
2 2 5,9 1 1 3,1 0,5 
O00232 
26S proteasome non-ATPase regulatory subunit 
12 
1 1 2,6 0 0 0 In liver only 
       
Proteasome alpha subunits        
Q8TAA3 Proteasome subunit alpha type 7-like 0 0 0 2 3 9,8 In HCC only 
P25786 Proteasome subunit alpha type 1 2 2 8,7 4 5 14,8 2,5 
O14818 Proteasome subunit alpha type 7 2 3 12,1 5 6 23,4 2,0 
P25789 Proteasome subunit alpha type 4 1 2 3,8 2 2 9,2 1,0 
P60900 Proteasome subunit alpha type 6 4 5 13 4 4 16,3 0,8 
P25787 Proteasome subunit alpha type 2 4 7 23,9 4 4 20,1 0,6 
P25788 Proteasome subunit alpha type 3 1 3 5,5 1 1 3,5 0,3 
P28066 Proteasome subunit alpha type 5 3 3 21,6 1 1 5 0,3 
Proteasome beta subunits        
P28072 Proteasome subunit beta type 1 1 4,6 3 3 13,4 3,0 
P49720 Proteasome subunit beta type 3 5 7 30,2 5 8 28,3 1,1 
P28070 Proteasome subunit beta type 4  1 2 8,3 2 2 11,7 1,0 
P49721 Proteasome subunit beta type 2 6 8 34,8 6 7 39,3 0,9 
P28065 Proteasome subunit beta type 9 3 4 12,3 3 3 12,8 0,8 
P20618 Proteasome subunit beta type 1 6 8 31,1 5 5 36,9 0,6 
P28074 Proteasome subunit beta type 5 1 1 6,3 0 0 0 
P28062 Proteasome subunit beta type 8 2 3 8,3 0 0 0 
P40306 Proteasome subunit beta type 10 1 1 7,3 0 0 0 
In liver only 
 
 
Table 15: Proteasome components identified by mass spectrometry. The number of 
distinct peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins 
of non-tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of 
Tp (HCC/liver) are quoted.  
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Figure 28: Abundance of proteasomal components in non-tumorous liver and HCC 
tissues determined by mass spectrometry 
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5.5 Glycolysis and glycogen metabolism 
Many tumors gain energy via aerobic glycolysis, known as Warburg effect [259]. The latter is 
characterized by the increased uptake of glucose and the concomitant reduction of oxidative 
phosphorylation even in the presence of oxygen. Hence, pyruvate is predominantly reduced to lactate 
in order to regenerate reduction equivalents (NAD
+
). Rapidly growing cells take up nutrients at high 
rates and use them for energy acquisition and for biosyntheses. The pyruvate kinase isoform M2 has 
recently gained center stage concerning the balance of catabolic and anabolic processes of tumor 
cells [260, 261]. In addition, the overexpression of glycolytic genes is considered a common feature of 
cancer cells [262]. However, hepatocytes primarily use intermediates of glycolysis for biosyntheses 
whereas its contribution for energy acquisition is negligible. Furthermore, the liver stores glucose as 
glycogen and releases it in response to insulin in order to keep blood glucose levels constant. Hence, 
the assumption of overexression of glycolytic enzymes is discussed in the face of data acquired via 
shotgun and correlated to immunohistochemical and EHCO data. Enzymes involved in glycolysis and 
glycogen metabolism are depicted in figure 29.  
 
Figure 29: Proteins involved in glucose metabolism identified via mass spectrometry 
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Shotgun data of proteins involved in glucose metabolism (glycolysis, gluconeogenesis, and glycogen 
metabolism) are listed in table 16. Mass spectrometrical, immunohistochemical, and EHCO data are 
compiled in figure 31. Neither hexokinase (3 isoforms) nor glucokinase (~hexokinase IV) which 
catalyze the first step in the utilization of glucose (phosphorylation) in glycolysis were detected. 
Interestingly, immunohistochemical data state unaltered expression of liver cancer compared to 
normal liver tissue (data not shown).  
The second step in glycolysis is catalyzed by glucose-6-phosphate isomerase (P06744) which was 
strongly downregulated in accordance to histologically derived and EHCO data. Phosphofructokinase 
(liver-form) which phosphorylates fructose-6-phosphate to fructose-1,6-bisphosphate was not 
detected, neither in HCC nor in non-tumorous liver tissue. Interestingly, data form “Human Protein 
Atlas” state downregulation or even loss of expression by tendency for that protein. 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of 
Tp 
(HCC/liver) 
P06744 Glucose-6-phosphate isomerase 3 7 8,2 3 3 7,5 0,4 
P09467 Fructose-1,6-bisphosphatase 1 15 27 53,3 9 25 36,7 0,9 
P05062 Fructose-bisphosphate aldolase B 15 29 41,2 13 25 38,7 0,9 
P04075 Fructose-bisphosphate aldolase A 1 2 5,5 3 5 12,9 2,5 
P09972 Fructose-bisphosphate aldolase C 1 2 4,4 1 3 4,4 1,5 
P60174 Triosephosphate isomerase 14 34 54,2 20 57 79,5 1,7 
P04406 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 14 23 50,4 13 30 53,4 1,3 
P00558 Phosphoglycerate kinase 1 14 17 51,1 8 18 34,3 1,1 
P18669 Phosphoglycerate mutase 1 6 12 40,6 8 19 47,6 1,6 
P06733 Alpha-enolase  15 47 54,6 25 73 68 1,6 
P30613 Pyruvate kinase isozymes R/L 
0 0 0 2 2 6,1 
In HCC 
only 
P14618 Pyruvate kinase isozymes M1/M2 2 3 5,3 0 0 0 In liver only 
         
P07195 L-lactate dehydrogenase B chain 2 2 7,5 0 0 0 In liver only 
P00338 L-lactate dehydrogenase A chain  9 20 33,1 3 3 10,8 0,2 
         
P11498 Pyruvate carboxylase, mitochondrial 
36 64 43,2 20 32 25,2 0,5 
Q16822 
Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial  
30 71 46,1 35 150 50,5 2,1 
P40926 Malate dehydrogenase, mitochondrial  
18 26 61,8 31 74 71,3 2,8 
         
P40925 Malate dehydrogenase, cytoplasmic  4 5 12,9 5 6 19,2 1,2 
P35558 Phosphoenolpyruvate carboxykinase, cytosolic [GTP]  
6 12 11,9 4 12 6,4 1,0 
         
P35573 Glycogen debranching enzyme  2 2 2,5 0 0 0 
P06737 Glycogen phosphorylase, liver form 16 37 23,6 0 0 0 
In liver only 
Q16851 UTP--glucose-1-phosphate uridylyltransferase 2  13 57 37,6 11 26 30,9 0,5 
P36871 Phosphoglucomutase-1  24 37 55,3 11 14 29,9 0,4 
 
Table 16: Proteins participating glucose metabolism identified by mass spectrometry. 
The number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. 
(%)) of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as 
well as the ratio of Tp (HCC/liver) are quoted. 
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Three tissue-specifically expressed or at least categorized isoforms of fructosebisphosphate aldolase 
were identified. Blasting of peptide sequences (NCBI Blast) confirmed the presence of aldolase B, 
liver-form (P05062), aldolase A (P04075), and aldolase C (P09972). Indeed, all peptides of aldolase A 
and C were specific for the respective isoform. Interestingly, EHCO data indicate a strong tendency for 
downregulation of aldolase B and upregulation of aldolase A in liver cancer. The latter is in 
accordance with shotgun and immunohistochemical data. Indeed, aldolase A was described as the 
predominant isoform in primary liver cancer and was suggested the more reliable serum marker than 
α-fetoprotein [263] which was not detected in the investigated sample (see also the enhanced 
expression of α-fetoprotein by the hepatoma-derived cell line Hep3B compared to primary human 
hepatocytes and in contrast to HepG2 [36]).Triosephosphate isomerase (P60174) was found to be 
moderately more abundant in HCC tissue. However, immunohistochemical evaluation revealed equal 
or downregulated expression rather than upregulation as suggested by EHCO data. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; P04406) was slightly more abundant in accordance to the 
immunohistochemically based estimation of about 73% of liver cancer samples showing unaltered 
expression (see proteinlist in appendix). However, this is in contrast to EHCO data with 6 citations (of 
8 datasets) stating upregulation of GAPDH. Phosphoglycerate mutase 1 (P18669) and α-enolase 
(P06733) were slightly upregulated in HCC whereas immunohistochemical and EHCO data indicate 
tendential downregulation of enolase. It is noteworthy that all enzymes described for the conversion of 
3-carbon glycolytic intermediates described thus far were slightly to moderately more abundant in 
HCC. In addition, pyruvate kinase isozymes R/L (P30613) and M1/M2 (P14618) were differentially 
expressed by being solely detected in HCC and liver, respectively. However, EHCO data state liver 
cancer-related upregulation for both isoforms which is at least confirmed for isoform M1/M2 by 
immunohistochemistry (data not shown, see www.proteinatlas.org).  
 
Interestingly, mitochondrial PEP carboxykinase (PEP: phosphoenolpyruvate; Q16822) and malate 
dehydrogenase (P40926) were significantly upregulated in HCC tissue in contrast to their catalytically 
equivalent cytoplasmic counterparts (P35558, P40925). They are involved in the conversion of 
oxalacetate, a metabolite of the citrate cycle, in mitochondria. However, citrate synthase (O75390) as 
well as transaminase A (P17174) were significantly downregulated, possibly reflecting a metabolic 
preference towards formation of PEP and malate instead of citrate and aspartate (Figure 30). 
 
Lactate dehydrogenase dehydrogenase chains A (P00338) and B (P07195) were detected solely in 
liver or pronouncedly less abundant in HCC, respectively. Lactate dehydrogenase catalyzes the 
interconversion of pyruvate and lactate and converts pyruvate to lactate in conditions of short oxygen 
supply. In addition, lactat dehydrogenase catalyzes the reverse reaction in the course of the Cori cycle 
in liver. The latter is crucial for gluconeogenesis from muscle-derived lactate by hepatocytes. Notably, 
increased lactate is characteristic for the Warburg effect. 
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Figure 30: Metabolism of oxalacetate (Abbreviations: PEPC Phosphoenolpyruvate 
carboxylase, PEPCK Phosphoenolpyruvate carboxykinase, MDH Malate) 
(derived from Wikipedia) 
 
Four enzymes involved in glycogen metabolism were detected (P35573, P06737, Q16851, P36871), 
all of which were significantly downregulated in HCC suggesting the impairment of this crucial liver-
specific pathway in liver cancer. For glycogen phosphorylase (P06737) and phosphoglucomutase-1 
(P36871) immunohistochemical expression data were available and confirmed the shotgun results.  
 
In conclusion: 
1. Glucose-6-phosphate isomerase was found to be less abundant in HCC tissue according to 
immunohistochemical and EHCO data. In addition, protein expression data for 
hexokinase/glucokinase and phosphofructokinase derived from “Human Protein Atlas” indicate 
the downregulation of both proteins in liver tumors.  
2. Aldolase isoform A normally repressed in adult liver was more abundant in HCC. This result 
was supported by immunohistochemical and EHCO data.  
3. Interestingly, the expression of enzymes for the conversion of 3-carbon glycolytic 
intermediates inclusive 2-phosphoglycerate were consistently upregulated in HCC. In addition, 
shotgun data indicate the differential expression of pyruvate kinase isoforms. 
4. Mitochondrial enzymes involved in the conversion of oxalacetate were differentially expressed 
in HCC and normal liver. Based on these data, a preference for the formation of 
phosphoenolpyruvate and malate might be supposed. 
5. Surprisingly, lactate dehydrogenase was found to be less abundant in HCC (see Warburg 
effect) 
6. Enzymes involved in glycogen metabolism were less abundant in HCC indicating the 
impairment of this liver-specific pathway 
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Figure 31: Shotgun data (above), immunohistochemical (below left), 
and EHCO data (below right) concerning the relative 
abundance of glycolytic enzymes in non-tumorous liver 
and liver cancer/HCC tissues The blue lines and numbers 
depicted in the boxplot denote the expression level of the 
respective proteins in normal liver tissue. 
 
 
 
 
Uniprot-ID up down 
P06744 No results 
P09467 0 4 
P05062 0 6 
P04075 3 0 
P09972 No results 
P60174 1 0 
P04406 4 0 
P18669 No results 
P06733 0 2 
P30613 1 0 
P14618 2 0 
   
P07195 0 1 
P00338 1 2 
   
P11498 0 1 
Q16822 0 4 
P40926 1 0 
   
P40925 1 0 
P35558 0 6 
   
P35573 1 1 
P06737 0 1 
Q16851 0 2 
P36871 0 1 
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5.6 Comparison of functions mediated by mitochondria and the peroxisomes 
 
5.6.1 Mitochondrial functions of HCC and liver- a global view 
Mitochondrial enzymes mediate liver-specific and common metabolic features. A part of the urea cycle 
takes place in mitochondria as well as fatty acid metabolism, the citrate cycle, and oxidative 
phosporylation. In terms of total peptides of mitochondrial proteins detected in liver and HCC tissue, 
the difference was negligible (2% difference) (Figure 32). However, a pronounced reduction of 
proteins invoved in amino acid metabolism and an increase in enzymes involved in energy metabolism 
and fatty acid metabolism was observed. Examples of amino acid-degrading enzymes found to be 
downregulated in HCC were glutamate dehydrogenase 1/2 (P00367/P49448 with Tp of 68/16 in 
liver/HCC), glycine dehydrogenase (P23378 with Tp of 8 detected exclusively in liver), and aspartate 
aminotransferase (P00505 with Tp of 41/14 in liver/HCC)). These data were consistent with 
immunohistochemical and EHCO data (data not shown). 
 
 
Figure 32: Functional comparison of mitochondrial proteins of liver (above) and HCC 
tissue (below). Percentage given for each functional group correspond to total 
peptide numbers of the respective group related to the total peptide number of 
proteins of non-tumorous liver tissue. 
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5.6.2 The urea cycle 
The metabolic conversion of ammonia to urea is a specific function of hepatocytes. Its physiological 
impact is underlined by “urea cycle disorders”, classified as “inborn errors of metabolism”, resulting 
from the genetic deficiency of enzymes involved in the urea cycle. Moreover, liver failure leads to 
hyperammonaemia and eventually manifests in “Coma hepaticum”. All enzymes, located in 
mitochondria and the cytoplasm, were identified by shotgun and mass spectrometry (Table 17).  
 
Uniprot-ID Description Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of 
Tp 
HCC/liver 
P31327 Carbamoyl-phosphate synthase 87 257 62,2 76 150 54,5 0,6 
P00480 Ornithine carbamoyltransferase 13 24 54 12 15 49,2 0,6 
         
P00966 Argininosuccinate synthase 12 19 37,4 4 5 18,4 0,3 
P04424 Argininosuccinate lyase 5 7 18,8 6 9 21,1 1,3 
P05089 Arginase-1 (liver-type) 19 31 57,8 14 16 50 0,5 
Table 17: Proteins of the urea cycle identified by mass spectrometry. The number of 
distinct peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins 
of non-tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of 
Tp (HCC/liver) are quoted. 
 
There is a remarkable trend towards lower expression levels compared to non-tumorous liver, 
indicating a reduced capability of tumorous cells to detoxify ammonia. The data are in accordance with 
immunohistochemical and protein expression data obtained from “Protein Atlas” and EHCO, 
respectively. Figure 34 depicts the expression levels of the respective proteins of HCC relative to non-
tumorous liver tissue. Immunohistochemical data were elaborated as described above. Expression 
levels of all urea cycle enzymes are comparably high in terms of intensity and quantity (exemplified in 
figure 33) resulting in a REL of 1. Figure 34 depicts shotgun data, relative values for REL derived from 
immunohistochemical data, and compiles the numbers of citations with respect to up- and 
downregulation from EHCO.  
 
Figure 33: Immunohistochemical detection of carbamoyl-phosphate synthase (P31327) 
in liver indicating strong expression (intensity: strong) of more than 75% of 
hepatocytes (quantity: >75%) (from www.proteinatlas.org). 
 
  80  
257
24 19
7
31
150
15
5 9
16
0
50
100
150
200
250
300
P31327 P00480 P00966 P04424 P05089
liver
HCC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of enzymes of the urea cycle 
in non-tumorous liver and liver cancer/HCC tissues. The blue lines and 
numbers depicted in the boxplot denote the expression level of the respective 
proteins in normal liver tissue. 
 
 
 
 
 
 
 
 
 
Uniprot-ID up down 
P31327 1 4 
P00480 0 2 
P00966 0 3 
P04424 No results 
P05089 0 6 
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5.6.3 Mitochondrial and peroxisomal β-oxidation of fatty acids 
 
The liver plays an essential role in the metabolism of fatty acids. The degradation of the latter is 
mediated by three distinct enzyme systems located in mitochondria (β-oxidation), peroxisomes (α- and 
β-oxidation), and microsomes (monooxygenases, e.g. Cyp4A1). Figure 35 illustrates the biochemical 
reactions and proteins involved in β-oxidation of mitochondria and peroxisomes. Proteins identified via 
mass spectrometry are in bold. The mitochondrial β-oxidation pathway is further subdivided into 
functional groups comprising enzymes mediating continuous rounds of acetyl-CoA and acyl-CoA (n-2) 
formation, enzymes involved in the conversion of propionyl-CoA derived from fatty acids with odd C-
atom numbers, enzymes involved in the degradation of unsaturated fatty acids, and enzymes 
mediating keton body formation.  
 
Figure 35: Proteins involved in fatty acid metabolism identified via mass spectrometry (in 
bold characters) 
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The alteration of the metabolism of long-chain fatty acids seems to be a common feature of tumors 
and is, indeed, observed in conjunction with hepatocellular carcinoma as well. It is reflected by 
increased plasma levels of free fatty acids observed e.g. in tumor-bearing rats [264], in mice with 
mammary tumors [265], and in patients with breast tumors [266]. In addition, the fatty acid composition 
of human non-tumorous and HCC tissue is significantly different with respect to alpha-linolenic acid 
and docosahexaenic acid, both being strongly reduced in liver cancer [267]. Moreover, free fatty acid 
levels were increased in ascites of patients with malignant abdominal tumors compared to that with 
liver cirrhosis and the ratio of unsaturated and saturated fatty acids was increased in patients with 
neoplasms [268, 269]. A similar result was obtained from patients suffering from primary and 
secondary liver tumors exhibiting a reduced ratio of stearic and oleic acid levels representing 
saturated and unsaturated C18-fatty acids, respectively [270]. Indeed, shotgun data supported 
alterations of the fatty acid metabolism at the protein expression level.  
 
5.6.3.1 Mitochondrial proteins 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P43155 Carnitine O-acetyltransferase (CAT) 3 3 7,5 0 0 0 0,0 
P23786 Carnitine O-palmitoyltransferase 2 (CPT II) 10 11 22,3 11 14 18,5 1,3 
Q86TX2/ 
P49753 
Acyl-coenzyme A thioesterase 1/2 8 20 30,4 5 21 17,8 1,1 
         
P49748 
Acyl-CoA dehydrogenase, very-long-chain specific; 
(VLCAD) 
18 27 35,3 2 3 5,5 0,1 
P11310 
Acyl-CoA dehydrogenase, medium-chain specific; 
(MCAD) 
14 18 36,1 7 8 28,3 0,4 
P16219 
Acyl-CoA dehydrogenase, short-chain specific, 
(SCAD) 
10 11 32,5 3 3 8,5 0,3 
Q16836 
Short chain 3-hydroxyacyl-CoA dehydrogenase, 
(HCDH) 
9 15 48,7 13 17 71,3 1,1 
P45954 
Acyl-CoA dehydrogenase, short/branched chain 
specific; (SBCAD) 
19 31 50,2 11 22 33,3 0,7 
         
P40939 Trifunctional enzyme alpha subunit, (TP-alpha) 29 62 51,1 29 70 46,5 1,1 
P30084 Enoyl-CoA hydratase, (SCEH) 19 60 65,9 18 48 63,8 0,8 
Q16836 
Short chain 3-hydroxyacyl-CoA dehydrogenase, 
(HCDH) 
9 15 48,7 13 17 71,3 1,1 
Q99714 3-hydroxyacyl-CoA dehydrogenase type II; HADH 14 38 82,8 19 36 87,4 0,9 
Q9Y2S2 Lambda-crystallin homolog 3 5 10,3 4 6 13,8 1,2 
         
P55084 Trifunctional enzyme subunit beta; (TP-beta) 15 28 41,6 7 10 16 0,4 
P42765 3-ketoacyl-CoA thiolase, (T1) 19 42 56,4 25 70 65,2 1,7 
Table 18: Proteins participating in mitochondrial beta-oxidation identified by mass 
spectrometry. The number of distinct peptides (Dp), total peptides (Tp), and 
coverage (Cov. (%)) of proteins of non-tumorous liver (blue) and/or HCC tissue 
(orange) as well as the ratio of Tp (HCC/liver) are quoted. 
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Mitochondrial β-oxidation is based on continuous rounds of fatty acid chain shortening. The first step is 
the oxidation of fatty acids catalyzed by various acyl-CoA dehydrogenases with distinct chain length 
specificity. Their physiological impact is reflected by recessive autosomal diseases due to deficiencies 
of the various acyl-CoA dehydrogenases. The loss of VLCAD (Very-long-chain-specific acyl-CoA 
dehydrogenase; P49748) function, for instance, leads to impaired long-chain fatty acid β-oxidation. 
VLCAD metabolizes long-chain fatty acids such as palmitoyl-CoA, mysritoyl-CoA and stearoyl-CoA to 
acyl chain lengths of 12 carbons. MCAD (Medium-chain-specific acyl-CoA dehydrogenase, P11310) is 
specific for acyl chain lengths of 4 to 16 C-atoms and SCAD (Short-chain-specific dehydrogenase, 
P16219) oxidizes butanoyl-CoA to 2-butenoyl-CoA. Interestingly, VLCAD, MCAD, and SCAD were 
significantly less abundant in HCC compared to non-tumorous liver tissue. In contrast, all other 
enzymes involved in the formation of acyl-CoA and acetyl-CoA were more or less equally abundant in 
both tissues (Figure 36, table 18). This suggests that reduced VLCAD/MCAD/SCAD levels constitute a 
functional bottleneck concerning mitochondrial fatty acid degradation. These data are in accordance 
with immunohistochemical data (Figure 37). VLCAD, MCAD and SCAD show the tendency for 
downregulation in histological slices of HCC compared to liver tissue. Downregulation of acyl-CoA 
dehydrogenases was also published in EHCO. However, proteins with unaltered expression levels in 
shotgun were stated to be downregulated (e.g. 7 of overall 8 datasets compiled in EHCO claim enoyl-
CoA hydratase (P30084) to be downregulated) (figure 37). This might indicate alternative ways for the 
modification of fatty acid metabolism realized by liver tumors. 
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Figure 36: Abundance of enzymes of the mitochondrial β-oxidation in non-tumorous liver 
and HCC tissues determined by mass spectrometry 
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Figure 37: Immunohistochemical (below left) and EHCO data (below right) concerning 
the relative abundance of mitochondrial enzymes involved in β-oxidation in 
non-tumorous liver and liver cancer/HCC tissues. The blue lines and numbers 
depicted in the boxplot denote the expression level of the respective proteins in 
normal liver tissue. 
 
 
The degradation of fatty acids with odd C-numbers finally results in the formation of propionyl-CoA 
(instead of acetyl-CoA) which is converted to succinyl-CoA. Three enzymes involved in this process 
have been identified: Propionyl-CoA carboxylase (PCC subunits alpha (P05165) and beta (P05166)), 
methylmalonyl-CoA mutase (P22033) and methylmalonyl-CoA epimerase (Q96PE7) (Table 19).  
 
Odd number fatty acids Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov.
(%) 
Ratio of Tp 
(HCC/liver) 
P05165 Propionyl-CoA carboxylase alpha chain; (PCCase subunit alpha) 9 9 19,3 0 0 0 0,0 
P05166 Propionyl-CoA carboxylase beta chain, (PCCase subunit beta) 15 24 38,4 7 9 19,7 0,4 
Q96PE7 Methylmalonyl-CoA epimerase 4 5 26,1 4 5 26,1 1,0 
P22033 Methylmalonyl-CoA mutase 15 22 28,1 1 2 2,1 0,1 
 
Table 19: Proteins for the conversion of propionyl-CoA identified by mass spectrometry. 
The number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. 
(%)) of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as 
well as the ratio of Tp (HCC/liver) are quoted. 
 
The impact of PCC on physiology is underlined by a hereditary disease leading to propionic acidemia 
due to PCC deficiency. Apart from its function in fatty acid metabolism it is also indispensable for the 
Uniprot-
ID up down 
P43155 0 1 
P23786 0 1 
Q86TX2/ 
P49753 0 1 
   
P49748 0 4 
P11310 0 2 
P16219 0 5 
Q16836 0 2 
P45954 0 6 
   
P40939 No results 
P30084 0 7 
Q16836 0 2 
Q99714 0 2 
Q9Y2S2 0 2 
   
P55084 0 2 
P42765 0 3 
   
Q13011 0 2 
P42126 0 1 
Q16698 0 3 
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breakdown of the essential amino acids valine, isoleucine, threonine, and methionine. Disruption of 
PCCA or PCCB prevents these acids from being metabolized leading to the accumulation of 
propionyl-CoA, propionic acid, ketones and other toxic compounds in the blood (Uniprot: P05165 and 
P05166). Methylmalonyl-CoA epimerase is also involved in the degradation of those amino acids as 
well as cholesterol via propionyl-CoA. Defects in this enzyme result in methylmalonic aciduria type 
mut. Methylmalonyl-CoA racemase catalyzes the interconversion of (R-) and (S-) methylmalonyl-CoA. 
Racemase deficiency causes methylmalonic aciduria type 3, an autosomal recessive disease leading 
to metabolic acidosis and secondary hyperammonaemia. PPCase subunits alpha and beta as well as 
methylmalonyl-CoA epimerase were significantly less abundant in HCC tissue indicating the tumor-
associated deficiency in the conversion of propionyl-CoA from β-oxidation of odd-chain fatty acids, the 
degradation of amino acids valine, threonine, isoleucine, and methione as well as cholesterin (Figure 
38, table 19). Unfortunately, immunohistochemical data for those proteins were not available and 
EHCO delivered contradictory data (Table 20). 
 
Uniprot-ID up down 
P05165 1 1 
P05166 1 0 
Q96PE7 1 0 
P22033 0 2 
Table 20: EHCO data for enzymes for the conversion of propionyl-CoA 
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Figure 38: Relative abundance of enzymes involved in the degradation of unsaturated 
fatty acids, fatty acids with odd C-numbers, and keton body formation 
determined via mass spectrometry 
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The degradation of unsaturated fatty acids requires the enzymes delta3,5-delta2,4-dienoyl-CoA 
isomerase (Q13011), 3,2-trans-enoyl-CoA isomerase (P42126), and 2,4-dienoyl-CoA reductase 
(Q16698). The latter two were strongly upregulated in HCC tissue (Figure 38, table 21).  
 
Unsaturated fatty acids Dp Tp 
Coverage 
(%) 
Dp Tp 
Coverage 
(%) 
Ratio of Tp 
(HCC/liver) 
Q13011 Delta3,5-delta2,4-dienoyl-CoA isomerase 10 22 35,7 15 24 57,3 1,1 
P42126 3,2-trans-enoyl-CoA isomerase 5 6 25,2 9 12 36,8 2,0 
Q16698 2,4-dienoyl-CoA reductase 6 11 26,3 10 22 35,8 2,0 
 
Table 21: Proteins participating in the degradation of unsaturated fatty acids identified by 
mass spectrometry. The number of distinct peptides (Dp), total peptides (Tp), 
and coverage (Cov. (%)) of proteins of non-tumorous liver (blue) and/or HCC 
tissue (orange) as well as the ratio of Tp (HCC/liver) are quoted. 
 
Histological data support the overexpression of 2,4-dienoyl-CoA reductase and the unaltered 
expression or slight upregulation of ∆3,5-delta2,4-dienoyl-CoA isomerase (Figure 39). Although both 
proteins show RELs of 1 for liver and tumorous tissue, there is indeed a significant difference in the 
expression levels (Figure 39). No data concerning the physiological impact of upregulation for these 
proteins were available. However, the impact of disruption of these enzymes on physiology is 
indicated by knock-out mouse models [271, 272].  
 
D
A B
C
 
Figure 39: Immunohistochemical detection of ∆3,5-delta2,4-dienoyl-CoA isomerase 
(Q13011; A, B) and 2,4-dienoyl-CoA reductase (Q16698; C, D) of normal liver 
(A, C) and liver cancer tissue (B, D) (derived from www.proteinatlas.org) 
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Keton bodies (acetone, acetoacetic acid, and beta-hydroxybutyric acid) are produced as by-products 
of fatty acid beta-oxidation by hepatocytes and serve as energy source for heart and brain. The 
abundance of enzymes involved in keton body formation (acetyl-CoA acetyltransferase (T2), P24752); 
HMG-CoA synthase, P54868; HMG-CoA lyase, P35914; D-beta-hydroxybutyrate dehydrogenase 
(BDH), Q02338) was equal or just slightly different in non-tumorous vs. HCC tissue (Table 22).  
 
Keton body formation Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P24752 Acetyl-CoA acetyltransferase; (T2) 20 37 44,5 14 36 37,5 1,0 
P54868 Hydroxymethylglutaryl-CoA synthase, (HMG-CoA synthase) 23 42 46,3 25 76 47 1,8 
P35914 Hydroxymethylglutaryl-CoA lyase, (HMG-CoA lyase) 8 19 28,6 12 17 36,6 0,9 
Q02338 D-beta-hydroxybutyrate dehydrogenase, (BDH) 9 16 28,3 9 10 32,9 0,6 
 
Table 22: Proteins participating keton body formation identified by mass spectrometry. 
The number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. 
(%)) of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as 
well as the ratio of Tp (HCC/liver) are quoted. 
 
 
However, immunohistochemical protein expression data for P24752 and P35914 show the tendency 
for downregulation of those proteins (Figure 37) which is in accordance with EHCO-derived 
expression data (Table 23). 
 
Uniprot-ID up down 
P24752 0 4 
P54868 0 3 
P35914 0 2 
Q02338 0 2 
 
Table 23: EHCO data for enzymes for keton body formation 
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5.6.3.2 Peroxisomal proteins 
 
Enzymes of peroxisomal β-oxidation identified via mass spectrometry are listed in table 24. The 
degradation of fatty acids in peroxisomes is limited to chain-shortening reactions producing fatty acids 
of reduced chain lengths which are consequently transferred to mitochondria in the form of carnitine 
esters. Nevertheless, peroxisomes contain enzymes of unique substrate specificity (figure 35, table 
24). Hexacosanoic acid (C26:0) derived from diet or by endogenous synthesis is exclusively 
metabolized in peroxisomes by acyl-CoA oxidase 1 (AOX; Q15067). Pristanic acid (2,6,10,14-
tetramethylpentadecanoic acid) is also solely oxidized by peroxisomal acyl-CoA oxidase 2 (THCCox; 
Q99424). The latter additionally mediates the conversion of dihydroxycholestanoic and 
trihydroxycholestanoic acid, both formed in the liver from cholesterol, to chenodeoxycholate and 
cholate, respectively, followed by their excretion into bile canaliculi [273]. 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver 
Q15067 Acyl-coenzyme A oxidase 1, (AOX) 5 5 11,5 4 4 10,5 0,80 
Q99424 Acyl-coenzyme A oxidase 2,  (THCCox) 2 3 4,6 0 0 0 In liver only 
         
P51659 
Peroxisomal multifunctional enzyme type 2, 
(DBP) 
18 30 28,3 6 10 10,3 0,33 
Q08426 Peroxisomal bifunctional enzyme (PBE) 22 33 34 26 52 41,8 1,58 
P09110 3-ketoacyl-CoA thiolase, (Beta-ketothiolase) 18 33 52,4 18 33 53,8 1,00 
         
P04040 Catalase 22 33 48 27 51 56,5 1,55 
         
Q9NUI1 Peroxisomal 2,4-dienoyl-CoA reductase (pDCR) 
0 0 0 2 2 4,1 
In HCC 
only 
O75521 
Peroxisomal 3,2-trans-enoyl-CoA isomerase; 
(DRS-1); (Hepatocellular carcinoma-associated 
antigen 88) 
10 13 36,5 8 9 27,3 0,69 
Table 24: Proteins of the peroxisomal degradation of fatty acids identified by mass 
spectrometry. The number of distinct peptides (Dp), total peptides (Tp), and 
coverage (Cov. (%)) of proteins of non-tumorous liver (blue) and/or HCC tissue 
(orange) as well as the ratio of Tp (HCC/liver) are quoted. 
 
AOX and THCCox are highly substrate-specific. Interestingly, AOX expression was unaltered whereas 
THCCox was exclusively detected in non-tumorous liver indicating an HCC-associated deficiency to 
metabolize pristanic acid and cholesterol derivatives including bile acids. The D-bifunctional protein 
(DBP; P51659) which is also indispensable for bile acid formation was significantly less abundant in 
HCC tissue. However, PBE (Q08426) upregulated in HCC exhibits slightly different substrate 
specificity and might compensate for the partial loss of DBP or reflect the altered abundance of fatty 
acid species. Interestingly, expression data for DBP are contradictory with downregulation via 
shotgun, EHCO (1 citation up, 2 citations down), and putative stable expression via 
immunohistochemistry (both tissues have REL 1). However, examination of histological slices 
revealed partially strong upregulation of DBP (as exemplified by figure 40). Shotgun data, 
immunohistochemical and EHCO data are compiled in figure 41. 
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Figure 40: Immunohistochemical detection of DBP (P51659) in slices of normal liver (A) 
and liver cancer tissue (B) (derived from www.proteinatlas.org) 
5
3
30
33 33 33
0
13
4
0
10
52
33
51
2
9
0
10
20
30
40
50
60
Q15067 Q99424 P51659 Q08426 P09110 P04040 Q9NUI1 O75521
Uniprot-ID
N
u
m
b
e
r 
o
f 
to
ta
l p
e
p
tid
e
s
 (
T
p
)
liver
HCC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of peroxisomal fatty acid-
degrading enzymes in non-tumorous liver and liver cancer/HCC tissues. The 
blue lines and numbers depicted in the boxplot denote the expression level of 
the respective proteins in normal liver tissue. 
Uniprot-ID up down 
Q15067 0 2 
Q99424 0 3 
P51659 1 2 
Q08426 0 1 
P09110 0 2 
P04040 0 6 
   
Q9NUI1 0 1 
O75521 No results 
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In conclusion, shotgun data suggest 
1. a pronouncedly reduced mitochondrial β-oxidation of fatty acids indicated by the low 
abundance of three distinct acyl-CoA dehydrogenases (VLCAD, MCAD, SCAD) 
2. that the conversion of propionyl-CoA (derived from the degradation of fatty acids with odd C-
number) to succinyl-CoA was strongly compromized in the investigated HCC sample. This 
assumption is based on three (of overall four) enzymes involved in this process found to be 
pronouncedly downregulated in the tumorous tissue in contrast to  
3. auxiliary enzymes for the conversion of unsaturated fatty acids. 
4. the impairment of the peroxisomal conversion of pristanc acid and other compounds mediated 
by the highly substrate-specific acyl-coenzyme A oxidase 2. In addition, the catalytically 
equivalent but potentially substrate-specifically distinct enzymes DBP and PBE were 
differentially expressed in the investigated tissue samples. 
Taken together, those results point to the adaptation or reorganization of the fatty acid metabolism by 
HCC tumors and underline findings gained by alternative methods at the functional proteome level. 
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5.7 Comparison of lysosome-mediated functions of liver and HCC 
 
The lysosome is primarily derived from the Golgi apparatus, secondarily from phagolysosomes and 
autophagolysosomes. It constitutes the principal digestive organ of the cell. Indeed, hepatocytes are 
capable to exhibit autophagy for e.g the removal and recycling of mitochondria. Moreover, endosomal 
vesicles end up in lysosomes resulting in the complete turn-over of the cell membrane within an hour. 
Lysosomes are acidified via H
+
-ATPase to a pH of <5 and contain degrading enzymes for biological 
macromolecules such as acid esterases (cleavage of ester bonds via phosphate or sulfate, DNAses, 
RNAses, 1,4-glucosidase (mutated/inactive in lysosomal storage disease Morbus Pompe), cathepsins 
A, D, E, and carboxypeptidase for the recycling of amino acids for protein synthesis.  
Overall 17 lysosomal proteins were identified in non-tumorous liver and HCC tissues. The proteins 
were assigned to four functional groups: Protein degradation, lipid degradation, polysaccharide 
degradation, and lysosomal acidification. The global comparison of those tissues revealed "loss of 
function" in protein and lipid degradation as well as "gain of function" in polysaccharide metabolism by 
lysosomes of tumor cells (Figure 42). Taking individual protein species within the functional groups 
into account a considerable metabolic diversification could be observed. The impact of enzymes 
mediating polysaccharide degradation is underlined by inherited storage disorders attributable to 
defects of the respective proteins. They frequently manifest in hepatomegaly in consequence of the 
deposition of excess non-degradable polysaccharides, lipids and/or metabolites thereof (table 25). 
Hence, HCC tissue might resemble liver tissue of patients suffering from storage diseases with respect 
to histologic and anatomical alterations. 
 
 
 
 
 
 
 
 
 
Figure 42: Functional comparison of liver (left) and HCC tissue (right). Percentage given 
for each functional group correspond to total peptide number of the respective 
group related to the total peptide number derived from lysosomal proteins of 
non-tumorous liver tissue. 
 
5.7.1 The lysosome as proteolytic organelle 
The abundance of lysosomal proteases and peptidases in non-tumorous liver and HCC tissue showed 
a pronounced diversification (Figure43, above). Cathepsins A (P10619) and Z (Q9UBR2) were solely 
detected or more abundant, respectively, in the tumor tissue. Cathepsin A is supposed to be essential 
for the activity and stability of β-galactosidase and neuraminidase. However, β-galactosidase 
(P16278) was significantly downregulated in HCC (see below). However, cathepsin A additionally 
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exerts carboxypeptidase-activity and can deamidate tachykinins. Tachykinin downregulation was 
implicated in gastric cancer and oesophageal cancer by hypermethylation of the TAC-1 promotor [274, 
275]. Cathepsin Z, a matrix-degrading enzyme, was found to be overexpressed in aggressive 
melanoma [276]. 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P10619 Cathepsin A 0 0 0 3 7 5 In HCC only 
Q9UBR2 Cathepsin Z  1 1 4 2 3 7 3 
P07339 Cathepsin D  9 19 24.8 11 14 39 0.7 
O14773 Tripeptidyl-peptidase I  3 7 9.8 3 4 10 0.6 
P07858 Cathepsin B  8 17 26.3 7 9 25 0.5 
Q9UHL4 Dipeptidyl-peptidase 2  2 2 6.5 1 1 4 0.5 
P25774 Cathepsin S  2 2 8.2 0 0 0 In liver only 
Table 25: Lysosomal proteins participating in proteolysis identified by mass spectrometry. 
The number of distinct peptides (Dp), total peptides (Tp), and coverage (Cov. 
(%)) of proteins of non-tumorous liver (blue) and/or HCC tissue (orange) as 
well as the ratio of Tp (HCC/liver) are quoted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of lysosomal proteins involved 
in proteolysis in non-tumorous liver and liver cancer/HCC tissues. The blue 
lines and numbers depicted in the boxplot denote the expression level of the 
respective proteins in normal liver tissue. 
Uniprot-ID up down 
P10619 3 0 
Q9UBR2 0 1 
P07339 1 1 
P07858 0 1 
Q9UHL4 0 1 
P25774 1 0 
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5.7.2 The lysosome as polysaccharide and lipid degrading organelle 
 
The abundance of polysaccharide- and lipid-degrading enzymes varied pronouncedly between liver 
and HCC tissue. Storage diseases associated with the malfunction of specific enzymes indicate their 
biological impact (table 26).  
 
Table 26: Lysosomal proteins participating in polysaccharide and lipid degradation 
identified by mass spectrometry. The number of distinct peptides (Dp), total 
peptides (Tp), and coverage (Cov. (%)) of proteins of non-tumorous liver (blue) 
and/or HCC tissue (orange) as well as the ratio of Tp (HCC/liver) are quoted. 
For enzymes associated with lysosomal storage diseases, the stored materials 
and anatomical alterations are given. 
 
The marked downregulation of β-galactosidase (P16278) and acid ceramidase (Q13510) is underlined 
by immunohistochemical data stating downregulation of beta-galactosidase and acid ceramidase by 
tendency. The inherited disturbance of acid ceramidase expression and activity manifests in Farber 
disease (syn. Farber lipogranulomatosis), a sphinoglipid disease characterized by subcutaneous lipid 
deposition, pain in joints and extremities and causes the early death of affected individuals. In 
addition, it is characterized by the marked accumulation of ceramide in lysosomes underlining the 
putative impact of ceramidase downregulation on histologically and analytically observable alterations 
of the lipid composition of HCC tumors and plasma. By the way, exogenous ceramide has been 
shown to exert a pro-apoptotic acitivity on a rat hepatoma cell line [277]. 
 
 
 
 
 
 
 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
Storage 
disease 
Stored 
material 
Hepato-
megaly 
O00754 
Lysosomal alpha-
mannosidase  
0 0 0 1 1 1 
Q9HAT2 
Sialate O-
acetylesterase  
0 0 0 1 1 3 
In HCC only 
P07686 
Beta-
hexosaminidase 
beta chain  
2 2 7.6 5 8 14 4.0 
P10253 
Lysosomal alpha-
glucosidase 
5 6 6.6 6 8 10 1.3 
      
P16278 Beta-
galactosidase  
3 6 7.1 1 1 3 0.2 
GM1-
gangliosidosis 
Ganglioside, 
keratan 
sulfate 
 +++ 
P08236 
Beta-
glucuronidase 
2 2 5.1 0 0 0 In liver only MPS VII 
Dermatan 
sulfate 
 +++ 
            
Q13510 Acid ceramidase 6 11 25.3 1 1 7 0.1 Farber Ceramid  +/- 
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Figure 44: Shotgun data (above) and immunohistochemical data (below) concerning the 
relative abundance of lysosomal proteins involved in polysaccharide and lipid 
degradation in non-tumorous liver and liver cancer/HCC tissues. The blue lines 
and numbers depicted in the boxplot denote the expression level of the 
respective proteins in normal liver tissue. 
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5.8 Proteins involved in detoxification of endobiotic and xenobiotic 
substances 
 
Detoxifying enzymes are of special relevance by mediating resistance against anti-tumor drugs. Phase 
I reactions comprise hydrolysis, oxidation, and reduction of xenobiotics, phase II reactions include 
glucuronidation, sulfation, acetylation, methylation, glutathione conjugation, amino acid conjugation 
(glycine, taurine, glutamic acid). Apart from methylation and acetylation, hydrophilicity is increased and 
thence biliary or urinary excretion of xenobiotic or potentially harmful endogeneous substances is 
fostered. Phase II enzymes require cofactors (UDP-GA, PAPS, Acetyl-CoA, SAM, glutathione, taurine, 
glycine, glutamine) and are mainly located in the cytosol (except from UDP-glucuronosyltransferases).  
 
5.8.1 Phase I- enzymes 
Enzymes involved in hydrolysis, reduction and oxidation identified via mass spectrometry are listed in 
table 27 and table 28. Shotgun data, immunohistochemical and EHCO data are compiled in figure 46 
and figure 48. 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
O00748 Carboxylesterase 2 precursor  6 7 17.4 9 24 25.4 3.4 
P23141 Liver carboxylesterase 1 precursor  32 85 58.9 27 62 50.1 0.7 
P27169 Serum paraoxonase/arylesterase 1  2 2 4.2 5 10 20.8 5.0 
         
P07099 Epoxide hydrolase 1  2 3 8.4 4 9 12.3 3.0 
P34913 Epoxide hydrolase 2  7 11 18 2 4 7.4 0.4 
         
P16152/O75828 Carbonyl reductase [NADPH] 1/3 10 16 45.8 16 39 60.3 2.4 
Table 27: Phase I-enzymes identified by mass spectrometry. The number of distinct 
peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins of non-
tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of Tp 
(HCC/liver) are quoted. 
 
5.8.1.1 Hydrolysis 
Hydrolysis of carboxylic acid esters, amides, thioesters as well as phosphoric acid esters and acid 
anhydrides are catalyzed by carboxylesterases, pseudocholinesterase, and paraoxonase. The first 
three reactions are mainly catalyzed by tissue-associated carboxylesterases and by two blood 
esterases (true acetylcholinesterase in the erythrocyte membrane, pseudocholinesterase in serum). 
Carboxylesterases are also involved in the conversion of xenobiotics to tumorigenic and toxic 
compounds (e.g. vinyl acetate) as well as in the activation of ester and amide prodrugs (e.g. 
lovastatin) and anti-tumor drugs (CPT-11). Two carboxylesterases were identified via shotgun, the 
liver carboxylesterase 1 (P23141), Carboxylesterase 2 (O00748), both located in the ER. 
Carboxylesterase 2 which is suggested to be highly expressed in small intestinum but just moderately 
in liver (Uniprot) was found to be significantly upregulated in HCC in contrast to liver tissue. Indeed, 
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carboxylesterase 2 expression was found to be high in normal liver tissue represented in “Human 
Protein Atlas” (corresponding to a REL of 1) but was consistently even higher in liver cancer tissue 
(exemplified in figure 45).  
A B
 
Figure 45: Immunohistochemical detection of carboxylesterase 2 (O00748) in liver (A) 
and liver cancer tissue (B) (derived from www.proteinatlas.org) 
 
Liver carboxylesterase was slightly less abundant in HCC. Accordingly, histological data suggested 
slight downregulation of liver carboxylesterase expression levels by tendency. However, it has to be 
stated that normal liver as well as six (of overall 11 immunohistochemically investigated tissue 
samples) were assigned REL of 1. As it was described for carboxylesterase 2 (see above), no 
conclusions concerning the possibly even higher expression by liver cancer cells could be drawn from 
these data. Nevertheless, examination of the histological slices confirmed the abundance of liver 
carboxylesterase partially exceeding that of normal liver (data not shown; corresponding to figure 45). 
This result indicates a narrow-range inter-tumour variation of expression levels which might explain 
contradictory data delivered by EHCO. 
 
Serum paraoxonase (P27169), a liver-derived serum protein, was found to be pronouncedly more 
abundant in HCC tissue. However, EHCO as well as immunohistochemically-derived data suggest 
downregulation for this protein. This discrepancy might arise from the local enrichment of paraoxonase 
even at reduced expression levels (see 5.3 “The tumor secretome”).  
 
Epoxide hydrolases catalyze water addition to epoxides and oxiranes resulting in trans-configurated 
vicinal diols. Among the five different forms of epoxide hydrolases (EH), the microsomal EH (mEH) 
(Epoxide hydrolase 1, P07099) and soluble EH (sEH) (Epoxide hydrolase 2, P34913) feature a broad 
substrate specificity and are involved in biotransformation of xenobiotics. In the liver, they colocalize 
with cytochrome P450 in the centrilobular region. Interestingly, mEH and sEH are not homologous and 
have different substrate specificities (e.g. oxirane almost exclusively by mEH). Microsomal EH is co-
induced with cytochrome P450 (e.g. by phenobarbital, trans-stilbene oxide) and is a marker for pre-
neoplastic alteration of induced foci and nodules. Epoxide hydrolase 1 and 2 were differentially 
expressed by being upregulated and downregulated, respectively, in HCC. The shotgun-derived 
expression data for sEH were in accordance to EHCO data. “Human Protein Atlas”, however, states 
unaltered expression of liver cancer compared to normal tissue. 
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5.8.1.2 Reduction 
The reduction of aldehydes and ketones to the corresponding alcohols is catalyzed by alcohol 
dehydrogenases and carbonyl reductases. Xenobiotic substrates are e.g. acetohexamide, warfarin, 
and the anti-tumor drug daunorubicin, physiologic target is prostaglandin. Carbonyl reductases (are 
present in blood, liver, and other tissues. Carbonyl reductase(s) (carbonyl reductase 1/3, 
P16152/O75828)- the highly homologous isoforms could not be uniquely distinguished by mass 
spectrometry- was (were) pronouncedly more abundant in HCC tissue. However, 
immunohistochemical data suggest downregulation in liver cancer by tendeny. In addition, aldo-keto 
reductase family members were slightly but consistently more abandant in tumorous tissue (data not 
shown). 
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Figure 46: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of hydrolytic and reducing 
phase I-enzymes in non-tumorous liver and liver cancer/HCC tissues. The blue 
lines and numbers depicted in the boxplot denote the expression level of the 
respective proteins in normal liver tissue. 
Uniprot-ID up down 
O00748 0 1 
P23141 1 2 
P27169 0 5 
   
P07099 0 1 
P34913 0 4 
   
P16152/O75828 No results 
0,6
1 1 1 1
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5.8.1.3 Oxidation 
The oxidation-reduction system for alcohols, aldehydes, and ketones comprises a variety of enzymes 
such as alcohol dehydrogenases, aldehyde dehydrogenases, carbonyl reductases, dihydrodiol 
dehydrogenase, aldehyde oxidase, and xanthine dehydrogenase/oxidase. For example, the 
metabolism of ethanol/methanol includes their conversion into the corresponding aldehydes by alcohol 
dehydrogenases followed by the aldehyde dehydrogenase-mediated oxidation to the respective 
carboxylic acids. 
 
Alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs) 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P07327/… Alcohol dehydrogenase 1A/1B/1C 19 106 45.6 11 75 22.1 0.7 
P08319 Alcohol dehydrogenase 4 25 59 78.2 15 38 55.5 0.6 
         
P00352 
Aldehyde dehydrogenase family 1 
member A1, cytoplasmic 22 56 49.3 14 40 33.7 0.7 
P05091 
Aldehyde dehydrogenase, 
mitochondrial 29 65 60.2 30 88 59 1.4 
P30837 
Aldehyde dehydrogenase X, 
mitochondrial 14 38 39.1 12 30 29.8 0.8 
P51648 
Aldehyde dehydrogenase, 
microsomal 1 1 2.7 0 0 0 In liver only 
 
Table 28: ADHs and ALDHs identified by mass spectrometry. The number of distinct 
peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins of non-
tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of Tp 
(HCC/liver) are quoted. 
 
The different isoforms of alcohol dehydrogenases are divided into four classes. Class I comprises the 
isozymes ADH1, ADH2, and ADH3 (P07327/..., 106/75), class II includes ADH4 (P08319, 59/38). 
Whereas class I ADHs catalyze the oxidation of ethanol, ADH4 preferentially uses larger aliphatic and 
aromatic alcohols as substrates. Alcohol dehydrogenases of class I and class II are expressed at high 
levels in liver. The slight to moderate downregulation of ADHs observed in shotgun was confirmed by 
immunohistochemical and EHCO data (Figure 46). Aldehyde dehydrogenases oxidize aldehydes to 
carboxylic acids using NAD as coenzyme and exhibit esterase activity. ALDH X (P30837) was found to 
be slightly less abundant in HCC which was in accordance with immunohistochemical data 
(exemplified in figure 47). 
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A B C
 
Figure 47: Immunohistochemical detection of ALDH X (P30837) in liver (A) and liver 
cancer (B and C, representing slightly different expression levels 
corresponding to REL of 1) (derived from www.proteinatlas.org) 
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Figure 48: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of oxidative phase I-enzymes 
in non-tumorous liver and liver cancer/HCC tissues. The blue lines and 
numbers depicted in the boxplot denote the expression level of the respective 
proteins in normal liver tissue. 
 
Uniprot-ID up down 
P07327/… 0 1 
P08319 0 5 
   
P00352 0 2 
P05091 0 5 
P30837 0 1 
P51648 0 2 
0,2
1 1
0,6
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Molybdenum hydroxylases 
Aldehyde oxidase (Q06278) and xanthine oxidase are molybdoenzymes which occur in significant 
amounts only in liver. They exhibit substrate specificity for aromatic aldehydes (e.g. benzaldehyde, 
tamoxifen aldehyde). Physiological substrates of these enzymes are homovanillyl aldehyde (from 
dopamine), 5-hydroxy-3-indolacetaldehyde (from serotonin), and retinal delivering retinoic acid, a 
regulator of cell proliferation and differentiation. Moreover, they are decisively implicated in the 
catabolism of biogenic amines and catecholamines and metabolize anti-cancer drugs such as O6-
benzylguanine and methotrexate. In general, they exhibit substrate specificity complementary to 
cytochrome P450 enzymes in contrast to flavin monooxygenases (see below). Aldehyde oxidase 
(Q06278) was exclusively detected in liver tissue which is in accordance to EHCO data (not 
represented in “Human Protein Atlas”). 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
Q06278 Aldehyde oxidase 2 3 2.2 0 0 0 In HCC only 
         
P27338 Monoamine oxidase type B (MAO-B) 5 7 13.7 0 0 0 In HCC only 
         
P31513 Hepatic flavin-containing monooxygenase 3 7 11 21.4 0 0 0 
P49326 Hepatic flavin-containing monooxygenase 5 (FMO 5) 1 2 2.8 0 0 0 In HCC only 
         
P05177 Cytochrome P450 1A2 1 2 3.7 0 0 0 In HCC only 
P11509/P20853/ 
Q16696 
Cytochrome P450 2A6/2A7/2A13 1 2 1.8 1 2 4.5 
1.0 
P11712 Cytochrome P450 2C9 5 9 13.9 0 0 0 
Q02928 Cytochrome P450 4A11 3 4 9.6 0 0 0 In HCC only 
         
P16435 NADPH--cytochrome P450 reductase 11 15 21.1 8 13 20.8 0.9 
P22570 NADPH:adrenodoxin oxidoreductase, mitochondrial 5 6 20.8 3 5 14.5 0.8 
P10109 Ferredoxin-1 (Hepatoredoxin) 2 4 14.1 1 1 4.9 0.3 
Table 29: Aldehyde oxidase, monoamine oxidases, and cytochrome P450 
monooxygenases identified by mass spectrometry. The number of distinct 
peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins of non-
tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of Tp 
(HCC/liver) are quoted. 
 
Monoamine oxidases (MAOs) and flavin monooxygenases (FMOs) 
Monoamine oxidases (isozymes MAO-A and –B) are members of the flavin-containing amine 
oxidoreductases. (MAO-B, P27338) catalyzing the oxidative deamination of biogenic and xenobiotic 
amines (Wikipedia) such as serotonin (MAO-A) and dopamin (MAO-B). Although MAOs are implicated 
in neurological disorders, they are also expressed in others than nervous tissues as well. MAO-B is 
indeed highly expressed in liver tissue (REL 1) and is tendentially downregulated in liver cancer as 
indicated by immunohistochemical data (Figure 49). Indeed, MAO-B was solely detected in non-
tumorous liver tissue by shotgun. 
Flavin monooxygenases oxidize nitrogen, sulphur, and phosphorus of a variety of xenobiotics. They 
are located in microsomes and require NADPH and molecular oxygen. Many FMO reactions are also 
catalyzed by cytochrome P450. Two hepatic flavin-monooxygenases (P31513; P49326) were 
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identified by shotgun, both exclusively detected in liver tissue. Downregulation of those enzymes is in 
accordance to histological data indicating a loss of FMO-mediated function by liver cancer. 
 
Cytochrome P450 (Cyt P450) 
The cytochrome P450 superfamily comprises the most important phase I-biotransforming enzymes 
with respect to pharmako- and toxicokinetics. They catalyze the monooxygenation of their substrates 
delivering highly reactive epoxides as targets for phase II-enzymes. Although ubiquitously expressed, 
they are most prominent in liver microsomes. Microsomal and mitochondrial cytochrome P450 
enzymes gain electrons from NADPH-cytochrome P450 reductase (P16435) and ferredoxin (P10109, 
4/1 (P16435, 15/13)/ferredoxin reductase (P22570, 6/5), respectively. They exert key roles as electron 
carriers in the metabolism of e.g. steroid hormones, bile acids, fat-soluble vitamins, fatty acids, and 
eicosanoids. Cytochrome P450 proteins were almost consistently downregulated in HCC (detected 
only in liver except for cytochrome P450 2A enzyme(s)). Interestingly, the downregulation of ferredoxin 
(but not the reductase) indicates compromized reduction capacity of mitochondrial cytochromes (not 
necessarily or just partially involved in detoxification). 
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Figure 49: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of oxidative phase I-enzymes 
in non-tumorous liver and liver cancer/HCC tissues. The blue lines and 
numbers depicted in the boxplot denote the expression level of the respective 
proteins in normal liver tissue. 
 
 
 
 
 
 
Uniprot-ID up down 
Q06278 0 2 
   
P27338 0 1 
   
P31513 0 1 
P49326 No results 
   
P05177 0 1 
P11509/ 
P20853/ 
Q16696 
0 3 
P11712 0 7 
Q02928 0 2 
   
P16435 0 3 
P22570 1 1 
P10109 0 1 
0,36
1
0,6 0,6 0,6
1 1
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5.8.2 Phase II- enzymes 
 
Enzymes involved in glucuronidation, sulfation, and methylation identified via mass spectrometry are 
listed in table 30. Shotgun data, immunohistochemical and EHCO data are compiled in figure 50. 
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P22309/P36509/ 
P22310/Q9HAW7 
UDP-glucuronosyltransferase 1-1/1-2/1-4/1-7 5 54 17.8 0 0 0 
P54855/O75795 UDP-glucuronosyltransferase 2B15/2B17 1 2 1.7 0 0 0 
In liver only 
         
Q06520 Bile-salt sulfotransferase 7 13 29.8 9 12 42.8 0.9 
P50225/P50226/ 
P50224 
Sulfotransferase 1A1/1A2/1A3 5 11 27.1 1 3 6.1 0.3 
P25325 3-mercaptopyruvate sulfurtransferase (MST) 7 13 39.1 8 14 42.1 1.1 
         
P21964 Catechol O-methyltransferase 5 7 19.9 0 0 0 
P40261 Nicotinamide N-methyltransferase 2 2 13.6 0 0 0 
Q00266 
S-adenosylmethionine synthetase isoform 
type-1 (MAT-I/III) 
3 3 9.9 0 0 0 
In liver only 
 
Table 30: Phase II-enzymes identified by mass spectrometry. The number of distinct 
peptides (Dp), total peptides (Tp), and coverage (Cov. (%)) of proteins of non-
tumorous liver (blue) and/or HCC tissue (orange) as well as the ratio of Tp 
(HCC/liver) are quoted.  
 
5.8.2.1 Glucuronidation 
Glucuronidation constitutes the major pathway in xenobiotic biotransformation. It depends on the 
cofactor UDP-glucuronic acid which is derived from glucose-1-phosphate and is catalyzed by UDP-
glucuronosyltransferases (UGTs) in the endoplasmic reticulum of liver and other tissues. The 
substrates of UGTs contain O, N, or S heteroatoms (e.g. aliphatic alcohols, phenols, carboxylic acids, 
primary and secondary aromatic aliphatic amines). Endogenous substrates comprise bilirubin, steroid 
hormones, and thyroid hormones. Glucuronide conjugates are polar, water-soluble and excreted via 
urine or bile depending on the size of the aglycon (<250 Da vs. >350 Da). However, glucuronic acid is 
the substrate for beta-glucuronidase (lysosomes, intestinal microflora) which reverts glucuronidation 
and hence fosters enterohepatic circulation of xenobiotics (delayed elimination). Moreover, co-factor 
availability limits the glucuronidation rate of drugs and xenobiotic glucuronidation can be impaired in 
vivo by factors depleting UDP-glucoronic acid levels (e.g. diethyl-ether, borneol, and galactosamin). 
UGTs as functional group (identified at the family level with P22309/…, P54855/…) were detected 
solely in liver tissue by shotgun.  
 
5.8.2.2 Sulfation 
Many xenobiotics and endogenous substrates can be alternatively glucuronidated or sulfated. 
Cytosolic sulfur transferases in liver and other tissues catalyze the formation of highly water-soluble 
sulfuric acid esters. Sulfur transferases require the co-factor PAPS (3'-phosphoadenosine-5'- 
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phosphosulfate) for the transfer of sulfonat to xenobiotics, phenols, aliphatic alcohols, and some 
aromatic amins (but not carboxylic acids). Sulfated substances are excreted mainly in urine, those 
released into bile are frequently hydrolyzed by microfloral amylsulfatases retarding their elimination 
(see glucuronidation). Due to the commonly low concentrations of PAPS, sulfation is regarded as a 
low-capacity pathway in the elimination of toxic compounds. Three sulfotransferases were identified by 
shotgun. Bile-salt sulfotransferase (Q06520) and 3-mercaptopyruvate sulfurtransferase (P25325) 
catalyzing the sulfation of steroids, bile acids and the degradation of cyanide compounds or being 
involved in thiosulfate biosynthesis compounds, respectively, were equally abundant in liver and HCC. 
However, sulfotransferase 1A members (identified at the family level with P50225/…) were 
pronouncedly downregulated in HCC. E.g. sulfotransferase 1A1 catalyzes the sulfate conjugation of 
catecholamines and phenolic drugs. In addition, it mediates the sulfonation of 2-methoxyestradiol, a 
chemotherapeutic for e.g. the treatment of malignant glioma [278], esophageal adenocarcinoma [279], 
and breast cancer [280]. The downregulation of sulfotransferase 1A might indicate the modulation of 
the reactivity to chemotherapeutics in liver cancer cells. 
 
5.8.2.3 Methylation 
Methylation is a common but generally minor pathway in detoxification although it is indispensable in 
amino acid and cofactor biosynthesis. The attachment of methyl-groups decreases watersolubility of 
compounds and requires the co-factor SAM (S-adenosylmethionine) which is formed by S-
adenosylmethionine synthetases from methionine, ATP and water. Phenols, catechols, aromatic and 
aliphatic amins, N-heterocyclics, and SH-containings compounds are the main substrates for 
methyltransferases such as phenol-O-methyltransferase and catechol-O- methlytransferase (P21964). 
The latter as well as nicotinamide N-methyltransferase (P40261) which is crucial for the 
biotransformation of drugs and xenobiotics by catalyzing the formation of pyridinium ions from 
pyridines (Uniprot) were solely detected in liver. Accordingly, S-adenosylmethionine synthetase 
(Q00266) which mediates the formation of SAM was also not detected in HCC. Taken together, these 
findings indicate a pronouncedly compromized methylation capacity of HCC cells at least with respect 
to detoxification. 
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Figure 50: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of phase II-enzymes in non-
tumorous liver and liver cancer/HCC tissues. The blue lines and numbers 
depicted in the boxplot denote the expression level of the respective proteins in 
normal liver tissue. 
 
 
 
 
 
 
 
 
Uniprot-ID up down 
P22309/… 0 0 
P54855/… 
No results 
   
Q06520 0 2 
P50225/… 0 2 
P25325 
No results 
   
P21964 1 1 
P40261 1 6 
Q00266 0 4 
0,2
1 1
0,6
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5.9 Proteins mediating cancer phenotypes 
 
Proteins described in detail are listed in table 31 and table 32. Shotgun, immunohistochemically 
derived and EHCO data are compiled in figure 51. 
 
5.9.1 Resistance against apoptosis 
 
Sorcin (P30626), a calcium-binding protein, was found to be overexpressed in multi-drug-resistant cell 
lines, in gastric cancer tissue, and in gemcitabine resistant non-small cell lung cancer [281-283]. 
Indeed, its expression correlates with the expression of P-glycoprotein in leukemia patients [281]. In 
addition, overexpression of sorcin resulted in decreased intracellular Ca-levels and increased 
resistance to apoptosis correlating with the upregulation of Bcl-2, downregulation of Bax and by 
interfering with caspase-3 expression and activity [284, 285]. Sorcin was solely detected in HCC 
tissue. Unfortunately, sorcin was neither represented in “protein atlas” nor in EHCO, hence, data 
concerning its expression in HCC were not obtainable and were not reported thus far. 
 
Cardiotrophin-1 (CT-1, Q16619) belongs to the IL-6 family of cytokines. It exerts anti-apoptotic effects 
on hepatocytes [286], cardiomyocytes and neurons by inducing the Jak-Stat pathway as well as other 
survival pathways [287, 288]. The Jak-Stat pathway mediates protection of hepatocytes against Fas-
induced apoptosis, oxidative stress in the course of hypoxia/reoxigenation, and T-cell mediated liver 
injury [289-291]. Thereof this pathway is considered a basic and crucial component of the natural 
defense of liver tissue against apoptosis [292]. In addition, the Jak/Stat pathway as well as the Ras 
pathway are ubiquitously activated in HCC and are considered as promising point of attack for therapy 
[293]. The importance of the Jak/Stat pathway in development of HCC with respect to apoptosis 
inhibition and proliferation enhancement and thereof poor prognosis is indicated by Yoshikawa et al. 
and Schmitz et al. [294, 295] . However, expression of cardiotrophin-1 at the mRNA level is not 
significantly different between liver and HCC (data not shown, see Oncomine: CT-1). Taken together, 
the known activation of the Jak-Stat pathway and the exclusive detection of cardiotrophin-1 in HCC 
without a significant increase of the mRNA expression level might be an indication for the local 
enrichment of factors as determinants of the tumor microenvironment.  
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
P30626 Sorcin (22 kDa protein) 0 0 0 3 6 17.2 
Q16619 Cardiotrophin-1 (CT-1) 0 0 0 1 4 10.4 
In HCC only 
 
Table 31: Proteins participating in the tumor phenotype “Resistance against apoptosis” 
identified by mass spectrometry. The number of distinct peptides (Dp), total 
peptides (Tp), and coverage (Cov. (%)) of proteins of non-tumorous liver (blue) 
and/or HCC tissue (orange) as well as the ratio of Tp (HCC/liver) are quoted. 
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5.9.2 Unrestricted proliferation 
 
NDRG2 (Q9UN36), a member of the N-Myc downstream-regulated gene family, was found to be 
downregulated in colorectal cancer tissue and to behave reversely to the expression of c-Myc. In 
addition, the decline of NDRG2 abundance correlated with the differentiation state of investigated 
samples [296]. Similar results were obtained for esophageal squamous-cell carcinoma [297] and oral 
squamous-cell carcinoma [298]. Constitutive expression of NDRG2 suppressed cell proliferation in a 
colon carcinoma cell line [299]. In addition, it exerts tumor metastasis-suppressive activity [300]. 
NDRG2 abundance was significantly decreased in HCC tissue compared to non-tumorous liver tissue 
which is in accordance to immunohistochemical data (Protein Atlas), EHCO, and data from literature 
[301].  
 
Uniprot-ID Protein name Dp Tp 
Cov. 
(%) 
Dp Tp 
Cov. 
(%) 
Ratio of Tp 
(HCC/liver) 
Q9UN36 Protein NDRG2  5 9 22.1 1 1 5.9 0.1 
Q92945 Far upstream element-binding protein 2  0 0 0 2 3 4.1 In HCC only 
O43598 c-Myc-responsive protein Rcl 3 3 16.7 4 6 25.3 2.0 
P16949 Stathmin  1 2 8.7 3 6 21.5 3.0 
         
Q86X76 Nitrilase homolog 1 0 0 0 3 3 14.4 
P49789 Bis(5’-adenosyl)-triphosphatase  0 0 0 1 1 6.8 
In HCC only 
         
P01112/ 
P01111/ 
P01116 
GTPase H/N/KRas 0 0 0 2 7 13.8 In HCC only 
Q15185 Prostaglandin E synthase 3  1 1 10.6 3 5 26.3 5.0 
Q9H7Z7 Prostaglandin E synthase 2 2 3 8.8 6 6 24.7 2.0 
         
Q04917 14-3-3 protein eta (Protein AS1) 0 0 0 3 12 12.2 In HCC only 
P27348 14-3-3 protein theta  2 2 9.8 4 15 20 7.5 
P61981 
14-3-3 protein gamma (Protein kinase C 
inhibitor protein 1) 
2 3 15.4 10 20 53 6.7 
P31946 14-3-3 protein beta/alpha  3 4 20.7 9 23 50.8 5.8 
P62258 14-3-3 protein epsilon (14-3-3E) 2 3 4.7 5 12 27.1 4.0 
P63104 14-3-3 protein zeta/delta  (KCIP-1) 5 5 31 8 17 42.9 3.4 
         
Q9P032 HRPAP20  0 0 0 4 8 28.6 In HCC only 
         
Q14696 Mesoderm development candidate 2  0 0 0 5 5 22.2 In HCC only 
         
P55327 Tumor protein D52  1 1 7.6 2 3 17.9 3.0 
         
P51858 
Hepatoma-derived growth factor 
(HDGF)  
0 0 0 1 1 6.7 In HCC only 
 
Table 32: Proteins participating in the tumor phenotype “Unrestricted proliferation” 
identified by mass spectrometry. The number of distinct peptides (Dp), total 
peptides (Tp), and coverage (Cov. (%)) of proteins of non-tumorous liver (blue) 
and/or HCC tissue (orange) as well as the ratio of Tp (HCC/liver) are quoted. 
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The expression of c-Myc might be indirectly concluded from the sole detection and increased 
abundance of Far upstream element-binding protein 2 (FUSE, FBP2; Q92945), a transcriptional 
activator of c-Myc [302], and c-Myc-responsive protein Rcl (O43598) exhibiting tumorgenic potential 
[303], respectively. In addition, FBPs promote tumor-relevant functions via stathmin (P16949), a 
microtubule-destabilizing protein, and are considered as targets for HCC treatment [304]. The 
significant coregulation of stathmin was confirmed by shotgun, immunohistochemical and EHCO data. 
 
Nitrilase 1 homolog (Q86X76) was found to be downregulated in esophageal adenomacarcinonma. In 
addition, it acts additively with Bis(5'-adenosyl)-triphosphatase (P49789) which shows also tumor-
suppressive activity [305]. Interestingly, both proteins were solely detected in HCC. 
 
At least one isoform of GTPase Ras proteins (P01112/P01111/P0111)- the different highly 
homologous isoforms H-, N-, and K-Ras were not distinguishable by shotgun- was significantly more 
abundant in HCC tissue. The aberrant activation of Ras/MAPK-signaling, in particular involving K-Ras, 
in hepatocarcinogenesis is commonly accepted [175]. Interestingly, mutations of Ras occur at low 
frequency in HCC [306] in contrast to its overexpression [293, 307]. Another mechanism leading to the 
augmentation of proliferation is the increased synthesis of prostaglandin E synthase 2 (PGE2) since it 
has been shown that prostaglandins are able to enhance the effect of the growth factor EGF 
(epidermal growth factor) on hepatocytes. Again, upregulation of Akt and Ras pathways are involved 
[308]. Indeed, in HCC tissue prostaglandin E synthases 3 (Q15185) and 2 (Q9H7Z7) were 
upregulated 5-fold and 2-fold, respectively.  
 
14-3-3 proteins (Q04917, P27348, P61981, P31946, P62258, P63104) are involved in a broad variety 
of cellular processes such as signal transduction, apoptosis, and cell-cycle regulation (reviewed in 
[309]). They are ubiquitous phospho-serine/threonine-binding proteins frequently dysregulated in 
cancer. Indeed, the expression of 14-3-3 proteins was found consistently and significantly upregulated 
in HCC. However, 14-3-3σ whose expression is regulated by p53 and is frequently downregulated in 
cancer was detected in neither of the tissues. 
 
Former UPF0240 C6orf66, now designated as hormone-regulated proliferation-associated 20 kDa 
protein (Q9P032; HRPAP20), was detected only in HCC. HRPAP20 has been identified as 
phosphoprotein enhancing growth and survival of hormone-responsive tumor cells [310]. Furthermore, 
it is described as marker for tamoxifen resistance in breast cancer and as being associated with breast 
cancer cell invasion [311, 312]. Unfortunately, this protein was not covered by EHCO and “Human 
Protein Atlas”. 
 
Mesoderm development candidate 2 (Mesd, NY-REN-61 antigen; Q14696) was detected solely in 
HCC tissue. Mesd is a chaperone for members of the LDLR-family and for co-receptors of canonical 
Wnt-signaling, LRP 5 and LRP6 [313, 314]. Mesd has recently been identified as potent inhibitor of 
Wnt-signaling in a prostate cancer cell line [315]. However, it has been shown that it is also 
indispensable for the modulation of Wnt-signaling via LRP6 since overexpression of the latter 
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enhanced Wnt-signaling only in the presence of co-expressed Msd [316]. This finding might provide 
an indication for participation of Wnt-signaling on hepatocarcinogenesis although LRP6 was not found 
in either tissue but protein LRP16 (Q9BQ69) which was upregulated in HCC. LRP16 is possibly 
involved in breast cancer suggested by its upregulation in a breast cancer cell line upon estrogen 
treatment [317]). 
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Figure 51: Shotgun data (above), immunohistochemical (below left), and EHCO data 
(below right) concerning the relative abundance of proteins mediating cancer 
phenotypes in non-tumorous liver and liver cancer/HCC tissues. The blue lines 
and numbers depicted in the boxplot denote the expression level of the 
respective proteins in normal liver tissue. 
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Tumor protein D52 (P55327) is overexpressed in prostate and breast cancer as well as various other 
cancers and exerts a proliferation-stimulatory effect, serves as an anti-apoptotic and/or survival factor 
and is additionally capable to promote migration of tumor cells [318, 319]. It is significantly more 
abundant in HCC (3/2 with coverage of 17.9% vs. 1/1) which is in accordance to EHCO data. To my 
knowledge it is the first report concerning the overexpression of TPD52 in HCC and thereby indicating 
a putative role of this protein in hepatocarcinogenesis. Moreover this protein might be a useful target 
for anti-cancer treatment since shutting down expression leads to increased apoptosis as 
demonstrated in a TPD25-overexpressing prostate cancer cell line [318]. 
 
Hepatoma-derived growth factor (P51858) is frequently found upregulated in HCC [320] which is in 
accordance to data gained via shotgun. Furthermore, its expression correlates with poor prognosis for 
HCC patients [321] and seems to be the decisive factor downregulated by vitamin-K(2) which has 
been reported to suppress the growth of human hepatocellular carcinoma (HCC) in vitro and 
hepatocarcinogenesis in hepatitis C virus (HCV)-related cirrhosis in vivo [322]. 
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8 Appendix 
 
Table 33: Compilation of shotgun data, immunohistochemically derived and EHCO data including their 
compliance. Proteins are listed in the order of their Uniprot-ID. Numbers in the column “Shotgun 
proteomics” correspond to the number of total peptides (Tp), those listed in the column “EHCO 
II-database” correspond to the number of citations (of overall 8 datasets) stating up-or 
downregulation of the protein. The column “data compilation” summarizes 
immunohistochemically derived data (see chapter 4.6) expressed as percentage of histological 
samples showing unaltered, up- and downregulation for the respective proteins as well as the 
relative abundances derived from shotgun (S or numbers in blue and bold, numbers in blue 
indicate tendency for altered expression with less than factor 2 difference in terms of Tp) and 
EHCO (http://ehco.iis.sinica.edu.tw/) (E or underlined numbers). In the case of strong expression 
of proteins in liver and HCC (both with REL: 1, see chapter 4.6) no conclusions concerning a 
putative overexpression can be drawn (“???” in the “data compilation” column). The data 
compliance derived from comparisons of shotgun and EHCO (SE), Shotgun and 
immunohistochemically derived data (SP, P from “Protein Atlas”) as well as EHCO and 
histological data (EP). 
 
Shotgun proteomics (Tp) EHCO II- database Data compilation Data compliance 
Uniprot-ID 
L
iv
e
r 
H
C
C
 
up down up unaltered down SE SP EP 
O00165 1 1 1 0 E S  ✗ n.d. n.d. 
O00217 4 4 1 1 54-36 36-55 9 ✗ ✔ ✔ 
O00231 2 1 2 0 E  S ✗ n.d. n.d. 
O00232 1 0 No results 0-9 64 36-27 n.d. ✔ n.d. 
O00264 10 7 1 2 ??? 25-33 75-67 ✗ ✔ ✔ 
O00299 2 3 5 0 92 0 8 ✗ ✗ ✔ 
O00303 2 0 No results   S n.d. n.d. n.d. 
O00305 0 1 No results 92-75 0-17 8 n.d. ✔ n.d. 
O00499 0 1 No results 41 42-0 16-58 n.d. ✔ n.d. 
O00625 0 2 3 0 0-9 55-45 45 ✔ ✔ ✔ 
O00629 1 0 No results   S n.d. n.d. n.d. 
O00748 7 24 0 1 ??? 100 0 ✗ ✔ ✗ 
O00754 0 1 No results S   n.d. n.d. n.d. 
O00764 4 4 No results  S  n.d. n.d. n.d. 
O14558 1 0 No results   S n.d. n.d. n.d. 
O14561 0 1 No results S   n.d. n.d. n.d. 
O14602 2 11 No results 17-42 25-0 59 n.d. ✔ n.d. 
O14618 0 1 0 1 0-17 0 100-83 ✗ ✔ ✔ 
O14737 0 1 2 0 S   ✔ n.d. n.d. 
O14745 0 3 2 0 25-42 58-0 17-58 ✔ ✔ ✔ 
O14773 7 4 No results  S s n.d. n.d. n.d. 
O14818 3 6 No results S   n.d. n.d. n.d. 
O14874 1 0 No results 90-80 0-10 10 n.d. ✔ n.d. 
O14880 1 0 1 0 E  S ✗ n.d. n.d. 
O14933 1 0 No results 10-20 70-60 20 n.d. ✔ n.d. 
O15116 1 1 No results 0 100 0 n.d. ✔ n.d. 
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O15145 4 4 2 1 33 25-8 42-58 ✗ ✔ ✔ 
O15173 0 1 No results S   n.d. n.d. n.d. 
O15511 4 2 No results 0-8 58-67 42-25 n.d. ✔ n.d. 
O43169 3 1 No results ??? 92 8 n.d. ✔ n.d. 
O43175 13 0 2 0 E  S ✗ n.d. n.d. 
O43181 3 0 No results 0-20 80-60 20 n.d. ✔ n.d. 
O43324 1 0 No results   S n.d. n.d. n.d. 
O43399 0 1 1 1 S  E ✔✗ n.d. n.d. 
O43464 1 2 1 0 S   ✔ n.d. n.d. 
O43488/O95154/ 
Q8NHP1 
11 13 0 1  S E ✗ n.d. n.d. 
O43598 3 6 No results S   n.d. n.d. n.d. 
O43615 0 1 No results S   n.d. n.d. n.d. 
O43617 4 2 No results   S n.d. n.d. n.d. 
O43708 0 1 0 3 ??? 45 55 ✗ ✔ ✔ 
O43852 0 4 1 1 S  E ✔✗ n.d. n.d. 
O43895 0 3 No results 45 55 0 n.d. ✔ n.d. 
O60218 4 18 2 1 S  E ✔✗ n.d. n.d. 
O60234 1 0 2 0 100 0 0 ✗ ✗ ✔ 
O60493 2 0 No results   S n.d. n.d. n.d. 
O60613 1 3 No results S   n.d. n.d. n.d. 
O60701 15 15 1 0 E S  ✗ n.d. n.d. 
O60888 4 3 1 0 E S  ✗ n.d. n.d. 
O75197 1 0 No results 36 45 18 n.d. ✔ n.d. 
O75208 2 3 No results  S  n.d. n.d. n.d. 
O75223 0 3 No results 75 25 0 n.d. ✔ n.d. 
O75340 10 5 1 0 0 25-58 75-42 ✗ ✔ ✗ 
O75347 3 6 2 0 S   ✔ n.d. n.d. 
O75356 10 4 0 1 ??? 0-10 100-90 ✔ ✔ ✔ 
O75368 4 1 No results   S n.d. n.d. n.d. 
O75369 0 2 2 0 100-91 0-9 0 ✔ ✔ ✔ 
O75380 0 1 No results S   n.d. n.d. n.d. 
O75390 3 1 1 0 E  S ✗ n.d. n.d. 
O75431 1 0 No results   S n.d. n.d. n.d. 
O75439 1 0 2 0 E  S ✗ n.d. n.d. 
O75489 12 6 1 0 8-33 50-25 42 ✗ ✔ ✔ 
O75521 13 9 No results ??? 42-67 58-33 n.d. ✔ n.d. 
O75608 6 10 No results s S  n.d. n.d. n.d. 
O75629 1 0 No results   S n.d. n.d. n.d. 
O75746/Q9UJS0 26 12 No results ??? 33-50 67-50 n.d. ✔ n.d. 
O75874 24 24 0 1  S E ✗ n.d. n.d. 
O75891 49 17 0 3   S ✔ n.d. n.d. 
O75947 17 16 1 0 E S  ✗ n.d. n.d. 
O75955 1 0 No results 0 0 100 n.d. ✔ n.d. 
O76054 3 1 0 1   S ✔ n.d. n.d. 
O94826 0 1 No results 0-8 0-75 100-17 n.d. ✔ n.d. 
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O94903 1 4 No results 0 83 17 n.d. ✗ n.d. 
O95050 1 0 No results   S n.d. n.d. n.d. 
O95168 2 0 1 0 E  S ✗ n.d. n.d. 
O95202 0 1 No results 100 0 0 n.d. ✔ n.d. 
O95210 1 3 No results 17-33 25-17 58-50 n.d. ✔ n.d. 
O95299 2 0 1 0 E  S ✗ n.d. n.d. 
O95336 0 5 No results S   n.d. n.d. n.d. 
O95372 0 2 No results S   n.d. n.d. n.d. 
O95479 16 5 0 0 ??? 73 27 ✗ ✔ ✔ 
O95563 2 0 2 1 E  S ✔✗ n.d. n.d. 
O95571 9 8 2 0 E S  ✗ n.d. n.d. 
O95777 2 0 No results 0 0-8 100-92 n.d. ✔ n.d. 
O95831 19 23 0 0 50 25 25 ✔ ✔ ✔ 
O95881 3 3 No results  S  n.d. n.d. n.d. 
O95954 20 0 0 2 42-25 0-8 58-67 ✔ ✔ ✔ 
O96000 5 2 No results   S n.d. n.d. n.d. 
O96008 3 2 No results 100-92 0-8 0 n.d. ✔ n.d. 
P00167 11 9 0 4 ??? 9-36 91-64 ✗ ✔ ✔ 
P00338 20 3 1 2 0 100 0 ✔✗ ✗ ✗ 
P00352 56 40 0 2  S E ✗ n.d. n.d. 
P00367/P49448 68 16 0 3   S ✔ n.d. n.d. 
P00390 2 0 0 0 60 40-0 0-40 ✗ ✔ ✔ 
P00403 3 3 No results ??? 73-82 27-18 n.d. ✔ n.d. 
P00439 5 0 0 3   S ✔ n.d. n.d. 
P00441 17 18 0 4 0 0 100 ✗ ✗ ✔ 
P00450 1 1 0 6 0-8 34-42 66-50 ✗ ✔ ✔ 
P00480 24 15 0 2 ??? 27-36 73-64 ✗ ✔ ✔ 
P00491 2 0 0 1 0-10 40-50 60-40 ✔ ✔ ✔ 
P00492 2 0 1 0 ??? 0-30 100-70 ✗ ✔ ✔ 
P00505 41 14 0 2 ??? 9-27 91-73 ✔ ✔ ✔ 
P00558 17 18 3 0 E S  ✗ n.d. n.d. 
P00568/Q9Y6K8 8 11 0 0 0 92 8 ✔ ✔ ✔ 
P00734 1 0 0 2 0-9 36 64-55 ✔ ✔ ✔ 
P00738/P00739 34 36 0 6 0-8 33-25 67 ✗ ✔ ✔ 
P00751 1 0 2 1 42-58 42-25 17 ✔✗ ✔ ✔ 
P00915 8 11 0 1 9 0 91 ✗ ✗ ✔ 
P00918 4 14 0 4 0-18 18-0 82 ✗ ✔ ✔ 
P00966 19 5 0 3 ??? 8-17 92-83 ✔ ✔ ✔ 
P01008 0 2 0 4 0-11 22-33 78-56 ✗ ✔ ✔ 
P01009 17 0 1 3 60 20 20 ✔✗ ✔ ✔ 
P01019 8 9 1 1 0-10 80-70 20 ✗ ✔ ✔ 
P01023 3 0 0 5 0-18 18 82-64 ✔ ✔ ✔ 
P01024 0 2 0 2 0-27 55-27 18-45 ✗ ✔ ✔ 
P01112/P01111/ 
P01116 
0 7 3 0 0 100 0 ✔ ✗ ✗ 
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P01591 0 1 0 3 S  E ✗ n.d. n.d. 
P01623/... 0 18 No results S   n.d. n.d. n.d. 
P01834 12 21 1 3 Es S E ✗ n.d. n.d. 
P01842 6 16 No results S   n.d. n.d. n.d. 
P01857 1 11 0 2 S  E ✗ n.d. n.d. 
P01871 2 0 0 2   S ✔ n.d. n.d. 
P02647 22 41 0 3 9 91 0 ✗ ✔ ✗ 
P02649 4 10 0 1 0-40 80-60 20-0 ✗ ✔ ✔ 
P02656 1 0 1 2 E  S ✔✗ n.d. n.d. 
P02671 2 0 0 4 58 42 0 ✔ ✗ ✗ 
P02675 4 3 1 5 10-30 40 50-30 ✗ ✔ ✔ 
P02679 1 1 1 5 E S E ✗ n.d. n.d. 
P02689 0 5 No results S   n.d. n.d. n.d. 
P02743 7 5 0 3 0-25 42-33 58-42 ✗ ✔ ✔ 
P02753 8 20 1 3 ??? 20-50 80-50 ✔✗ ✔ ✔ 
P02763 4 3 1 3 ??? 0-9 100-91 ✗ ✔ ✔ 
P02766 5 13 0 5 0 30-40 70-60 ✗ ✗ ✔ 
P02768 70 186 0 8 17-25 67-42 17-33 ✗ ✔ ✔ 
P02774 3 1 0 3 36-55 45-0 15-45 ✔ ✔ ✔ 
P02787 38 91 1 6 45-64 9-0 45-36 ✔✗ ✔ ✔ 
P02790 2 0 0 2 11 11-0 78-89 ✔ ✔ ✔ 
P02792 24 17 0 2 ??? 0-30 100-70 ✗ ✔ ✔ 
P02794 8 10 1 0 ??? 0-25 100-75 ✗ ✔ ✔ 
P04004 7 10 0 4 40 10-0 50-60 ✗ ✔ ✔ 
P04040 33 51 0 6 0-8 42-58 58-33 ✗ ✔ ✔ 
P04075 2 5 3 0 S   ✔ n.d. n.d. 
P04080 5 4 1 1 E S E ✗ n.d. n.d. 
P04083 10 6 3 0 50-33 0-17 50 ✗ ✔ ✔ 
P04179 63 36 0 1 ??? 91 9 ✗ ✔ ✔ 
P04196 0 5 0 3 S  E ✗ n.d. n.d. 
P04217 4 11 0 1 8 92 0 ✗ ✔ ✗ 
P04229 10 0 0 0  E S ✗ n.d. n.d. 
P04264 16 0 No results   S n.d. n.d. n.d. 
P04406 23 30 4 0 0 73 27 ✗ ✔ ✗ 
P04424 7 9 No results ??? 40 60 n.d. ✔ n.d. 
P04632 4 6 No results 89-78 0 11-22 n.d. ✗ n.d. 
P04792 3 19 4 1 0 11 89 ✔✗ ✗ ✔✗ 
P04844 1 0 0 2 60 40 0 ✔ ✗ ✗ 
P05062 29 25 0 6 ??? 0-11 100-89 ✗ ✔ ✔ 
P05089 31 16 0 6 ??? 0-30 100-70 ✗ ✔ ✔ 
P05090 4 0 No results   S n.d. n.d. n.d. 
P05091 65 88 0 5 s S E ✗ n.d. n.d. 
P05109 1 0 0 2 0 100 0 ✔ ✗ ✗ 
P05155 3 1 1 4 E  S ✔✗ n.d. n.d. 
P05165 9 0 1 1 E  S ✔✗ n.d. n.d. 
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P05166 24 9 1 0 E  S ✗ n.d. n.d. 
P05177 2 0 0 1 0 0-27 100-73 ✔ ✔ ✔ 
P05386 1 4 3 0 70 30 0 ✔ ✔ ✔ 
P05386 1 4   S   n.d. n.d. n.d. 
P05387 10 7 2 0 E S s ✗ n.d. n.d. 
P05388 7 6 3 0 67 33 0 ✗ ✔ ✔ 
P05413 5 0 No results   S n.d. n.d. n.d. 
P05556 1 2 1 1 ??? 92 8 ✔✗ ✔ ✔ 
P05783 17 0 No results   S n.d. n.d. n.d. 
P05787 30 0 1 2 E  S ✔✗ n.d. n.d. 
P05976 3 0 No results   S n.d. n.d. n.d. 
P06132 0 1 No results 0-8 0 100-92 n.d. ✔ n.d. 
P06396 3 0 0 1   S ✔ n.d. n.d. 
P06576 48 69 No results 9-45 82-18 9-36 n.d. ✔ n.d. 
P06702 1 0 No results 36 64 0 n.d. ✗ n.d. 
P06733 47 73 0 2 0 36-64 64-36 ✗ ✔ ✔ 
P06737 37 0 0 1 ??? 0-17 100-83 ✔ ✔ ✔ 
P06744 7 3 No results 0-8 0 100-92 n.d. ✔ n.d. 
P07029 2 0 No results   S n.d. n.d. n.d. 
P07099 3 9 0 1 S  E ✗ n.d. n.d. 
P07108 0 1 2 0 75-83 8 17-8 ✔ ✔ ✔ 
P07148 45 16 3 5 ??? 0-9 100-91 ✔ ✔ ✔ 
P07195 2 0 0 1   S ✔ n.d. n.d. 
P07203 18 15 1 1 0 0 100 ✗ ✗ ✔✗ 
P07237 50 69 0 2 25 75-67 0-8 ✗ ✔ ✔ 
P07327/P00325/ 
P00326 
106 75 0 1 ??? 22-36 78-64 ✗ ✔ ✔ 
P07339 19 14 1 1 ??? 8-50 92-50 ✗ ✔ ✔ 
P07355 18 27 3 1 Es S E ✗ n.d. n.d. 
P07437/Q13885/ 
Q9BVA1/P68371/ 
Q13509/P04350 
157 77 4 1 E  S ✔✗ n.d. n.d. 
P07686 2 8 No results S   n.d. n.d. n.d. 
P07737 24 19 No results  S s n.d. n.d. n.d. 
P07741 12 10 1 0 91 0 9 ✗ ✗ ✔ 
P07858 17 9 0 1 ??? 0-13 100-88 ✗ ✔ ✔ 
P07900/P08238 67 43 3 0 50 50 0 ✗ ✔ ✔ 
P07910 3 2 1 0 100-75 0-25 0 ✗ ✔ ✔ 
P07954 18 37 1 1 ??? 33 67 ✔✗ ✔ ✔ 
P08107/P54652/P17
066 
31 58 2 1 67-42 0-8 33-50 ✗ ✔ ✔ 
P08133 62 49 No results 30 0 70 n.d. ✗ n.d. 
P08134 14 9 2 0 27 73 0 ✗ ✔ ✔ 
P08236 2 0 0 1   S ✔ n.d. n.d. 
P08263/P09210/Q1
6772/Q7RTV2 
249 69 1 2 ??? 0-17 100-83 ✔✗ ✔ ✔ 
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P08311 1 0 No results 0 100 0 n.d. ✗ n.d. 
P08319 59 38 0 5 0 0-8 100-92 ✗ ✔ ✔ 
P08559 1 0 No results   S n.d. n.d. n.d. 
P08574 2 5 2 0 56-67 33-22 11 ✔ ✔ ✔ 
P08670 27 16 3 0 E S s ✗ n.d. n.d. 
P08697 1 0 0 3 0 91 9 ✔ ✔ ✔ 
P08708 8 8 1 0 E S  ✗ n.d. n.d. 
P08758 18 10 2 0 E S s ✗ n.d. n.d. 
P08865 4 0 4 0 E  S ✗ n.d. n.d. 
P09110 33 33 0 2 0 0 100 ✗ ✗ ✔ 
P09211 12 7 0 0 17-34 17 67-50 ✔ ✔ ✔ 
P09382 4 2 0 0 8 0 92 ✗ ✔ ✗ 
P09417 2 5 0 2 S  E ✗ n.d. n.d. 
P09429 0 1 1 1 ??? 67 33 ✔✗ ✔ ✔ 
P09455 20 0 0 2   S ✔ n.d. n.d. 
P09467 27 25 0 4 ??? 8-33 92-67 ✗ ✔ ✔ 
P09488/Q03013/ 
P46439 
42 104 0 0 0-9 0 100-91 ✗ ✔ ✗ 
P09493/P06753/ 
P67936/P07951 
17 38 1 0 0-11 0 100-89 ✔ n.d. n.d. 
P09496 0 1 1 0 ??? 55-64 45-36 ✔ ✔ ✔ 
P09525 13 7 No results 0-20 60-30 40-50 n.d. ✔ n.d. 
P09622 8 14 1 0 Es S  ✗ n.d. n.d. 
P09960 1 0 No results 73-45 0-27 27 n.d. ✔ n.d. 
P09972 2 3 No results 42 25 33 n.d. ✔ n.d. 
P0C0L4/P0C0L5 18 12 1 2 18 64 18 ✗ ✔ ✔ 
P10109 4 1 0 1   S ✔ n.d. n.d. 
P10253 6 8 1 0 Es S  ✗ n.d. n.d. 
P10515 0 3 No results 100 0 0 n.d. ✔ n.d. 
P10599 4 5 2 0 100 0 0 ✗ ✗ ✔ 
P10606 7 10 1 1 Es S E ✗ n.d. n.d. 
P10619 0 7 3 0 ??? 58 42 ✔ ✔ ✔ 
P10620 2 1 0 1   S ✔ n.d. n.d. 
P10768 4 2 0 1   S ✔ n.d. n.d. 
P10809 96 114 3 1 ??? 89 11 ✗ ✔ ✔ 
P10909 1 7 2 2 25-16 8-17 67 ✗✔ ✔ ✔ 
P11021 52 92 3 1 18 82 0 ✗ ✔ ✗✔ 
P11142 46 47 4 0 0 0-18 100-82 ✗ ✔ ✗ 
P11168 0 1 0 2 0 0 100 ✗ ✗ ✔ 
P11177 3 9 No results S   n.d. n.d. n.d. 
P11182 8 5 1 0 91-73 0-18 9 ✗ ✔ ✔ 
P11310 18 8 0 2 ??? 67-75 33-25 ✔ ✔ ✔ 
P11498 64 32 0 1   S ✔ n.d. n.d. 
P11509/P20853/Q1
6696 
2 2 0 3  S E ✗ n.d. n.d. 
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P11586 41 39 0 6 ??? 0-9 100-91 ✗ ✔ ✔ 
P11712 9 0 0 7 ??? 0-10 100-90 ✔ ✔ ✔ 
P12268 0 1 No results 75 25 0 n.d. ✔ n.d. 
P12429 1 0 1 0 E  S ✗ n.d. n.d. 
P12694 7 0 0 1   S ✔ n.d. n.d. 
P12814/P35609/O4
3707 
40 24 No results  S s n.d. n.d. n.d. 
P12955 4 2 1 2 100-91 0-9 0 ✗✔ ✗ ✗✔ 
P12956 1 0 No results   S n.d. n.d. n.d. 
P13489 2 0 No results   S n.d. n.d. n.d. 
P13639 24 4 1 0 91-82 0-9 9 ✗ ✔ ✔ 
P13645 3 0 0 1   S ✔ n.d. n.d. 
P13667 23 29 No results 64 27 9 n.d. ✔ n.d. 
P13674 0 3 No results 67 33 0 n.d. ✔ n.d. 
P13693 5 9 0 4 42 58 0 ✗ ✔ ✗ 
P13716 2 4 0 1 0-9 27 73-64 ✗ ✔ ✔ 
P13796 28 9 0 1 0 100 0 ✔ ✗ ✗ 
P13797 17 3 No results   S n.d. n.d. n.d. 
P13798 2 0 No results   S n.d. n.d. n.d. 
P13804 19 30 0 3 ??? 82 18 ✗ ✔ ✔ 
P13861 2 0 No results 100-91 0-9 0 n.d. ✗ n.d. 
P14174 2 1 2 1 20 40-20 40-60 ✗✔ ✔ ✔ 
P14314 13 15 No results ??? 67 33 n.d. ✔ n.d. 
P14324 0 1 4 0 S   ✔ n.d. n.d. 
P14550 7 11 0 1 33 67 0 ✗ ✔ ✗ 
P14618 3 0 2 0 E  S ✗ n.d. n.d. 
P14625 102 110 1 3 100 0 0 ✗ ✗ ✗✔ 
P14923 1 0 No results 18-9 18 64-73 n.d. ✔ n.d. 
P14927 4 5 4 0 Es S  ✗ n.d. n.d. 
P15090 0 7 No results 0 100 0 n.d. ✗ n.d. 
P15104 0 5 1 2 50-58 17-0 33-41 ✗✔ ✔ ✔ 
P15121 1 0 1 0 30 20 50 ✗ ✔ ✔ 
P15311 13 0 2 0   S ✔ n.d. n.d. 
P15374 0 3 1 0 8 92 0 ✔ ✔ ✔ 
P15531/P22392 24 37 7 0 70 30 0 ✗ ✔ ✔ 
P15880 3 0 1 1 E  S ✗✔ n.d. n.d. 
P16083/Q08257 12 10 No results ??? 0-17 100-83 n.d. ✔ n.d. 
P16152/O75828 16 39 No results ??? 0-8 100-92 n.d. ✔ n.d. 
P16219 11 3 0 5 0-33 75-33 25-33 ✔ ✔ ✔ 
P16278 6 1 No results 0-25 17-8 83-67 n.d. ✔ n.d. 
P16402 10 0 No results   S n.d. n.d. n.d. 
P16435 15 13 0 3 ??? 60 40 ✗ ✔ ✔ 
P16455 0 1 0 0 ??? 0-11 100-89 ✗ ✔ ✔ 
P16930 9 11 0 5 s S E ✗ n.d. n.d. 
P16949 2 6 4 0 75 25 0 ✔ ✔ ✔ 
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P17174 19 15 0 1  S Es ✗ n.d. n.d. 
P18077 1 0 1 0 E  S ✗ n.d. n.d. 
P18124 4 4 2 0 E S  ✗ n.d. n.d. 
P18206 19 3 No results   S n.d. n.d. n.d. 
P18283 1 0 1 1 E  S ✗✔ n.d. n.d. 
P18621 2 0 No results   S n.d. n.d. n.d. 
P18669 12 19 No results s S  n.d. n.d. n.d. 
P19013 1 0 0 0  E S ✗ n.d. n.d. 
P19105 12 7 No results  S s n.d. n.d. n.d. 
P19404 2 3 No results 0-27 73-27 27-45 n.d. ✔ n.d. 
P19440 3 0 0 0  E S ✗ n.d. n.d. 
P19971 8 11 No results 92 8 0 n.d. ✔ n.d. 
P20073 3 0 0 1 83-67 0-17 17 ✔ n.d. n.d. 
P20132 1 0 0 1   S ✔ n.d. n.d. 
P20290 1 1 No results 50-58 42-33 8 n.d. ✔ n.d. 
P20339/P51148 4 8 No results 45 55 0 n.d. ✔ n.d. 
P20340/Q9NRW1 8 0 0 1 18-55 9-0 73-45 ✔ ✔ ✔ 
P20618 8 5 1 0 E S s ✗ n.d. n.d. 
P20674 4 5 0 1  S E ✗ n.d. n.d. 
P20962 2 1 No results   S n.d. n.d. n.d. 
P21266 1 0 0 2 0 100 0 ✔ ✗ ✗ 
P21281 4 0 1 0 27-36 9 64-55 ✗ ✔ ✔ 
P21291 2 3 0 1 s S E ✗ n.d. n.d. 
P21333 1 0 No results 0 100 0 n.d. ✗ n.d. 
P21399 23 33 0 3 45 0 55 ✗ ✗ ✔ 
P21549 49 48 2 4 E S E ✗ n.d. n.d. 
P21695 8 16 0 1 S  E ✗ n.d. n.d. 
P21757 0 1 No results 55 45 0 n.d. ✔ n.d. 
P21796 11 19 No results ??? 100 0 n.d. ✔ n.d. 
P21912 11 19 0 1 27-55 27-0 45 ✗ ✔ ✔ 
P21953 3 2 0 1  S Es ✗ n.d. n.d. 
P21964 7 0 1 1 75 25 0 ✔✗ ✗ ✔✗ 
P22033 22 2 0 2   S ✔ n.d. n.d. 
P22061 0 5 1 1 S  E ✔✗ n.d. n.d. 
P22234 3 0 No results   S n.d. n.d. n.d. 
P22307 44 84 0 7 0 0 100 ✗ ✗ ✔ 
P22309/P36509/P22
310/Q9HAW7 
54 0 0 0  E S ✗ n.d. n.d. 
P22314 13 0 No results 18 82 0 n.d. ✗ n.d. 
P22352 4 0 0 2   S ✔ n.d. n.d. 
P22570 6 5 1 1 100 0 0 ✗ ✗ ✔✗ 
P22626 0 5 3 0 80 0 20 ✔ ✔ ✔ 
P22695 10 3 No results 0-25 75-33 25-42 n.d. ✔ n.d. 
P22792 0 2 0 2 67 25 8 ✗ ✔ ✔ 
P22830 5 2 No results   S n.d. n.d. n.d. 
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P23141 85 62 1 2 ??? 45-55 55-45 ✗ ✔ ✔ 
P23284 24 37 3 1 0 64-82 36-18 ✔✗ ✔ ✔ 
P23378 8 0 0-29 0 100-71 n.d. ✔ n.d. 
P23381 1 0   S n.d. n.d. n.d. 
P23396 1 1 
No results 
 S  n.d. n.d. n.d. 
P23434 3 2 0 1  S Es ✗ n.d. n.d. 
P23526 1 0 1 1  E S ✗ n.d. n.d. 
P23528 25 23 No results  S  n.d. n.d. n.d. 
P23786 11 14 0 1 s S E ✗ n.d. n.d. 
P24298 3 0 0 0  E S ✗ n.d. n.d. 
P24534 1 2 No results 67 0 33 n.d. ✔ n.d. 
P24539 4 0 1 0 E  S ✗ n.d. n.d. 
P24666 11 5 No results   S n.d. n.d. n.d. 
P24752 37 36 0 4 ??? 9-55 91-45 ✗ ✔ ✔ 
P25311 2 0 0 3 0-8 33-50 67-42 ✔ ✔ ✔ 
P25325 13 14 No results 75-83 25-8 0-8 n.d. ✔ n.d. 
P25398 5 6 No results 25 75 0 n.d. ✔ n.d. 
P25705 50 70 1 1 ??? 83 17 ✗ ✔ ✔ 
P25774 2 0 1 0 17 33 50 ✗ ✔ ✔ 
P25786 2 5 1 0 S   ✔ n.d. n.d. 
P25787 7 4 No results 50-58 50-17 0-25 n.d. ✔ n.d. 
P25788 3 1 0 1 0-8 75 25-17 ✔ ✔ ✔ 
P25789 2 2 1 1 0-50 90-0 10-50 ✗ ✔ ✔ 
P26038 24 10 0 0-9 100-91 n.d. ✔ n.d. 
P26373 5 1 
No results 
  S n.d. n.d. n.d. 
P26440 9 14 0 2 s S E ✗ n.d. n.d. 
P26599 5 3 1 0 82 18 0 ✗ ✔ ✔ 
P26641 2 0 1 0 0-10 0-10 100-80 ✗ ✔ ✔ 
P26885 7 8 No results 33 67 0 n.d. ✔ n.d. 
P27105 2 0 0 2 0-42 33-0 67-58 ✔ ✔ ✔ 
P27144 8 15 1 1 Es S E ✗ n.d. n.d. 
P27169 2 10 0 5 ??? 6 94 ✗ ✔ ✔ 
P27338 7 0 0 1 ??? 75 25 ✔ ✔ ✔ 
P27348 2 15 92-67 0-17 8-16 n.d. ✔ n.d. 
P27708 0 6 
No results 
18-27 55-45 27 n.d. n.d. n.d. 
P27797 10 17 2 0 67 33-8 0-25 ✗ ✔ ✔ 
P27824 0 2 2 1 56 22 22 ✔✗ ✔ ✔ 
P28062 3 0 0 1   S ✔ n.d. n.d. 
P28065 4 3 0 0 92 8 0 ✔ n.d. n.d. 
P28066 3 1 No results   S n.d. n.d. n.d. 
P28070 2 2 3 0 0 0-25 100-75 ✗ ✔ ✗ 
P28072 1 3 ??? 8-33 92-67 n.d. ✔ n.d. 
P28074 1 0   S n.d. n.d. n.d. 
P28331 19 6 
No results 
  S n.d. n.d. n.d. 
P28838 17 20 0 2  S E ✗ n.d. n.d. 
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P29401 14 6 No results   S n.d. n.d. n.d. 
P29692 5 8 2 0 Es S  ✗ n.d. n.d. 
P29966 2 0 1 0 27-18 18-9 55-72 ✗ ✔ ✔ 
P30038 26 24 1 2 ??? 36-55 64-45 ✗ ✔ ✔ 
P30039 10 4 0 2   S ✔ n.d. n.d. 
P30040 6 10 No results s S  n.d. n.d. n.d. 
P30041 37 71 1 3 ??? 42-50 58-50 ✔✗ ✔ ✔ 
P30042 8 18 0 1 S  E ✗ n.d. n.d. 
P30043 10 20 1 2 S  E ✔✗ n.d. n.d. 
P30044 29 27 No results 83 17 0 n.d. n.d. n.d. 
P30046 5 5 0 3  S E ✗ n.d. n.d. 
P30048 28 23 0 1 17-55 75-18 8-27 ✗ ✔ ✔ 
P30049 12 4 0 1 8-25 92-58 0-17 ✔ ✔ ✔ 
P30050 6 6 1 0 30-50 40-10 30-40 ✗ ✔ ✔ 
P30084 60 48 0 7 ??? 91 9 ✗ n.d. n.d. 
P30085 10 15 1 0 Es S  ✗ n.d. n.d. 
P30086 32 30 0 2 0 0 100 ✗ ✗ ✔ 
P30101 33 41 3 0 100 0 0 ✗ ✗ ✔ 
P30153 12 3 1 0 60-70 30-20 10 ✗ ✔ ✔ 
P30405 5 1 No results   S n.d. n.d. n.d. 
P30613 0 2 1 0 10 90 0 ✔ n.d. n.d. 
P30626 0 6 No results S   n.d. n.d. n.d. 
P30711 6 3 0 0   S n.d. n.d. n.d. 
P30837 38 30 0 1 ??? 100 0 ✗ ✔ ✗ 
P31040 10 8  S  n.d. n.d. n.d. 
P31150/P50395 15 4 
No results 
8-17 8-0 83 n.d. ✔ n.d. 
P31327 257 150 1 4 ??? 0-40 100-60 ✗ ✔ ✔ 
P31513 11 0 0 1 00 27-36 73-64 ✔ ✔ ✔ 
P31930 12 7 1 0 90 10 0 ✗ ✔ ✗ 
P31937 13 23 0 1 ??? 58-67 42-33 ✗ ✔ ✔ 
P31946 4 23 1 0 S   ✔ n.d. n.d. 
P31948 2 2 1 0 E S  ✗ n.d. n.d. 
P32119 24 42 No results 67 33-0 0-33 n.d. ✔ n.d. 
P32754 13 9 0 6  S Es ✗ n.d. n.d. 
P32929 3 2 0 2 ??? 0-8 100-92 ✗ ✔ ✔ 
P32969 2 1 No results 64-45 0-18 36 n.d. ✔ n.d. 
P33121 19 1 0 4 ??? 27-45 73-55 ✔ n.d. n.d. 
P33316 0 10 1 0 S   ✔ n.d. n.d. 
P34741 0 4 1 2 18-27 73-64 9 ✔✗ ✔ ✔ 
P34896 8 4 0 3 ??? 42-50 58-50 ✔ ✔ ✔ 
P34897 10 12 0 1 0-17 33-25 67-58 ✗ ✔ ✔ 
P34913 11 4 0 4 0 83 17 ✔ ✔ ✔ 
P35221 0 3 1 0 ??? 80 20 ✔ ✔ ✔ 
P35222 1 0 3 1 ??? 8 92 ✔✗ ✔ ✔ 
P35232 31 19 1 1 ??? 100 0 ✗ ✔ ✔✗ 
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P35268 7 8 1 0 E S  ✗ n.d. n.d. 
P35270 10 17 No results s S  n.d. n.d. n.d. 
P35520 0 1 0 2 0 0 100 ✔ ✔ ✔ 
P35542 2 2 0 2 11 22 67 ✗ ✔ ✔ 
P35558 12 12 0 6 0-9 0-9 100-82 ✗ ✔ ✔ 
P35573 2 0 1 1 E  S ✔✗ n.d. n.d. 
P35579 10 0 1 0 E  S ✗ n.d. n.d. 
P35590 1 0 0 0  E S ✗ n.d. n.d. 
P35914 19 17 0 2 ??? 0-22 100-78 ✗ ✔ ✔ 
P36269 8 0 0 1 0 0 100 ✔ ✔ ✔ 
P36404 0 1 2 0 S   ✔ n.d. n.d. 
P36406 1 0 0 1   S ✔ n.d. n.d. 
P36542 6 7 No results  S  n.d. n.d. n.d. 
P36543 1 4 1 0 0 0-17 100-83 ✔ ✗ ✗ 
P36551 0 3 50-33 0-17 50 n.d. ✔ n.d. 
P36578 5 0 
No results 
  S n.d. n.d. n.d. 
P36776 16 10 0 1 73 27-9 0-18 ✗ ✔ ✔ 
P36871 37 14 0 1 ??? 0-25 100-75 ✔ ✔ ✔ 
P36957 11 5 ??? 20-30 80-70 n.d. ✔ n.d. 
P36969 3 1 0 9 91 n.d. ✔ n.d. 
P37235 4 1 
No results 
  S n.d. n.d. n.d. 
P37802 18 26 3 1 17 83 0 ✗ ✔ ✔✗ 
P37837 5 4 2 0 E S  ✗ n.d. n.d. 
P37840 0 1 No results S   n.d. n.d. n.d. 
P38117 26 30 1 0 ??? 100 0 ✗ ✔ ✔ 
P38159 2 0   S n.d. n.d. n.d. 
P38606 3 0 
No results 
No results 78 22 0 n.d. ✗ n.d. 
P38646 34 67 2 0 Es S  ✔ n.d. n.d. 
P39019 11 8 3 0 E S s ✗ n.d. n.d. 
P39023 2 0 1 0 17-33 58-42 25 ✗ ✔ ✔ 
P39687 0 1 No results 80 20 0 n.d. ✔ n.d. 
P40121 3 1 3 0 100 0 0 ✗ ✗ ✔ 
P40227 4 4 2 0 E S  ✗ n.d. n.d. 
P40261 2 0 1 6 E  S ✔✗ n.d. n.d. 
P40306 1 0 0 1   S ✔ n.d. n.d. 
P40429 0 1 No results S   n.d. n.d. n.d. 
P40925 5 6 1 0 E S  ✗ n.d. n.d. 
P40926 26 74 1 0 ??? 83 17 ✔ ✔ ✔ 
P40939 62 70 No results 0-17 75-58 25 n.d. ✔ n.d. 
P42126 6 12 0 1 S  E ✗ n.d. n.d. 
P42704 7 1 No results   S n.d. n.d. n.d. 
P42765 42 70 0 3 s S E ✗ n.d. n.d. 
P42766 3 0 2 1 83-58 0-25 17 ✔✗ ✔ ✔ 
P43155 3 0 0 1 92 0 8 ✔ ✔ ✔ 
P43487 0 1 No results S   n.d. n.d. n.d. 
  142  
P43490 9 9 0 3  S E ✗ n.d. n.d. 
P43686 0 1 1 0 30-40 40-0 30-60 ✔ n.d. n.d. 
P45880 2 4 1 0 S   ✔ n.d. n.d. 
P45954 31 22 0 6  S Es ✗ n.d. n.d. 
P46108 0 1 1 0 0 0 100 ✔ ✗ ✗ 
P46459 1 0 1 0 75 25 0 ✗ ✗ ✔ 
P46776 1 2 No results S   n.d. n.d. n.d. 
P46777 3 1 1 0 E  S ✗ n.d. n.d. 
P46779 0 3 No results S   n.d. n.d. n.d. 
P46782 5 5 2 0 E S  ✗ n.d. n.d. 
P46783 11 5 2 0 E  S ✗ n.d. n.d. 
P46940 3 0 1 0 50 0 50 ✗ ✔ ✔ 
P46952 6 6 0 1  S E ✗ n.d. n.d. 
P47914 1 1 2 0 E S  ✗ n.d. n.d. 
P47985 7 7  S  n.d. n.d. n.d. 
P48047 20 16 83 17 0 n.d. ✔ n.d. 
P48147 1 0 
No results 
0 27 73 n.d. ✔ n.d. 
P48556 0 1 1 1 0-30 10-0 90-70 ✔✗ ✔ ✔ 
P48637 0 1 No results S   n.d. n.d. n.d. 
P48643 3 0 5 0 90 10 0 ✗ ✗ ✔ 
P48735 48 32 No results 91-82 0-9 9 n.d. ✔ n.d. 
P49189 5 3 2 0 ??? 33 67 ✗ ✔ ✔ 
P49207 0 1 S   n.d. n.d. n.d. 
P49326 2 0 
No results 
0 0-25 100-75 n.d. ✔ n.d. 
P49327 24 6 0 1 25-33 58-17 17-50 ✔ ✔ ✔ 
P49411 7 9 0 2 42-50 42-0 17-50 ✗ ✔ ✔ 
P49419 20 14 0 1 0 58 42 ✗ ✔ ✗ 
P49588 1 0 No results   S n.d. n.d. n.d. 
P49593 0 1 2 0 S   ✔ n.d. n.d. 
P49720 7 8 1 0 E S  ✗ n.d. n.d. 
P49721 8 7 No results 0 0 100 n.d. ✗ n.d. 
P49748 27 3 0 4 ??? 25 75 ✔ n.d. n.d. 
P49755 0 2 1 0 S   ✔ n.d. n.d. 
P49773 9 3 1 1 E  S ✔✗ n.d. n.d. 
P49789 0 1 1 0 67 22 11 ✔ ✔ ✔ 
P49821 
2 0 
No 
results 
   S n.d. n.d. n.d. 
P49914 0 2 0 1 ??? 64 36 ✔ ✔ ✔ 
P50053 3 1 2 4 ??? 0-22 100-78 ✔✗ ✔ ✔ 
P50213 4 8 0 1 S  E ✗ n.d. n.d. 
P50225/P50226/ 
P50224 
11 3 0 2 ??? 50 50 ✔ ✔ ✔ 
P50440 37 64 0 3 ??? 0-17 100-83 ✗ ✔ ✔ 
P50502/Q8IZP2 4 0 1 0 0 55-64 45-36 ✗ ✔ ✗ 
P50914 5 5 No results 9-27 73-55 18 n.d. ✔ n.d. 
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P50990 4 2 92-83 0-8 8 n.d. ✔ n.d. 
P50995 6 0 80-90 10-0 10 n.d. ✔ n.d. 
P51149 20 17 8 33 58 n.d. n.d. n.d. 
P51452 7 5 
 
 S  n.d. n.d. n.d. 
P51570 4 4 1 0 27-75 64-0 9-25 ✗ ✔ ✔ 
P51571 5 1 No results   S n.d. n.d. n.d. 
P51648 1 0 0 2 36-45 27-0 36-55 ✔ ✔ ✔ 
P51649 4 7 No results s S  n.d. n.d. n.d. 
P51659 30 10 1 2 ??? 83 17 ✔✗ ✔ ✔ 
P51687 4 3 No results  S  n.d. n.d. n.d. 
P51857 1 0 0 2   S ✔ n.d. n.d. 
P51858 0 1 4 0 50-60 50-30 0-10 ✔ ✔ ✔ 
P51884 
16 3 
No 
results 
 33 22 44 n.d. n.d. n.d. 
P51888 6 0 0 1   S ✔ n.d. n.d. 
P51970 2 1 No results   S n.d. n.d. n.d. 
P52565 3 3 1 1 58 42 0 ✗ ✔ ✔✗ 
P52566 4 1 0 1 0 100 0 ✔ ✗ ✗ 
P52597 2 2 No results 67-50 0-17 33 n.d. ✔ n.d. 
P52758 8 10 0 6 ??? 17 83 ✗ ✔ ✔ 
P52815 2 9 1 0 91 0 9 ✔ ✔ ✔ 
P52907 1 0   S n.d. n.d. n.d. 
P52943 1 0   S n.d. n.d. n.d. 
P53597 3 5 
No results 
s S  n.d. n.d. n.d. 
P54578 1 0 1 0 0 75 25 ✗ ✔ ✗ 
P54819 14 34 82 18 0 n.d. ✔ n.d. 
P54855/O75795 2 0 
No results 
  S n.d. n.d. n.d. 
P54868 42 76 0 3 s S E ✗ n.d. n.d. 
P54886 1 0 2 0 0-8 8-0 92 ✗ ✔ ✔ 
P54920/Q9H115 2 0 0 1 91 0 9 ✔ n.d. n.d. 
P55072 28 52 3 0 92 8 0 ✔ ✔ ✔ 
P55083 1 0 0 1   S ✔ n.d. n.d. 
P55084 28 10 0 2   S ✔ n.d. n.d. 
P55145 9 7 1 0 ??? 58 42 ✗ ✔ ✔ 
P55157 15 0 0 1   S ✔ n.d. n.d. 
P55263 0 1 0 2 S  E ✗ n.d. n.d. 
P55327 1 3 2 0 S   ✔ n.d. n.d. 
P55735 1 0 1 0 E  S ✗ n.d. n.d. 
P55957 4 7 No results 40-36 50-9 10-55 n.d. ✔ n.d. 
P56134 1 0 1 0 E  S ✗ n.d. n.d. 
P56470 2 1   S n.d. n.d. n.d. 
P56537 1 1  S  n.d. n.d. n.d. 
P56556 2 1   S n.d. n.d. n.d. 
P57105 3 0 100-92 0-8 0 n.d. ✗ n.d. 
P59190 4 1 
No results 
  S n.d. n.d. n.d. 
P60174 34 57 1 0 11-22 56-22 33-56 ✗ ✔ ✔ 
  144  
P60604 0 1 58 42 0 n.d. ✔ n.d. 
P60660 19 19 
No results 
 S  n.d. n.d. n.d. 
P60709/P63261 146 80 3 0 E S  ✗ n.d. n.d. 
P60842 2 0 0 2   S ✔ n.d. n.d. 
P60866 8 5 2 1 42 42 17 ✗ ✔ ✔ 
P60900 5 4 91 0 9 n.d. ✗ n.d. 
P60953 18 16 
No results 
80 20 0 n.d. ✔ n.d. 
P60981 15 4 0 0  E S ✗ n.d. n.d. 
P60983 6 2 1 1 100 0 0 ✗✔ ✗ ✗✔ 
P61019 0 3 No results 20 80 0 n.d. ✔ n.d. 
P61081 2 4 2 0 55 45 0 ✔ ✔ ✔ 
P61088 8 6 1 0 0 0-17 100-83 ✗ ✔ ✗ 
P61106 41 0 0 1 0-9 64-73 36-18 ✔ ✔ ✔ 
P61158 1 1 1 0 42-67 17-0 42-33 ✗ ✔ ✔ 
P61201 1 0 8 0 92 n.d. ✔ n.d. 
P61224/P62834 19 13 0 100 0 n.d. ✔ n.d. 
P61247 0 1 
No results 
S   n.d. n.d. n.d. 
P61353 0 1 1 0 ??? 60 40 ✔ ✔ ✔ 
P61457 0 1 0 2 S  E ✗ n.d. n.d. 
P61586 20 10 3 0 91 9 0 ✗ ✗ ✔ 
P61604 2 3 1 0 100 0 0 ✗ ✗ ✔ 
P61626 2 0 3 0 58 42 0 ✗ ✗ ✔ 
P61916 3 2 No results 0 0 100 n.d. ✗ n.d. 
P61956 6 9 1 0 s S  n.d. n.d. n.d. 
P61978 6 5 1 0 75 25 0 ✗ ✔ ✔ 
P61981 3 20 No results 92-83 0-8 8 n.d. ✔ n.d. 
P62081 10 9 2 0 E S  ✗ n.d. n.d. 
P62136/P62140 7 0 0 1 0 0 100 ✔ ✔ ✔ 
P62158 7 14 1 0 0 67 33 ✔ ✗ ✗ 
P62191 1 1 No results 0 0-8 100-92 n.d. ✔ n.d. 
P62195 0 1 3 1 42 50 8 ✗✔ ✔ ✔ 
P62241 6 2 2 0 E  S ✗ n.d. n.d. 
P62244 5 3 No results  S s n.d. n.d. n.d. 
P62249 7 7 3 0 E S  ✗ n.d. n.d. 
P62256 0 1 0-30 40-10 60 n.d. ✔ n.d. 
P62258 3 12 S   n.d. n.d. n.d. 
P62263 12 7 0 73 27 n.d. ✔ n.d. 
P62266 0 2 
No results 
S   n.d. n.d. n.d. 
P62269 16 27 1 0 Es S  ✗ n.d. n.d. 
P62277 13 12  S  n.d. n.d. n.d. 
P62280 2 0   S n.d. n.d. n.d. 
P62318 1 0 
No results 
100 0 0 n.d. ✗ n.d. 
P62330 7 5 1 1 0 80 20 ✗ ✔ ✗✔ 
P62333 4 0   S n.d. n.d. n.d. 
P62424 6 2 
No results 
  S n.d. n.d. n.d. 
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P62491/Q15907 8 0 2 0 17 67 17 ✗ ✔ ✔ 
P62633 0 1 2 1 S  E ✗✔ n.d. n.d. 
P62701 4 4 1 0 80-90 20-0 0-10 ✗ ✔ ✔ 
P62750 2 4 1 0 S   ✔ n.d. n.d. 
P62753 2 3 1 0 58 42-33 0-8 ✗ ✔ ✔ 
P62805 7 1 No results   S n.d. n.d. n.d. 
P62820/Q9H0U4/Q1
5286 
45 6 1 0 ??? 82 18 ✗ ✔ ✔ 
P62826 3 4 1 0 E S  ✗ n.d. n.d. 
P62829 4 4 No results ??? 18 82 n.d. n.d. n.d. 
P62837 0 4 1 0 S   ✔ n.d. n.d. 
P62841 5 3 No results  S s n.d. n.d. n.d. 
P62847 5 4 3 0 8 92 0 ✗ ✔ ✔ 
P62851 5 4 No results  S  n.d. n.d. n.d. 
P62854 5 3 0 1 E S s ✗ n.d. n.d. 
P62873/P62879 3 0 2 0 58 42 0 ✗ ✗ ✔ 
P62888 6 3 4 0 88 13 0 ✗ ✗ ✔ 
P62899 0 3 S   n.d. n.d. n.d. 
P62910 3 2  S  n.d. n.d. n.d. 
P62913 6 5 
No results 
89-56 0-33 11 n.d. ✔ n.d. 
P62917 1 4 2 0 S   ✔ n.d. n.d. 
P62937 24 23 5 0 67 33 0 ✗ ✔ ✔ 
P62942 2 2 1 0 11 89 0 ✗ ✔ ✔ 
P63000/P15153 25 21 1 0 18 82 0 ✗ ✔ ✔ 
P63027 0 2 No results S   n.d. n.d. n.d. 
P63104 5 17 2 0 100 0 0 ✔ ✔ ✔ 
P63208 0 4 No results 42-33 50-33 8-33 n.d. ✔ n.d. 
P63241 
18 16 
No 
results 
 70-60 0-10 30 n.d. ✔ n.d. 
P63244 6 5 2 0 100 0 0 ✗ ✗ ✔ 
P68036 7 4 1 0 E S s ✗ n.d. n.d. 
P68104 11 9 0 1  S E ✗ n.d. n.d. 
P68363/P68366 90 40 3 0 ??? 64-73 36-27 ✗ ✔ ✔ 
P68402 1 0 No results   S n.d. n.d. n.d. 
P68871/... 54 84 1 1 Es S E ✗ n.d. n.d. 
P78371 4 1 1 0 E  S ✗ n.d. n.d. 
P78417 16 11 0 3  S Es ✗ n.d. n.d. 
P78560 1 0 0 2 27 9 64 ✔ ✔ ✔ 
P80404 55 50 1 1 E S E ✗ n.d. n.d. 
P82650 0 1 ??? 38 63 n.d. n.d. n.d. 
P82909 0 1 
No results 
S   n.d. n.d. n.d. 
P82980 3 3 0 1  S E ✗ n.d. n.d. 
P83111 3 0 No results   S n.d. n.d. n.d. 
P83731 0 4 1 0 S   ✔ n.d. n.d. 
P84077/P61204/P18
085 
48 67 1 0 0 100 0 ✗ ✔ ✗ 
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P84243/P68431 33 0 2 1 E  S ✗✔ n.d. n.d. 
P99999 12 12 ??? 100 0 n.d. ✔ n.d. 
Q00059 0 1 
No results 
S   n.d. n.d. n.d. 
Q00266 3 0 0 4   S ✔ n.d. n.d. 
Q00341 0 1 No results 18 82 0 n.d. ✔ n.d. 
Q00796 10 14 0 2 s S E ✗ n.d. n.d. 
Q01082 1 0 No results   S n.d. n.d. n.d. 
Q01469 2 3 3 0 10 90 0 ✗ ✔ ✔ 
Q01518 11 1 No results   S n.d. n.d. n.d. 
Q01581 7 7 1 0 E S  ✗ n.d. n.d. 
Q01995 25 5 0 1 18 82 0 ✔ ✗ ✗ 
Q02218 2 0 No results 0 25 75 n.d. ✔ n.d. 
Q02252 48 37 0 1  S E ✗ n.d. n.d. 
Q02338 16 10 0 2  S Es ✗ n.d. n.d. 
Q02818 5 4 1 2 75 17 8 ✗ ✔ ✔ 
Q02878 5 1 2 0 E  S ✗ n.d. n.d. 
Q02928 4 0 0 2   S ✔ n.d. n.d. 
Q03154 8 8 0 3 0 0 100 ✗ ✗ ✔ 
Q04760 10 17 No results s S  n.d. n.d. n.d. 
Q04828/P52895/ 
P42330/P17516 
28 36 0 0  S  ✔ n.d. n.d. 
Q04837 14 19 1 0 75-88 0 25-13 ✗ ✗ ✔ 
Q04917 0 12 2 0 S   n.d. n.d. n.d. 
Q05639 5 0   S n.d. n.d. n.d. 
Q05682 2 0 
No results 
0 100 0 n.d. ✗ n.d. 
Q06278 3 0 0 2   S ✔ n.d. n.d. 
Q06323 8 11 No results 10-50 60-10 30-40 n.d. ✔ n.d. 
Q06520 13 12 0 2 ??? 73 27 ✗ ✔ ✔ 
Q06830 48 59 2 3 60 30-0 10-40 ✗ ✔ ✔ 
Q07020 5 3 No results  S  n.d. n.d. n.d. 
Q07021 0 1 0 1 S  E ✗ n.d. n.d. 
Q07065 2 0 1 0 55-45 27 18-27 ✗ ✔ ✔ 
Q07131 57 25 0 2   S n.d. n.d. n.d. 
Q08380 3 0 1 0 42-33 0 58-66 ✗ ✔ ✔ 
Q08426 33 52 0 1 s S E ✗ n.d. n.d. 
Q10713 4 0 0 1 50 42 8 ✔ ✔ ✔ 
Q12849 0 2 S   n.d. n.d. n.d. 
Q12931 11 7 
No results 
0 0-10 100-90 n.d. ✔ n.d. 
Q13011 22 24 0 2 ??? 91 9 ✗ ✔ ✔ 
Q13126 1 2 0 1 S   n.d. n.d. n.d. 
Q13162 37 39 0 1 0 82 18 ✗ ✔ ✔ 
Q13228 18 37 0 3 ??? 0-17 100-83 ✗ ✔ ✔ 
Q13268 0 35 0 0 S E  ✗ n.d. n.d. 
Q13404 14 7 No results   S n.d. n.d. n.d. 
Q13405 2 3 1 0 Es S  ✗✔ n.d. n.d. 
Q13409 1 0 No results   S n.d. n.d. n.d. 
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Q13418 1 0 0 0 58 42 0 n.d. ✗ n.d. 
Q13423 2 0 No results 27-36 27-18 45 n.d. ✔ n.d. 
Q13510 11 1 No results 0 17-50 83-50 n.d. ✔ n.d. 
Q13526 1 1 1 0 0 100 0 ✗ ✔ ✗ 
Q13561 1 0   S n.d. n.d. n.d. 
Q13576 2 0 
No results 
78 22 0 n.d. ✗ n.d. 
Q13813 15 3 1 0 E  S ✗ n.d. n.d. 
Q13907 2 6 3 0 S   ✔ n.d. n.d. 
Q14011 0 3 0 0 S E  ✗ n.d. n.d. 
Q14019 11 2 0 1   S ✔ ✔ ✔ 
Q14032 9 9 0 1  S E ✗ n.d. n.d. 
Q14103 3 5 No results 91 9 0 n.d. ✔ n.d. 
Q14117 5 1 0 1 0 25-33 75-67 ✔ ✔ ✔ 
Q14165 1 0 0-9 18-27 82-64 n.d. ✔ n.d. 
Q14197 1 2 0 91 9 n.d. ✗ n.d. 
Q14203 2 0 
No results 
100-83 0-17 0 n.d. ✗ n.d. 
Q14353 2 5 0 4 S  E ✗ n.d. n.d. 
Q14696 0 5 S   n.d. n.d. n.d. 
Q14697 42 37 
No results 
100-73 0-27 0 n.d. ✔ n.d. 
Q14749 6 6 1 2 ??? 33 67 ✗ ✔ ✔ 
Q14914 9 3   S n.d. n.d. n.d. 
Q14964 3 0   S n.d. n.d. n.d. 
Q15056 0 1 
No results 
S   n.d. n.d. n.d. 
Q15067 5 4 0 2 ??? 27 73 ✗ ✔ ✔ 
Q15084 22 25 0 1  S E ✗ n.d. n.d. 
Q15121 1 0 3 0 E  S ✗ n.d. n.d. 
Q15126 3 3  S  n.d. n.d. n.d. 
Q15181 4 6 
No results 
58-67 42-25 8 n.d. ✔ n.d. 
Q15185 1 5 1 0 S   ✔ n.d. n.d. 
Q15274 0 7 No results S   n.d. n.d. n.d. 
Q15293 1 2 0 3 S  E ✗ n.d. n.d. 
Q15363 2 0 3 1 50 50 0 ✔✗ ✗ ✔✗ 
Q15365 1 0 0 1   S ✔ n.d. n.d. 
Q15370 1 0 1 1 E  S ✔✗ n.d. n.d. 
Q15404 0 3 No results S   n.d. n.d. n.d. 
Q15435 1 0 1 0 E  S ✗ n.d. n.d. 
Q15436 3 0 0 1   S ✔ n.d. n.d. 
Q15493 2 2 1 5 E S E ✗ n.d. n.d. 
Q15819 15 0 No results   S n.d. n.d. n.d. 
Q16134 12 6 0 1   S ✔ n.d. n.d. 
Q16540 1 3 No results S   n.d. n.d. n.d. 
Q16543 1 0 1 0 E  S ✗ n.d. n.d. 
Q16595 2 1 0 1 0 0-18 100-82 ✔ ✔ ✔ 
Q16619 0 4 0 0 S E  ✗ n.d. n.d. 
Q16698 11 22 0 3 ??? 82 18 ✗ ✔ ✔ 
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Q16718 1 1 1 1 E S E ✗ n.d. n.d. 
Q16740 0 3 0 1 100 0 0 ✗ ✔ ✗ 
Q16762 18 26 1 4 ??? 83 17 ✗ ✔ ✔ 
Q16775 5 14 0 1 S  E ✗ n.d. n.d. 
Q16822 71 150 0 4 0 36 64 ✗ ✗ ✔ 
Q16836 15 17 0 2  S E ✗ n.d. n.d. 
Q16851 57 26 0 2   S ✔ n.d. n.d. 
Q16891 6 3 No results 0 9-45 91-55 n.d. ✔ n.d. 
Q3LXA3 29 31 0 2  S  n.d. n.d. n.d. 
Q4VC31 1 0   S n.d. n.d. n.d. 
Q5HYK3 2 6 
No results 
S   n.d. n.d. n.d. 
Q5T2W1 2 1 2 0 0 0-27 100-73 ✗ ✔ ✗ 
Q6IBS0 4 1 1 0   S ✔ ✔ ✔ 
Q6P587 5 6 0-30 30-20 70-50 n.d. ✔ n.d. 
Q7KZF4 2 0 
No results 
100 0 0 n.d. ✗ n.d. 
Q7Z4W1 23 37 0 3 ??? 67-75 33-25 ✗ ✔ ✔ 
Q7Z5P4 9 21 S   n.d. n.d. n.d. 
Q86SX6 1 2 
No results 
S   n.d. n.d. n.d. 
Q86TX2/P49753 20 21 0 1  S E ✗ n.d. n.d. 
Q86UP2 4 3 No results 100 0 0 n.d. ✗ n.d. 
Q86VB7 1 0 1 3 0 100 0 ✔✗ ✗ ✗ 
Q86WA6 4 19 No results S   n.d. n.d. n.d. 
Q86WU2 5 5 0 1  S E ✗ n.d. n.d. 
Q86X76 0 3 0 1 0-18 0 100-82 ✗ ✔ ✔ 
Q86X83 1 0   S n.d. n.d. n.d. 
Q8IVH4 1 0   S n.d. n.d. n.d. 
Q8N4P3 0 4 S   n.d. n.d. n.d. 
Q8N5N7 1 3 ??? 8-9 92-91 n.d. ✔ n.d. 
Q8N655 0 1 S   n.d. n.d. n.d. 
Q8N668 0 2 
No results 
S   n.d. n.d. n.d. 
Q8N983 2 1 2 0 E  S ✗ n.d. n.d. 
Q8NBJ7 4 5 No results 58-33 8-17 33-50 n.d. ✔ n.d. 
Q8NBQ5 2 0 0 1 ??? 0-33 100-67 ✔ ✔ ✔ 
Q8NBS9 8 8 1 0 E S  ✗ n.d. n.d. 
Q8NBX0 0 2 S   n.d. n.d. n.d. 
Q8NE62 7 0   S n.d. n.d. n.d. 
Q8NI60 1 2 83-92 17-0 0-8 n.d. ✔ n.d. 
Q8TAA3 0 3 25 63 13 n.d. ✔ n.d. 
Q8TCD5 1 1 
No results 
50 50 0 n.d. ✔ n.d. 
Q8TD30 0 1 0 1 S  E ✗ n.d. n.d. 
Q8TF76 1 1  S  n.d. n.d. n.d. 
Q8WUM4 1 0 9-45 36-0 55 n.d. ✔ n.d. 
Q8WVJ2 2 0   S n.d. n.d. n.d. 
Q8WW59 14 23 s S  n.d. n.d. n.d. 
Q92506 6 7 
No results 
 S  n.d. n.d. n.d. 
Q92558 0 3 1 0 0-40 30-0 70-60 ✔ ✔ ✔ 
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Q92688 0 1 No results S   n.d. n.d. n.d. 
Q92820 0 3 0 2 ??? 67 33 ✗ ✔ ✔ 
Q92882 1 1  S  n.d. n.d. n.d. 
Q92945 0 3 
No results 
S   n.d. n.d. n.d. 
Q92947 7 4 0 1  S Es ✔ n.d. n.d. 
Q93052 1 0 No results 45 55 0 n.d. ✗ n.d. 
Q93077/... 96 0 3 0 E  S ✗ n.d. n.d. 
Q93079/... 78 0 No results   S n.d. n.d. n.d. 
Q93088 33 43 1 5 e S E ✗ n.d. n.d. 
Q93099 6 2 0 2   S ✔ n.d. n.d. 
Q969H8 5 7  S  n.d. n.d. n.d. 
Q96AB3 15 27  S  n.d. n.d. n.d. 
Q96C23 0 1 S   n.d. n.d. n.d. 
Q96CN7 2 0   S n.d. n.d. n.d. 
Q96DE0 0 3 
No results 
S   n.d. n.d. n.d. 
Q96EY1 0 1 1 0 S   ✔ n.d. n.d. 
Q96EY8 4 7 1 0 Es S  ✔ n.d. n.d. 
Q96F10 1 0 0 1 0-17 50 50-33 ✔ ✔ ✔ 
Q96FV2 1 0 No results 0 0-9 100-91 n.d. ✔ n.d. 
Q96HR9 4 4 0 1 0-8 67-58 33 ✗ ✔ ✔ 
Q96I99 17 14 0 1  S  n.d. n.d. n.d. 
Q96IU4 11 18 No results s S  n.d. n.d. n.d. 
Q96KP4 12 3 0 1 0 90 10 ✔ ✔ ✔ 
Q96LJ7 5 7 0 1 ??? 9 91 ✗ ✔ ✔ 
Q96PE7 5 5 1 0 E S  ✗ n.d. n.d. 
Q96R05 0 1 No results S   n.d. n.d. n.d. 
Q96RQ3 12 0 No results 36 64 0 n.d. ✗ n.d. 
Q99424 3 0 0 3   S ✔ n.d. n.d. 
Q99439 0 1 0 1 S  E ✗ n.d. n.d. 
Q99471 1 0 No results 73-55 0 27-45 n.d. ✔ n.d. 
Q99497 16 26 No results 9 36 55 n.d. ✔ n.d. 
Q99611 0 1 1 1 S  E ✗✔ n.d. n.d. 
Q99623 9 10 40-50 60-40 0 n.d. ✔ n.d. 
Q99627 2 0   S n.d. n.d. n.d. 
Q99653 0 2 
No results 
0 0-33 100-67 n.d. ✗ n.d. 
Q99714 38 36 0 2 75-83 25-8 0-8 ✗ ✔ ✔ 
Q99733 0 1 No results 0-18 73-55 27 n.d. ✔ n.d. 
Q99798 23 38 1 0 100-52 0 0-47 ✔ ✔ ✔ 
Q99807 3 4 No results  S  n.d. n.d. n.d. 
Q99832 2 0 3 0 0-9 91-82 0-9 ✗ ✔ ✔ 
Q9BPW8 4 14 0 1 S   n.d. n.d. n.d. 
Q9BQ69 1 2 No results S   n.d. n.d. n.d. 
Q9BRA2 1 0 67-60 17-40 0 n.d. ✗ n.d. 
Q9BRG1 10 0   S n.d. n.d. n.d. 
Q9BRX8 0 4 
No results 
??? 18 82 n.d. ✔ n.d. 
Q9BS26 3 3 2 0 E S  ✗ n.d. n.d. 
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Q9BSE5 1 7 92-83 0-8 8 n.d. ✔ n.d. 
Q9BSH4 0 1 
No results 
??? 42-58 58-42 n.d. ✔ n.d. 
Q9BTZ2 8 10 0 1 0 0-17 100-83 ✗ ✔ ✔ 
Q9BU02 2 0   S n.d. n.d. n.d. 
Q9BUE6 0 1 
No results 
S   n.d. n.d. n.d. 
Q9BUP3 0 2 2 1 92 0 8 ✗✔ ✔ ✔ 
Q9BUR5 1 4 No results 18-45 27-18 55-36 n.d. ✔ n.d. 
Q9BV57 8 5 0 2  S Es ✗✔ n.d. n.d. 
Q9BVJ7 3 3 No results  S  n.d. n.d. n.d. 
Q9BVK6 2 3 1 1 58 42 0 n.d. ✔ n.d. 
Q9BVL4 1 0 No results   S n.d. n.d. n.d. 
Q9BWD1 4 2 0 0 ??? 0-10 100-90 ✗ ✔ ✔ 
Q9BX68 13 16 No results 92-67 8-17 0-17 n.d. ✔ n.d. 
Q9BXW7 3 3 64 36 0 n.d. ✔ n.d. 
Q9BY32 0 1 0 40-60 60-40 n.d. ✗ n.d. 
Q9BYD1 0 4 S   n.d. n.d. n.d. 
Q9BYV1 1 0   S n.d. n.d. n.d. 
Q9GZT3 3 4 50 0 50 n.d. ✗ n.d. 
Q9H082 3 0 
No results 
  S n.d. n.d. n.d. 
Q9H0W9 10 3 0 1   S ✔ n.d. n.d. 
Q9H2L5 0 1 S   n.d. n.d. n.d. 
Q9H2U2 10 5 
No results 
  S n.d. n.d. n.d. 
Q9H2W6 0 2 0 1 S  E ✗ n.d. n.d. 
Q9H7Z7 3 6 2 0 ??? 0-8 100-92 ✔ ✗ ✗ 
Q9H8H3 3 0 0-8 0 100-92 n.d. ✔ n.d. 
Q9H936/Q9H1K4 7 9 s S  n.d. n.d. n.d. 
Q9H9B4/Q9BWM7 4 5 ??? 42-67 58-33 n.d. ✔ n.d. 
Q9H9J2 0 4 S   n.d. n.d. n.d. 
Q9HAT2 0 1 S   n.d. n.d. n.d. 
Q9HAV7 4 12 S   n.d. n.d. n.d. 
Q9HCC0 11 11 
No results 
 S  n.d. n.d. n.d. 
Q9HCN8 5 0 0 0 0-64 35-36 65-0 ✗ ✔ ✔ 
Q9HDC9 3 4 0 2 ??? 44-67 56-33 ✗ ✔ ✔ 
Q9NNW7 3 0 0 0 0 36-45 64-55 ✗ ✔ ✔ 
Q9NP72 3 1 ??? 9-36 91-64 n.d. ✔ n.d. 
Q9NPJ3 8 5 
No results 
??? 9-36 91-64 n.d. ✔ n.d. 
Q9NQ50 0 2 0 1 20-60 70-0 10-40 ✗ ✔ ✔ 
Q9NQP4 0 1 No results 83-67 0-17 17 n.d. ✔ n.d. 
Q9NQX3 1 0 0 1   S ✔ n.d. n.d. 
Q9NR28 8 6 0 0 100-80 0-20 0 ✔ ✔ ✗ 
Q9NR31/Q9Y6B6 7 4 0 0 82-55 9-18 9-27 ✔ ✔ ✔ 
Q9NR45 0 1 1 0 67 33 0 ✔ ✔ ✔ 
Q9NR77 4 0 0 2   S ✔ n.d. n.d. 
Q9NRV9 3 6 0 1 S  E ✗ n.d. n.d. 
Q9NRX2 0 1 S   n.d. n.d. n.d. 
Q9NS69 1 0 
No results 
??? 90 10 n.d. ✔ n.d. 
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Q9NSE4 3 0 2 0 0-17 83-67 17 ✗ ✔ ✔ 
Q9NTM9 0 1 No results S   n.d. n.d. n.d. 
Q9NUI1 0 2 0 1 S  E ✗ n.d. n.d. 
Q9NVI7 1 0 No results   S n.d. n.d. n.d. 
Q9NVS9 8 11 0 1 58-75 17-8 25-17 ✗ ✔ ✔ 
Q9NX63 2 6 No results S   n.d. n.d. n.d. 
Q9NYL4 1 1 2 1 E S e ✗ n.d. n.d. 
Q9NYU2 1 0 No results ??? 33 67 n.d. ✔ n.d. 
Q9NZN3 2 0 0 1   S ✔ n.d. n.d. 
Q9P000 1 1 33-58 25-0 42-25 n.d. ✔ n.d. 
Q9P032 0 8 S   n.d. n.d. n.d. 
Q9P0J0 2 0 
No results 
  S n.d. n.d. n.d. 
Q9P0Z9 3 2 0 2 ??? 83 16 ✗ ✔ ✔ 
Q9P2E9 35 7 0 2 ??? 73 27 ✔ ✔ ✔ 
Q9P2K3 0 2 S   n.d. n.d. n.d. 
Q9UBQ0 0 1 
No results 
S   n.d. n.d. n.d. 
Q9UBQ7 18 13 0 2 0-17 8-0 92-83 ✗ ✔ ✔ 
Q9UBR1 4 0 0 1 0 0-18 100-82 ✔ ✔ ✔ 
Q9UBR2 1 3 0 1 ??? 33-50 67-50 ✗ ✔ ✔ 
Q9UBS4 1 2 No results 9 91 0 n.d. ✔ n.d. 
Q9UDR5 25 18 0 1 0 0 100 ✗ ✗ ✔ 
Q9UFN0 2 4 No results S   n.d. n.d. n.d. 
Q9UHK6 1 0 0 1   S ✔ n.d. n.d. 
Q9UHL4 2 1 0 1 0-17 25-17 75-67 ✔ ✔ ✔ 
Q9UHV9 4 1 1 0   S ✗ n.d. n.d. 
Q9UI09 2 0 1 0 E  S ✗ n.d. n.d. 
Q9UI17 36 8 No results   S n.d. n.d. n.d. 
Q9UIJ7 9 33 1 1 SE  E ✔✗ n.d. n.d. 
Q9UJ68 1 1 0-8 42-33 58 n.d. ✔ n.d. 
Q9UJ70 1 0   S n.d. n.d. v 
Q9UJD0 1 2 
No results 
58-67 33-25 8 n.d. ✔ n.d. 
Q9UJM8 32 31 0 2  S E ✗ n.d. n.d. 
Q9UJZ1 6 8 No results 82 9 9 n.d. ✔ n.d. 
Q9UKK9 0 6 2 0 0 8-33 92-67 ✔ ✗ ✗ 
Q9UL12 21 6 0 1   S ✔ n.d. n.d. 
Q9UL46 8 13 s S  n.d. n.d. n.d. 
Q9ULZ3 6 4 
No results 
36 18 45 n.d. ✔ n.d. 
Q9UN36 9 1 0 3 0 36-45 64-55 ✔ ✔ ✔ 
Q9UNM6 2 2 1 0 E S  ✗ n.d. n.d. 
Q9UPN3 4 0 No results   S n.d. n.d. n.d. 
Q9Y224 3 0 1 0 E  S ✗ n.d. n.d. 
Q9Y237 0 1 No results S   n.d. n.d. n.d. 
Q9Y277 3 3 0 0 0-18 73-55 27 ✔ ✔ ✔ 
Q9Y2B0 10 12 1 0 Es S  ✗ n.d. n.d. 
Q9Y2Q3 11 25 No results ??? 50-58 50-42 n.d. ✔ n.d. 
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Q9Y2Q9 1 0 1 0 E  S ✗ n.d. n.d. 
Q9Y2S2 5 6 0 2  S E ✗ n.d. n.d. 
Q9Y2T3 2 2 ??? 67 33 n.d. ✔ n.d. 
Q9Y2V2 0 1 S   n.d. n.d. n.d. 
Q9Y3A6 1 0   S n.d. n.d. n.d. 
Q9Y3B7 0 5 S   n.d. n.d. n.d. 
Q9Y3B8 0 1 S   n.d. n.d. n.d. 
Q9Y3C6 1 0   S n.d. n.d. n.d. 
Q9Y3D2 0 4 S   n.d. n.d. n.d. 
Q9Y3D6 12 7 
No results 
45 55 0 n.d. ✔ n.d. 
Q9Y3D9 2 2 1 0 25-33 58-50 17-16 ✗ ✔ ✔ 
Q9Y3E5 1 0 ??? 91 9 n.d. ✔ n.d. 
Q9Y3I0 1 0 100 0 0 n.d. ✗ n.d. 
Q9Y490 31 5 
No results 
  S n.d. n.d. n.d. 
Q9Y4L1 14 18 No results s S  n.d. n.d. n.d. 
Q9Y4Z0 1 0 2 0 E  S ✗ n.d. n.d. 
Q9Y5Z4 3 3 0 1 0 50-67 50-33 ✗ ✔ ✔ 
Q9Y617 8 0 0 0-38 100-63 n.d. ✔ n.d. 
Q9Y6H1 0 3 S   n.d. n.d. n.d. 
Q9Y6M9 2 0   S n.d. n.d. n.d. 
Q9Y6N5 4 0 
No results 
??? 100 0 n.d. ✗ n.d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 34: List of functionally classified proteins identified in liver (blue) and HCC (orange) by mass 
spectrometry (see following pages). Proteins are assigned to metabolic pathways based on the 
databases Brenda (www.brenda-enzymes.org), Kegg pathway database 
(www.genome.jp/kegg/pathway.html) and Uniprot (www.uniprot.org) as well as biochemical and 
cell biological literature. In addition, the subcellular location is given for each protein based on 
informations from Uniprot and PubMed. (Abbreviations used in this table: b: biosynthesis, cytor c: 
cytoplasma (cytosol), d: degradation, ER: endoplasmic reticulum, lys: lysosome, m: metabolism, 
mito: mitochondrium, ns: non specified, p: peroxisome, rec: receptor, t: transfer, sec or s: 
secreted) 
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